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Intra-spinal transplantation of olfactory ensheathing cells (OECs) and delivery of chondroitinase ABC 
(chABC) have separately shown promise as therapies for spinal cord injury (SCI). Efficacy has been 
demonstrated for both these approaches in trials using dogs with naturally occurring SCI, a model 
which may represent a means of bridging the gap in translation between laboratory interventions and 
clinical treatments. However, their individual effect was limited and combination therapy, including a 
means to increase OEC survival, may improve outcomes.  
 
It was recently demonstrated that OECs can be modified to express chABC (OEC-chABC), providing a 
combination therapy and novel delivery method of chABC. This thesis builds on that work by testing 
the functional benefit of this modified OEC transplant in two rodent models of SCI, as well as delivery 
of OECs within hydrogels to increase cell survival.  
 
We tested the effect of canine OEC-chABC compared to OECs alone on forepaw reaching in an acute 
incomplete SCI model (dorsal column crush injury), demonstrating greater recovery in OEC-chABC 
transplanted animals and proof of concept of this therapy. We further tested the effect of canine OEC-
chABC on locomotion in a more severe chronic thoracic contusion model, showing no significant 
behavioural recovery compared to controls in this xenotransplant model with low OEC survival.  
 
We used a chronic cervical dorsal column crush injury in rats to test injection of canine OECs 
encapsulated in collagen hydrogel, demonstrating an average 7.5-fold increase in surviving OEC 
number at 2 weeks after transplant. Stiffness matching between implant and host tissue is necessary 
to reduce inflammatory reaction and prevent iatrogenic damage. Therefore, to facilitate hydrogel 
delivery on clinics, and to address a knowledge gap in the literature regarding the in vivo stiffness of 
SCI, we established an intraoperative ultrasound elastography approach to stiffness matching in dogs 
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1.1 The Spinal Cord and Injury 
1.1.1 The Spinal Cord 
The spinal cord relays information in the form of electrical signals from the brain to the rest of the 
body and vice versa. These motor or sensory signals are carried by specific and specialised myelinated 
axons, arranged into a well-defined architecture of ascending and descending tracts within the white 
matter of the spinal cord. Specific tracts of the spinal cord carry fibres relevant to different functions 
on the ipsilateral side (e.g. proprioception, fine motor control, pain) and these tracts have longitudinal 
symmetry along the midline of the cord. The central, ‘H’ shaped, grey matter of the spinal cord is 
composed largely of cell bodies and axon terminals and also contains inter-neurons that relay 
information between sensory and motor neurons and modulate inhibitory and excitatory input at a 
more local level1. 
 
White matter tracts are mostly conserved between species, but there are differences in their exact 
anatomical arrangement. In rats the majority of corticospinal tract (CST) axons are found in the dorsal 
funiculus of the spinal cord, with smaller numbers in the lateral funiculus alongside the rubrospinal 
tract. Progressively more CST axons are found lateral and ventral in carnivores and primates, including 
humans2, who also have a relatively much smaller rubrospinal tract (see Figure 1-1). In dogs the 
majority of the CST is found in the lateral funiculus, with less than 25% of CST axons found ventrally3. 
Additionally, in contrast to humans, the canine rubrospinal tract and CST are of similar size4.  
 
 
Figure 1-1. Comparison of rat and human spinal cord tracts viewed in transverse section 
(Kjell et al. 20165 and Watson et al. 20096)  
 
The specialised architecture and soft consistency7 of the spinal cord make it particularly sensitive to 
damage, with potentially devastating consequences in terms of loss of motor and/or sensory function 
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that are dependent on the level and severity of injury. However, the plasticity of the central nervous 
system also means that with incomplete injuries, tracts can adapt and ‘rewire’ to regain function. The 
inherently poor regenerative capacity of central nervous system axons and prevalence of inhibitory 
substrates at the site of injury, particularly in the chronic phase, limits spontaneous regeneration.   
 
1.1.2 Clinical Perspective of Injury 
Clinically, for both veterinary and human patients, this poor regenerative capacity means a potentially 
life-long chronic and irreversible paralysis and incontinence after injury, seriously affecting quality of 
life.  
 
Treatment for the spinal cord in the acute phase (hours to days) after injury is currently limited to 
surgical intervention to stabilise or decompress the cord and maintenance of blood perfusion through 
management of blood pressure. Pharmacological intervention in the acute phase remains 
controversial, with large scale trials of promising experimental treatments (e.g. 
monosialotetrahexosylganglioside and naloxone) failing to show benefit8. Steroid administration (high 
dose methylprednisolone) is particularly controversial; guidelines in 2002 stated the “evidence 
suggesting harmful side effects [was] more consistent than any suggestion of clinical benefit”9, but a 
Cochrane review in 2012 found a 4 point increase in ASIA motor score with 24 hours of 
methylprednisolone started within 8 hours of injury10. The evidence is still debated today (for reviews 
see Ahuja et al. 201711 and Fehlings et al. 201712) but methylprednisolone and naloxone were 
specifically contraindicated in acute spinal cord injury (SCI) in recent UK NICE guidelines13. 
 
In the longer-term, management involves prevention and treatment of secondary complications of 
SCI, for example urinary tract and respiratory infections8. Rehabilitation is a mainstay of therapy 
following SCI in human and veterinary clinics, with initial passive exercises to reduce contracture and 
muscle atrophy and longer-term rehabilitation to enhance and improve any remaining function14. The 
mechanism by which rehabilitation is able to mediate functional recovery is not clear and is an area 
of ongoing research but it is thought to be related to an induction of plasticity within spinal circuits 
and the promotion of functional reorganisation of remaining spinal connections15,16.   
 
The severity of injury to the spinal cord can of course vary, and consequently the degree of 
neurological deficit in terms of motor, sensory or autonomic function will vary. This is classified in 
people on the American Spinal Injury Association Impairment Scale (AIS)17, which ranges from grade 
AIS A denoting complete injury with no sensory or motor function below the lesion, through sensory 
 4 
and motor incomplete grades AIS B-D, to grade AIS E denoting normal function (see Table 1-1 for 
details). It is important to note, however, that even in functionally complete AIS A injury most injuries 
are not anatomically complete and 1-10% of white matter volume is spared18. Dogs are commonly 
classified on a similar modified Frankel score19 where grade 1 = pain with no neurological deficits, 2 = 
ambulatory paraparesis, 3 = non-ambulatory paraparesis, 4 = paraplegia, and 5 = paraplegia with loss 
of conscious pain perception20.  
 
The likelihood of spontaneous recovery after injury, and conversion between AIS grades, is correlated 
to the severity of injury and related to initial grade of injury21. For example, around 10% of patients 
presenting and classified as AIS A within 72 hours of injury will improve to AIS B and 10% will improve 
to AIS C, although of these only 14% will recover walking function. The proportion recovering is higher 
in higher AIS grades, with the majority of patients (~60%) diagnosed as AIS B by 72 hours after injury 
improving to AIS C or D and 33% recovering walking ability (for review and further details see 
Scivoletto et al. 201421). Importantly, 80% of patients that show recovery will do so within 3 months, 
and 95% within 1 year 22.   
 
AIS  Injury Description 
A Complete No motor or sensory function is preserved in the sacral segments S4–S5. 
B Incomplete Sensory but not motor function is preserved below the neurological level 
and includes the sacral segments S4-5 (light touch or pin prick at S4-5 or 
deep anal pressure). 
C Incomplete Motor function is preserved below the neurological level,  
Motor function is preserved at the most caudal sacral segments for 
voluntary anal contraction (VAC) OR the patient meets ASIA B and has 
some sparing of motor function more than three levels below the 
ipsilateral motor level on either side of the body. 
D Incomplete Motor function is preserved below the neurological level, and at least half 
of key muscles below the neurological level have a muscle grade of 3 or 
more. 
E Normal Motor and sensory function are normal. 
Table 1-1: American Spinal Injury Association Impairment Scale 
In dogs, prediction of recovery based on clinical severity is not as sensitive or well characterised, but 
the principle remains the same with virtually all dogs presenting at grade 4 (or less severe) recovering 
walking with appropriate management including surgery. Around 50-60% of dogs with grade 5 injury 
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(paraplegic without pain sensation) will recover ambulation, with 62-97% of those that recover doing 
so within 1 month20,23,24.  
 
Interpretation of any studies assessing treatment interventions for SCI must therefore be made with 
consideration of the patient population, its heterogeneity, and the degree of spontaneous recovery 
expected (particularly if a direct control group is not available).  
 
1.1.3 Epidemiology  
Spinal cord injury is a global problem. Estimates for incidence of SCI in humans vary between 3.6 and 
195.4 cases per million per year depending on country25, with an estimated worldwide incidence of 
130 cases per million per year26. Prevalence rates are high due to the chronic nature of the disease, 
with an estimated 27 million (95% confidence interval: 25 – 30 million) people affected worldwide26. 
The most common cause of injury is traumatic injury, with the majority of these being road traffic 
accidents27. In the UK, around 50,000 people suffer with SCI with over 1000 new cases per year28.  
 
As management of the acute phase of injury and longer-term complications improves (e.g. urinary 
incontinence, urinary and respiratory tract infections) more people are surviving initial injuries and 
living longer with chronic SCI29,30. This is of course to be celebrated, but also increases the financial 
burden on healthcare systems due to the high associated costs of long-term management; in the UK 
this cost is estimated at £1.4 billion per annum31, making novel treatment strategies desirable.  
 
Spinal cord injury occurs in many species and is a particularly common clinical problem in dogs, often 
related to chondrodystrophic breeds predisposed to degenerative disc disease and subsequent disc 
herniation32,33, causing compressive / contusive SCI. Incidence in the dog population is less clear, but 
a random sample of ~4000 dogs attending 89 UK veterinary practices recorded as part of the Royal 
Veterinary College ‘VetCompass’ project showed a prevalence of 0.7% (7000 per million) for 
intervertebral disc disease of all severities34.  
 
1.1.4 Experimental Therapeutic Approaches 
The large number of people affected worldwide and the severe nature of the disease have stimulated 
a long-standing research interest in developing new therapies for SCI. These have focussed on 
treatments both in the acute stages after injury, mainly to prevent further damage to the cord, and in 
the chronic phase to facilitate axonal regeneration. Experimental treatments delivered in the acute 
phase are more challenging to translate to human clinics given the difficulty selecting an appropriate 
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test population that does not unnecessarily expose patients who would otherwise recover with 
conventional treatment to experimental therapies. As such, interventions in the chronic phase of 
injury are perhaps more clinically applicable, and are the focus of this thesis.  
 
There has been wide investigation across many disciplines including cellular transplant35,36 (e.g. 
olfactory ensheathing cells, Schwann cells, neural stem/progenitor cells and mesenchymal stem cells), 
molecular therapies37 (including chondroitinase ABC, anti-Nogo antibodies), delivery of neurotrophic 
and/or growth factors and more recently an increase in the use of engineering approaches; both the 
use of electrical stimulation38 and tissue engineering and biomaterial implantation39–41. While many of 
these therapies have achieved some success experimentally, and some have even progressed to phase 
1 human clinical trials (olfactory ensheathing cell42 , Schwann cell transplant43 mesenchymal stem cell 
transplant44, and anti-Nogo-A antibodies45) there remains no reliable validated treatment on clinics. 
To achieve a clinically successful therapy for SCI it is widely accepted that a combination of therapeutic 
interventions will be required to combat the multi-faceted and complex pathophysiology seen in the 
spinal cord after injury46.  
 
1.2 Pathophysiology of Spinal Cord Injury 
1.2.1 Initial events after injury 
Initial trauma to the spinal cord, in the form of contusion, compression, laceration or less commonly 
ischaemic damage, inflicts direct neuronal and cellular injury. This primary injury also triggers a 
cascade of events causing a subsequent secondary injury to the cord that spreads further damage 
over an area much larger than that of the initial injury. This secondary injury is highly active through 
acute (<48 hours) and sub-acute (48 hours to 14 days) phases41,47, before stabilising into a chronic 
phase discussed in more detail below.  
 
The acute and sub-acute phases are driven by a number of different processes: (i) vascular disruption 
leads to poor perfusion and ischaemia, which can be followed by reperfusion injury, as well as oedema 
and necrosis; (ii) cell membrane disruption leads to ionic imbalance as well as glutamate release 
causing excitotoxicity, calcium influx, cell death and increased reactive oxidative species; (iii) damage 
from free radicals and many of the above processes trigger cell death through apoptosis; (iv) microglia 
and astrocytes resident within the spinal cord become activated and are recruited to the lesion, and; 
(v) vascular disruption allows invasion of systemic leucocytes (mainly macrophages) that release pro-
inflammatory cytokines (for reviews see8,41,48,49). Subsequent inflammation can have beneficial and 
damaging effects50–52, and its regulation in the acute and sub-acute phases is dynamic and complex53.  
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In addition, death of oligodendrocytes leads to demyelination of remaining axons41,50 and this 
demyelination – alongside initial death of neurons within the primary or secondary injury site – causes 
axon degeneration spreading from the lesion, with anterograde Wallerian degeneration and 
retrograde axonal dieback41,50,54.  
 
These cellular processes within the first few hours (e.g. microglial activation) to days (e.g. macrophage 
infiltration begins by 4 days) of injury51 are responsible for remodelling the spinal cord and creating 
the classic structure seen in the chronic phase after injury (see Figure 1-2). 
 
 
Figure 1-2. Illustration of processes occurring in acute and chronic phases after spinal cord injury  
(Katoh et al. 201941) 
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1.2.2 The injury environment in the chronic phase 
1.2.2.1 The glial scar 
One of the defining characteristics of the chronic phase of injury is the glial scar forming a border 
around a central non-cellular lesion cavity created by phagocytosis and removal of necrotic debris 
from cell death. This glial scar is able to maintain this barrier as it is largely composed of reactive 
hypertrophic astrocytes which form close gap and tight junctions between cells55, and it is thought 
necessary to restore the CNS-blood barrier and limit massive inflammation.  
 
Experimental ablation or disruption of the glial scar during its development in mice caused more 
widespread tissue damage, and an increase in demyelination and motor deficits compared to control 
animals following contusion56 and crush57 injuries, supporting this theory. Additionally, the glial scar 
is remarkably preserved through mammalian evolution58, suggesting a survival benefit.  
 
Despite its importance in this regard, it has been long been observed that in the chronic phase of 
injury the glial scar forms a structural and molecular barrier to axon regeneration59,60. There is more 
recent evidence, however, suggesting that the interaction between the astrocytic component of the 
glial scar and axons is not a complete explanation for lack of regeneration; after crush injury in mice, 
ablation of astrocytes 5 weeks after injury did not result in spontaneous axonal regeneration61.  
 
However, the glial scar contains more than astrocytes alone, and many other cell types and molecules 
within the glial scar have been shown to be inhibitory. Both mature oligodendrocytes and myelin 
(many fragments of which are present from demyelinating neurons) express molecules that are 
inhibitory to axon growth, e.g. nogo62,63 and myelin associated glycoprotein64. One of the key 
inhibitory components of the glial scar are chondroitin sulphate proteoglycans (CSPGs)55.   
 
1.2.2.2 Chondroitin sulphate proteoglycans 
CSPGs are macromolecules consisting of glycosaminoglycan (GAG) side-chains attached to a core 
protein forming a backbone. The most common GAGs include hyaluranon (which is found unbound in 
the CNS) and chondroitin sulphate found in repeating disaccharides65. There are a number of different 
CSPGs, defined by the core protein and the number and type of side chains and they can be found 
either in extracellular matrix (ECM) or on cell membranes. The main groups are lecticans (including 
aggrecan, versican, neurocan, brevican), phosphacan/receptor-type protein–tyrosine phosphatase β 
and the small leucine-rich proteoglycans decorin and biglycan)66.  
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CSPGs are normal constituents of the ECM of the spinal cord. Unlike most tissues in the body which 
consist of predominantly collagen and fibronectin, the spinal cord consists mainly of glycoproteins and 
proteoglycans67. These CSPGs are involved in the normal function of the adult CNS, particularly with 
cell migration, survival and differentiation66, and are important during development where they aid 
guidance of neural cells and create borders to prevent aberrant growth of developing fibres68. CSPGs 
also form a key part of perineuronal nets (PNNs); specialised dense areas of ECM sitting amongst glial 
cell processes and surrounding nerve cell bodies, dendrites and synapses69. The function of these 
PNNs is not entirely clear, although they appear to have a wide role throughout the CNS related to 
controlling plasticity; being involved in learning and memory and only fully forming at the end of the 
‘critical period’ in visual, motor and somatosensory systems70.   
 
After injury to the spinal cord CSPG levels increase. This is seen in rats from 24 hours until at least 6 
months after unilateral dorsal stab injury71 and dorsal column crush injury72,73, as well as thoracic 
contusion74 injury, although with some variation in the exact location, time-course and peak 
expression of the different types of CSPG dependent on injury (for a detailed review see Burnside et 
al. 201467).  These CSPGs appear to be produced mainly by reactive astrocytes in the glial scar75 but 
are secreted by all cell types in the CNS including macrophages, oligodendrocyte precursor cells and 
microglia76,77.  
 
This upregulation of CSPGs correlated precisely with abortive regeneration of dorsal root ganglion 
cells transplanted into white matter tracts of rat brain78, and CSPGs have been shown to inhibit axon 
growth in vitro. Dorsal root ganglion neurite outgrowth was reduced in a concentration dependent 
manner when CSPG was added to laminin or fibronectin substrates79.  Neurite length was reduced 
when grown in co-culture with inhibitory astrocyte lines, but increased again in the presence of a 
proteoglycan inhibitor80. Growth of retinal neurons increased over gliotic rodent explants when CSPGs 
were selectively degraded by chondroitinase ABC (chABC)81 – an enzyme which degrades GAG side 
chains and will be discussed in more detail as a potential therapeutic approach later (see section 1.5). 
The inhibitory effect of CSPGs appears therefore to be dependent on the GAG side-chains rather than 
the core protein82 and has been reported to be mediated through a number of receptors 
including protein tyrosine phosphatase sigma83, leucocyte common antigen-related phosphatase84, 
EGF receptor85 and Nogo receptors NgR1 and NgR386.  
 
Some interesting work suggests that rather than the presumed repulsion effect CSPGs have on 
regenerating axons, their inhibitory action may actually be due to conversion of growth cones into 
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dystrophic axons via protein tyrosine phosphatase sigma and an increased adhesion of these axons to 
CSPGs87,88, likely via GAGs as chABC ‘releases’ these axons89. This may also explain why CSPG inhibition 
of neurite growth is relative rather than absolute in that increasing laminin can overwhelm CSPG 
presence, at least in vitro90. This has relevance to the in vivo situation where there is likely to be a 
balance between inhibitory substrates and permissive factors that is as yet poorly understood91.  
 
1.2.2.3 Lack of support for regeneration  
One of the key ‘macro’ barriers to regeneration is the large, cystic, non-cellular lesion core within the 
glial scar where there is complete absence of structure or supportive matrix for axon (or cellular) 
growth. Intuitively, it can be seen that even in the absence of any active inhibition, axons will not be 
able to bridge this space. Indeed, in the study above61, where ablation of the chronic astrocytic scar 
did not lead to axon regeneration, an implant of growth factors and hydrogel providing a supportive 
structure and more pro-regenerative environment did lead to axon growth. Hydrogel biomaterials and 
replacement ECM or structural support will be discussed in more detail later (see section 1.6).  
 
In summary, in the chronic phase of injury there are a number of factors that limit axon regeneration; 
both factors intrinsic to neurons, and extrinsic in terms of inhibitory ECM and lack of facilitatory 
molecular factors or physical structural substrates. This presumed balance between inhibitory and 
pro-regenerative factors within the SCI environment is important to consider in the context of 
potential treatments. 
 
1.3 Animals models of spinal cord injury 
There are a wide range of animal models of SCI used to investigate experimental treatments for SCI, 
across different species and with different injury types.  
 
1.3.1 Rodent models of spinal cord injury 
Mice and rats are the most common animals used SCI research. They are cheap and easily accessible 
by most researchers, compared to large animal models or clinical situations discussed below. Injury 
paradigms are often well-developed and produce relatively consistent, homogenous lesions meaning 
less variation within and between experimental groups, therefore lowering the number of animals 
required to discriminate statistically significant differences. The ethical framework for rodents is well 
established to allow a number of interventions more difficult in clinical situations, such as genetic 
modification, and transgenic lines in mice are available which can provide important mechanistic 
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insights.  Established behavioural paradigms allow for quantifiable functional analysis and there are 
readily available immunohistochemistry approaches and reagents (e.g. verified antibodies).  
 
A number of types of injury are used, commonly transections, crush injuries (e.g. using forceps), 
compression injuries (e.g. using clips), contusion injuries using force impactors or weight drops92, or 
chemical injuries (for a review see92). These can be more localised affecting only a specific tract (e.g. 
dorsal column crush injury specifically ablating the dorsal CST) or more widespread (e.g. high force 
thoracolumbar contusion injuries). The impact of these injuries on the animal is also determined by 
the location in the spinal cord – high severity complete injuries could not be used in cervical cord as 
the animal’s respiratory function would likely be compromised and the animal would not survive.  
 
1.3.1.1 Behavioural testing in rodent models of spinal cord injury 
Behaviour testing giving an indication of functional recovery is, from a clinical perspective, the most 
important outcome after a SCI intervention. The type and localisation of injury impacts on what 
functional or behaviour testing is most important or relevant to use; walking and bladder function 
after thoracolumbar injury, and respiratory or forepaw function after cervical injury. There are, 
however, a number of issues surrounding behavioural testing which need to be considered.  
 
Firstly, although injuries are generally consistent and well-characterised93, severity of injury is not 
necessarily closely predictive of behavioural function. For example a study which varied the 
percentage unilateral hemisection of the spinal cord at C4 and then tested recovery of forepaw pellet 
retrieval found no correlation between lesion extent and pellet retrieval94, with particularly variable 
results where lesion sizes were 15-40% of cross sectional area.  
 
Secondly, there is limited standardisation of testing with refinements and adaptations to tests 
between labs – made for good reasons – making comparison of results difficult95. Even where standard 
tests exist, for example in the case of fore paw reaching with Montoya staircase96 and Whishaw 
reaching tasks97 (discussed in more detail in Chapter 3) the presence of multiple tests of the same 
behaviour can limit comparison. For walking recovery after thoracolumbar (originally T9) contusion, 
the Basso-Beattie-Bresnahan (BBB) open field locomotion score98 is widely used and considered 
standard, at least allowing effective comparison between studies. However, even in this case caution 
must be taken as it has been shown that the BBB score is non-linear with clustering of animals at 
different scores during recovery that may mask differences between intervention groups99. More 
quantitative aspects of gait analysis can also be used to assess aspects of walking ability in a more 
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continuous manner, whether simply done using ink and paper or with more technologically advanced 
techniques for example by using the digitised “CatWalk” system100 or by advanced image analysis of 
high-speed video101.  
 
Thirdly, behavioural assessment can be – to some degree – subjective, meaning that unintentional 
bias of an experimenter can have a large effect on results102. This highlights the importance of 
randomisation and blinding, alongside appropriate controls, when interpreting results. Indeed, meta-
analysis of an intervention in rodent models of stroke shows a significant reduction in effect size for 
studies reporting blinding and randomisation103 and a meta-analysis of olfactory ensheathing  cell 
transplantation after SCI in rats104 (discussed in more detail later, see section 1.4) shows a significant 
effect of blinding.  
 
Finally, an animal’s performance, even when measured objectively on the same test, is influenced by 
stress and environmental factors which can be very difficult to control. For example, it has been shown 
that the sex of the researcher handling animals can affect results105 and that housing animals in the 
same room as a group that has just had surgery is enough to reduce forepaw reaching success rate95.  
 
1.3.1.2 Translational barriers from animal models 
Rodent injury models are incredibly useful and have allowed detailed study of SCI and potential 
therapies, demonstrating proof-of-concept and allowing some of these to progress to clinical trials42–
45,106. However it is clear, in part due to the lack of any of these interventions to go on and show robust 
improvements in humans after SCI in phase 2 trials, that there is a barrier in translation from therapies 
successful in rodents to humans. There are a number of possible reasons for this, some of which relate 
to limitations inherent in the use of rodents.  
 
The type of injury is likely important. Complete transection injuries are quite commonly used in 
rodents, but are rare in clinical lesions, which are more commonly contusive with some fibres surviving 
at the periphery of the lesion107. There are key species differences to bear in mind. In mice, there is a 
suggestion that regeneration can occur after transection injuries108, which does not occur in rats or 
humans93. Even after contusion injuries, mice also tend to have cell proliferation after injury with 
minimal cystic lesion formation109. Interventions in animal models are also often made in the acute 
phase as this is considerably simpler. This is clearly appropriate for initial proof-of-concept studies, 
but the acute and chronic environment after SCI is significantly different and it is the chronic 
environment in which therapies would be most likely trialled in humans.  
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Ultimately, rodent testing is vital to test potential therapies, but its limitations, and the limitations of 
each model must be understood. Testing in multiple models is important as differing results can 
advance understanding of mechanistic processes, for example single high-dose injection of chABC into 
spinal cord lesions showed axonal regeneration in hemisection but not contusion injuries110. Testing 
in multiple models can potentially also aid in guiding translation to clinics by determining which types 
of injuries certain interventions are most likely to be most efficacious in. Indeed, a survey of 27 SCI 
researchers reported that potential therapies should be tested in more than one model, including a 
large animal and contusion model, and independently replicated in a second lab106.  
 
1.3.2 Large animal models of spinal cord injury 
Experimental cats111, dogs112 and monkeys113 have been used as large animal models of SCI. Their 
weight, and therefore spinal cord and SCI lesion size114, is around an order of magnitude larger than 
rats and closer to the size of human injury. The physical size of the spinal cord lesion, including the 
volume of the cystic cavity, and therefore the distance required of axon regeneration is considered 
one of the translational barriers between rodent experimental work and human clinical work5. Scaling 
and dosing questions, particularly with cell transplant paradigms, also make these models important. 
Monkeys, particularly, are immunologically most similar to humans115 meaning they are an important 
step for translation to human clinics, again particularly in cell transplantation paradigms where cell 
rejection may be a concern, as well as in immunomodulatory approaches. Ethical concerns around the 
use of primates, and the expense and facilities required for this type of research, however, mean it is 
necessarily limited.  
 
1.3.2.1 Canine clinical model of spinal cord injury 
As mentioned earlier dogs have naturally occurring SCI often related to disc disease, which is a 
common presentation to neurology departments at veterinary referral hospitals116. This disc disease 
is normally either due to age-related or breed associated degeneration of the nucleus pulposus 
(chondroid metaplasia)32 which eventually leads to intervertebral disc herniation upwards into the 
ventral spinal cord (for a review, see Jeffery et al. 2013117). Although the most common cause of SCI 
in humans is external trauma (e.g. road traffic accident) both this and disc injury cause mixed 
compressive-contusive forces to the spinal cord with a resulting similar pathology between dogs and 
humans in chronic SCI107,118–120 (see Figure 1-3).  
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Figure 1-3. Comparison of histopathology of canine and human spinal cord injury 
Transverse sections from canine (A) and human (B) spinal cord at different time points after injury show similar 
disruption of tissue architecture. Scale bar A = 1mm, B = 2mm. (Smith and Jeffery 2006119 and Norenberg et al. 
2004107 as adapted by Carwardine 2017121)  
 
This clinical trauma in dogs results in heterogenous lesions, distinct from the more homogeneous 
lesions seen in rodent experimental injuries. For a number of years it has been suggested that this 
provides an opportunity to test pre-clinical experimental therapies in a more translational, clinically 
relevant (to humans) lesion and to establish if an intervention showing a statistically significant 
difference in the lab is able to elicit a clinically relevant effect114. These dogs can have behavioural 
testing similar to rodent models, with established locomotor scores122 and kinematic gait analysis123, 
and with scope for histopathology at an earlier time-point than human patients114. Demonstrating an 
effect in these dogs also shows a treatment is robust enough to trigger a functional change that can 
be seen above the noise of more variable ages, sexes and co-morbidities seen in the clinical situation 
as compared to experimental rodents.  
 
These pet dogs therefore represent an available cohort of animals with naturally occurring injury to 
the spinal cord which otherwise have incurable paraplegia and incontinence. They provide a 
translational model that allows investigation of SCI and ‘screening’ of potential experimental therapies 
in a more clinically relevant situation. Presence of heterogenous injuries, variation in age and 
concomitant co-morbidities test an intervention for clinically relevant efficacy beyond the statistical 
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improvement that is tested in more homogenous pre-clinical models; they allow testing of therapies 
from the ‘lab’ in the ‘Labrador’, to translate ‘bench’ therapies to the ‘bedside’! A number of trials have 
been conducted in this model120 and more are planned124. One of the most well-publicised, and part 
of the motivation for this thesis, involved transplantation of olfactory ensheathing cells (OECs)123.  
 
1.4 Olfactory Ensheathing Cells 
Olfactory ensheathing cells (OECs) are one of the most promising cell transplant therapies for SCI (for 
reviews see35,125). They have been shown to facilitate functional recovery in rodents after transplant 
into sites of SCI, with perhaps the most robust evidence coming from 2 large independent meta-
analyses that both found significant functional improvements after transplant. One meta-analysis 
determined an average improvement of 20.3% in BBB score126, whilst the other found a large effect 
of transplant on walking and forepaw reaching combined (standard mean difference of 1.36 between 
control and transplanted animals across all studies)104 – where a large effect is defined as standard 
mean difference (or Cohen’s d) >0.8127.  
 
Olfactory ensheathing cells have been tested in a randomised double-blinded trial in the canine 
translational model showing a ~20% improvement in fore-hind limb coordination, remarkably 
consistent with the meta-analysis BBB improvement.  Olfactory ensheathing cells have also been used 
in humans in a number of phase 1 trials128–132 with some reported improvements132,133, however 
differences in methods between studies, particularly intensive rehabilitation in some treatment 
groups, and lack of control groups make these trials difficult to interpret. A recent meta-analysis of 
nearly 1200 transplanted patients did show an overall AIS improvement rate of 39%, as well as 
improvements in motor, light touch and pin prick scores in transplanted patients, implying some 
efficacy of OEC transplant, but the main conclusion that can be taken from these studies is that OEC 
transplantation into the spinal cord in humans is safe42.  
 
However, it is important to note that risks remain. In the above meta-analysis42 the adverse event rate 
was ~7.7%, with the most common event being CSF leakage (~7.0%). More serious adverse events 
including death (0.35%), lung infection (0.18%) and sensory deterioration (0.7%) are also reported. 
There have also been 3 reports (4 cases) of intramedullary spinal masses up to 10 years after OEC 
transplantation in people134–136, although all these patients received transplant of olfactory mucosa 
without purification of OECs and the masses were histologically consistent with ectopic mucosa.  
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Despite the lack of robust human trials of OEC transplantation there has been widespread publicity, 
and arguably hype, about their potential (as well as that of stem cells generally). There is ongoing 
concern that the gap between this reporting and the unmet clinical need of patients drives potentially 
vulnerable people to “stem cell tourism”; travelling abroad for unregulated procedures where they 
are not fully informed of the risks of an intervention, or likely chance of success, and may not have 
appropriate follow-up care137,138.  
 
1.4.1 Normal physiology of olfactory ensheathing cells 
One of the main advantages of OECs, which has in part allowed their progression to human trials, is 
the ability to relatively non-invasively access the cells for autologous transplantation. They are found 
in olfactory mucosa (OM) and in the olfactory bulb (OB) so, rarely for glial cells, are found in both the 
peripheral and central nervous system. 
 
Their normal function is to facilitate growth and regeneration of olfactory neurons. Olfactory neurons 
are of particular interest due to their unique capacity to regenerate through life and repair after 
injury139, with their axons growing from basal cells in the olfactory epithelium through the lamina 
propria and into the olfactory bulb140. This transition zone from peripheral to central nervous system 
is populated by OECs141 where these cells are believed to aid damaged olfactory neurons re-innervate 
central neurons142. It is this capacity of OECs that triggered initial excitement in the potential of OEC 
transplant as a therapy for SCI (discussed later, see section 1.4.2).  
 
1.4.1.1 Culture and identification of OECs 
Olfactory mucosa contains high numbers of OECs, as distinct from respiratory epithelium which lines 
the rest of the nasal cavity143,144, and in the dog can be identified by its more yellow/brown colour 
compared to the rest of the nasal lining145. These easily identifiable areas provide a readily clinically 
accessibly source of OECs in the dog, avoiding the need for craniotomy to access the OB145. Non-
invasive access to the OM by nasal endoscopic biopsy has been shown to provide sufficient OECs for 
transplantation in dogs (consistently providing ~5 million cells with ~70% OECs), similar to a keyhole 
frontal sinus approach146. Nasal endoscopic biopsy to obtain OECs has also been demonstrated safe in 
humans, with no impact on nasal function or reduction in sense of smell147.  
 
As mentioned above, around 70% of the cells in these canine primary OM cultures are identified as 
OECs at 21 days of culture. The other cell types found in OM, and therefore potentially present in 
these cultures are endothelial cells, smooth muscle cells, olfactory neurons, Schwann cells, olfactory 
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nerve fibroblasts and the more recently identified putative OM mesenchymal stem cells (MSCs)148,149. 
Careful dissection during cell processing to remove connective tissue and blood vessels reduces the 
numbers of these ‘contaminant’ cells in culture. In addition, a number of purification steps have been 
demonstrated to increase OEC proportion in culture. These range from relatively simple steps to 
differentially trypsinise OECs by taking advantage of their lesser attachment strength compared to 
fibroblasts150,151, through modifications to culture media where OECs preferentially grow in serum-
free media152, to more complex purification processes using immunopanning, fluorescence-activated 
cell sorting or magnetic nanoparticles (for a review see Higginson and Barnett 2011153).  
 
Olfactory ensheathing cells have a characteristic appearance in culture; they are spindle shaped with 
long fine processes. This makes them fairly easy to distinguish from fibroblasts, which tend to be larger 
and rounder with few, short processes. They are, however, fairly similar in appearance to Schwann 
cells. While Schwann cells can also to some degree be minimised in culture by dissection and removal 
of blood vessels from the biopsy sample (Schwann cells will mostly be found in peripheral nerves 
running alongside these vessels)146, many markers used to identify OECs are also common to Schwann 
cells making precise characterisation of culture populations challenging. Schwann cells and OECs can 
both express nerve growth factor receptor p75 (p75), S100ß protein, glial fibrillary acidic protein 
(GFAP) and cell-adhesion molecule NCAM153,154. These markers are further variable in culture (e.g. 
fibronectin has been reported to be expressed in vitro but not in vivo155) and are dependent on culture 
conditions156–158 (for a review, see Kawaja et al. 2009154) and precise source, e.g. OM or OB, of cells159. 
The assumption made by most groups, and made in this thesis, is that p75-positive cells in this culture 
population will be OECs due to the means of sourcing and culturing the cells and the high proportion 
of OECs in the clearly identifiable source biopsy location (OM)146,154. 
 
It is important to bear in mind that although from a scientific and mechanistic research perspective it 
would clearly be desirable to fully characterise the transplant population and be able to purify OECs, 
the other ‘contaminant’ cells in culture may also have therapeutic benefit on their own, particularly 
OM MSCs160. It has also been shown that transplantation of mixed cultures of ~50% fibroblasts and 
OECs have beneficial effects on forepaw reaching in rats after transplant at the time of injury161 and 
following transplant 8 weeks after injury162, and even that cultures with up to 95% fibroblasts can have 
similar beneficial effects on directed forepaw in the acute phase163.  
 
While canine OECs are the focus of investigation in this thesis, it is worth noting that there are species 
differences reported between OECs, particularly in terms of their in vitro behaviour. Specifically, unlike 
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rodent OECs, primate and human OECs do not require mitogens for in vitro expansion, do not become 
senescent as rapidly, do not respond to increases in cAMP and stably express p75164. Canine OECs are 
reported to be more similar to human OECs in that they also proliferate for multiple passages in the 
absence of growth factors and do not become senescent until at least 3 months in culture165 (for a 
review see Wewetzer et al. 2011166). It has been reported that human OECs transplanted into a rat 
contusion model show more marked improvements in walking ability (BBB score) than rodent OECs in 
similar testing167, but the various difference in precise source of cells (species and OM or OB) and 
culture conditions make this sort of comparison very challenging; this will be discussed in further detail 
below.  
 
1.4.2 Efficacy of OECs in rodent models of SCI 
The possibility that OECs might provide benefit for regeneration of the spinal cord after injury has 
been studied for over 25 years since it was demonstrated that the dorsal root at T10 could project 
axons, alongside migrating OECs, into the contralateral spinal cord grey matter after rhizotomy168. 
Evidence of regeneration of the CST in the spinal cord followed a few years later when recovery of 
forepaw reaching was shown by the Raisman group in animals where OECs transplanted at the time 
of unilateral cervical CST transection created a ‘continuous bridge’ across the lesion site169. This 
‘bridge’ histology was also shown after a cervical electrolytic lesion by the same group a year later170.  
 
Since these studies there has been ongoing research into the efficacy of OEC transplant with OECs 
derived from both OB and OM171. There is robust evidence from rodent models that OECs promote 
axonal regeneration, with reports across multiple lesion types including electrolytic CST lesions170, 
hemisection161, transection172 and contusion173 lesions including chronic transections174. Additionally 
OECs have been shown to: promote functional reconnection of axons as shown by 
electrophysiology175; have tissue sparing effects176 and reduce glial scar and cavity formation177; 
reduce CSPG expression176; remyelinate damaged axons178–180; and phagocytose axonal fragments and 
modulate the immune response181. Functional behavioural outcomes have also been shown to be 
improved by OEC transplant following SCI in multiple rodent models161,169,172,176, including after 
transplant in the chronic phase of injury162,179. Specifically, OECs have been shown to: improve directed 
forepaw reaching after acute169 and chronic162 transplant; improve breathing movement and phrenic 
nerve activity161; increase voluntary hindlimb movement and weight bearing172; improve climbing 
skill161,172; and improve walking as assessed by BBB score176,179,182. 
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However, not all these findings are consistently reported, or always reproducible. For example, a 
carefully controlled, blinded study in rats was conducted in which OM samples containing OECs were 
transplanted 4 weeks after T10 transection, resulting in an increased BBB score and increased number 
of serotonin (5HT) fibres caudal to the lesion compared to control rats (receiving respiratory 
epithelium transplants)179. On exact replication of method, no difference in BBB scores or 5HT fibres 
was seen183. Serotonergic fibres caudal to rat transection injury have been reported in other studies 
as well172,184, but is not consistent even when functional recovery is still observed185. Differential 
regeneration of fibres is seen, for example after xenotransplant of primate OECs into nude rat T9/10 
transection 5HT but not CST regeneration was noted, alongside BBB improvement186. Similarly no CST 
regeneration, but also no BBB improvement, was seen after rat OB OEC transplant within a fibroblast 
biomatrix 4 weeks after a dorsal hemisection187 (for comprehensive reviews of OEC rodent studies see 
Richter and Roskams 2008188, Tetzlaff et al. 201135, Gomez et al. 2018159).  
 
Much of the difficulty in interpreting these results come from differences in study design. Meta-
analyses have shown significant effects of injury type and location, timing of cell transplant (acute, 
sub-acute, chronic) cell source (OB or OM OECs), species of cells (autologous/allogenic or 
xenotransplant) and precise method of transplant (e.g. volume and number of injections, number of 
cells injected, dissection of spinal cord scar tissue at time of transplant)104,126. The weight of evidence 
in the literature suggests that OEC transplantation is beneficial to functional outcomes, and both 
meta-analyses highlighted above suggest publication bias is minimal104,126, but the number of variables 
possible, and approaches reported in the literature mean that OEC efficacy is best considered in the 
context of more specific parameters, e.g. lesion type and location. As such, evidence related 
specifically to cervical injury and forepaw reaching, and thoracolumbar contusion injury and walking 
ability will be discussed in more detail in relevant chapters of this thesis (chapters 3 and 4 
respectively).  
 
1.4.2.1 Proposed mechanisms of action of OECs 
Despite the huge body of literature, and in part due to the variation in study design, the mechanism 
by which OECs exert their functional benefits in experimental models is not clear. One of the original 
hypotheses proposed that OECs were able to provide ‘pathway’ channels providing structural support 
to regenerating axons, and that through their unique interaction with astrocytes could ‘open a door’ 
back into the CNS as per their innate function in the olfactory system189. Early evidence supporting 
this theory showed histological images of regenerating axons encompassed by olfactory bulb OECs 
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(transplanted as a mixed population with fibroblasts) as they extended through lesion areas, and 
correlated this to increased forelimb reaching or hind limb movement169,170,172.  
 
Later evidence (some from the same Raisman group) showed, however, that recovery of forepaw 
reaching could be seen even when regeneration of axons across the lesion was not seen after OEC 
transplant163. In a dorsal column transection rat model, ‘bridging’ of the lesion by OECs was seen 
within 1 hour of transplant raising questions that some migration and bridging of OECs may be related 
to physical injection forces190. Even when OECs bridge the lesion, long tract axons are not always seen 
to extend with them across the lesion190, although it must be noted there is some compelling evidence 
for a return of long-tract axons in a study where motor evoked potentials returned with OEC 
transplantation after transection and then were abolished by re-transection at the lesion191. However, 
there is certainly evidence that mechanisms other than the suggested ‘pathway’ hypothesis may also 
mediate the functional effects of OECs.  
 
Firstly, there is evidence that OECs increase plasticity and sprouting either side of the lesion192 and 
this can lead to functional improvement193,194 particularly in incomplete lesions (although these 
studies used modified OECs). The importance of plasticity and spared axons will be considered in more 
detail in the next section.  
 
Secondly, OECs are also known to express and secrete a number of pro-regenerative neurotrophic 
factors, adhesion molecules, cytokines and proteases that may be important for axonal regeneration 
(for a full review see Gomez et al. 2018159). In particular rat OECs (in vitro) express matrix 
metalloproteases including MMP2195, which digest CSPGs196. They also secrete glial cell-derived 
neurotrophic factor, nerve growth factor, and to a lesser extent brain derived neurotrophic factor197, 
which increases axon outgrowth from retinal neurons in vitro198. Interestingly OECs also secrete 
neuregulin (in a clonal cell line in vitro)199; neuregulin is known to facilitate OEC growth as it is used in 
OEC culture media123,152 and has recently been shown to regulate a number of CNS injury and repair 
processes200 including increase remyelination201.  
 
These mechanisms are not mutually exclusive, and it is perhaps likely there is a combination of factors 
contributing to repair. For example, it has been suggested that OECs migrate ahead of axons as they 
develop, releasing neurotrophic factors which stimulate growth202. Migration of OECs is therefore 
believed to be important to their function, and different sub-populations of OECs have been shown 
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to have different migratory properties (e.g. OB-OECs migrate faster than OM-OECs203) with the 
suggestion that this may impact on their regenerative capacity.  
 
1.4.2.2 Limitations of OEC transplantation 
Despite the unclear mechanism of action, the weight of evidence in rodents is supportive that OECs 
provide a functional benefit after SCI. As mentioned, OECs have also been shown safe in phase 1 
human trials but there has clearly been a barrier to translation of OECs, with efficacy not 
demonstrated in human clinical patients. A lack of standardised biopsy and culture conditions or 
robust identification of OECs might raise regulatory concerns and may be a source of the variation in 
pre-clinical experimental studies, for example with longer-term cultured OECs showing less 
regenerative ability204, but the canine trial in pet dogs with chronic injuries to the spinal cord highlights 
the main issues of translation. Improvements in walking in terms of fore-hindlimb coordination were 
seen, but these were relatively limited (although clinically significant and allowing ambulation in some 
cases) and no evidence of long tract axon regeneration was seen (no improvement in motor or 
somatosensory evoked potentials)123. Additionally, cell survival at 3-6 months after transplant was low 
with only few scant cells found 3-6 months after transplantation of ~5 million cells.  
 
Cell survival is one of the main limitations of cell transplant therapies for SCI generally, with cells 
surviving poorly in the active inflammatory environment of the injured spinal cord48. This is particularly 
true of xenotransplant cells where a graft versus host reaction can occur unless appropriate 
immunosuppression (or athymic experimental animals) are used. In rodents, low OEC survival is 
reported even in allogenic transplants with 3.1% of transplanted cells reported to survive at 3 weeks205 
and 2.3% at 2 months206 after transplant into contusion injury. OECs do not seem to proliferate after 
transplantation into spinal cord lesions (in dogs123, humans42 and laboratory rodents205,207). There is 
evidence that absolute OEC number and survival is important with suggestion of a dose-response 
effect of increasing cell number relating to increased functional outcome in meta-analysis126. 
Approaches to improve cell delivery and survival in this hostile environment, for example through 
encapsulation within hydrogel biomaterials are therefore important. These will be discussed later (see 
section 1.6) and form part of the investigation of this thesis.  
 
Although OECs modulate the environment of injured spinal cord to some degree, as discussed above 
through release of pro-regenerative factors and immunomodulation, they show minimal anti-
inhibitory effects. It seems reasonable then that any combination therapy with OECs should be 
focussed on reducing the inhibitory environment of SCI, for example with chondroitinase ABC (chABC).  
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1.5 Chondroitinase ABC 
Chondroitinase ABC (chABC) is another of the most promising experimental treatments for SCI, and 
acts to digest CSPGs which are known to be inhibitory to axon regeneration (see section 1.2.2.2). There 
is no meta-analysis available for chABC use in SCI, nor have there yet been any human clinical trials in 
SCI. There has, however, been a recent phase 2 randomised and blinded canine clinical trial showing 
a 23% improvement in fore-hindlimb coordination and 10% (3 of 30) of dogs receiving chABC 
recovered independent ambulation (no control dogs recovered ambulation)208. The pre-clinical 
evidence for chABC is strong, with functional recovery seen in rodents after multiple injury types 
including crush209, transection210 and the more directly clinically relevant contusion injury211,212 as well 
as after delivery in both the acute and chronic213,214 phases of injury. These functional benefits have 
been replicated across multiple laboratories, and have also been seen in large animal experimental 
models in cats111,215,216 and non-human primates113,217. Recent reports of phase 2/3 human trials of 
chABC for lumbar disc herniation showing no adverse effects, including no immunological reaction to 
chABC and no detectable plasma concentrations after injection into discs218,219, are promising for 
future human trials in SCI.   
 
1.5.1 Digestion of chondroitin sulphate proteoglycans  
Chondroitinase ABC is a bacterial enzyme derived from Proteus vulgaris that digests CSPGs by cleaving 
the GAG chondroitin sulphate side-chains at their glycosidic bond into soluble disaccharides or 
tetrasaccharides220. Chondroitinase ABC also digest small amounts of hyaluronic acid dermatan 
sulphate (previously known as chondroitin sulphate B)221,222.  
 
The effect on axon growth over CSPG substrates of chABC was first demonstrated in vitro using chick 
retinal ganglion cells, with increased neurite outgrowth over CNS gliotic scars after application of 
chABC81. This same effect was replicated with increased chick retinal ganglion cell neurite outgrowth 
over sections from injured spinal cord after chABC application223 and with dorsal root ganglion cells in 
co-culture with inhibitory astrocytic cell lines82.  
 
In vivo digestion of CSPGs surrounding CNS injury was first demonstrated in the rat brain (nigrostriatal 
tract)224 and shortly afterwards in the spinal cord after cervical dorsal column crush209. After a single 
injection of chABC in vivo into rat nigrostriatum, digestion of GAGs was present by 24 hours and chABC 
activity could be detected for 10 days, although a maximum of 50% of the GAG content was 
digested225. In vitro, however, it has been shown that chABC activity is significantly reduced by 3 days 
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at body temperature (37°C), with complete loss of activity by 7 days and variation between batches 
of enzyme meaning some batches lost activity sooner than this226.  
 
The consensus opinion is that clinical treatment with chABC would require longer-term delivery than 
a single injection of chABC provides227, and this loss of activity at body temperature would therefore 
necessitate repeated injection of chABC, or intrathecal pump administration. This is feasible in 
experimental animals and has been shown to improve regeneration of CST axons and locomotion209 
and forepaw reaching228 in rats, but on clinics such repeated bolus delivery risks iatrogenic damage to 
any remaining functional axons and increases the risk of infection thus limiting its use. As such, 
considerable research has been invested in alternative delivery methods of chABC.  
 
1.5.2 Delivery of chondroitinase ABC 
The conceptually simplest approach to longer-term delivery of chABC is through thermostabilisation 
and preventing or reducing its degradation at 37°C. This has been achieved by molecular stabilisation 
with sugars, both trehalose and sucrose. Sucrose stabilisation has been reported most recently, with 
chABC remaining active for 14 days in vitro229. This study also demonstrated a slight improvement in 
BBB score after single injection of sucrose stabilised chABC 4 weeks after thoracolumbar contusion 
injury. This is encouraging given the severity of the lesion and treatment in the chronic phase. 
Stabilising chABC in trehalose and embedding in lipid microtubules similarly increases in vitro activity 
to 15 days230, and this preparation was used in the canine trial mentioned earlier (severe clinical 
injuries with delivery in chronic phase of injury) which showed some improvement in fore-hindlimb 
coordination208.  
 
Stabilisation of chABC within biomaterial hydrogels has also been demonstrated (biomaterials and 
hydrogels will be described further in section 1.6). For example, a cross-linked methyl cellulose 
hydrogel has been reported to give sustained release of chABC for 14 days, digesting CSPGs in vivo 
after thoracolumbar clip compression but showing no effect on BBB score231. Other synthetic 
preparations have been reported which stabilise chABC for 10-14 days but these also show minimal 
improvement in BBB score when delivered in the acute phase after transection injuries (for a review 
see Muir et al. 2019232). It is possible these preparations do not deliver sufficient chABC to effect 
functional change.  
 
Gene therapy has proved a robust means of providing long-term chABC within the spinal cord and has 
been used widely in experimental models. Proof of principle of this approach was first demonstrated 
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by in vitro transduction with an adenoviral vector of an astrocytoma cell line which secreted active 
chABC and increased neurite outgrowth across CSPG substrates233. However, the quantity of secreted 
chABC was considered low and further progression of gene therapy work was made possible by 
modification of the bacterial chondroitinase ABC gene such that it can be expressed from mammalian 
cells more efficiently; by addition of a mammalian signal sequence for secretion (mouse matrix 
metalloprotease 2), an optimised Kozak sequence and removal of certain N-glycosylation sites which 
would otherwise prevent secretion in eukaryote cells234. Transduction of many or all cells at the injury 
site (or site of viral vector injection) means that chABC can be continuously produced in relatively high 
concentrations, essentially indefinitely, and potentially across a wide area. This has been 
demonstrated in thoracolumbar and cervical contusion models in rats with accompanying functional 
improvement211,212.  
 
A more temporally controlled viral delivery of chABC, which may be more acceptable to regulatory 
bodies for delivery on clinics, has been developed using a tetracycline responsive element (TRE) to 
control chABC expression using doxycycline235. This also shows widespread digestion of CSPGs and 
functional improvement in forepaw reaching after cervical contusion injury. This doxycycline inducible 
system will be an important research tool to investigate the effect of temporal delivery of chABC and 
what time-period of chABC is required for functional recovery and could be applied to a number of 
models of injury.  
 
The final method of chABC delivery reported is via transplant of cells modified such that they 
constitutively express chABC, providing a combined treatment and possible synergistic effects. This 
approach has been reported in Schwann cells which were modified by lentiviral transduction to 
express either chABC or neurotrophin. Allogenic rat Schwann cells were transplanted at 7 days after 
thoracolumbar contusion injury and showed increased axon regeneration but little effect on BBB 
score236. This approach has also been the focus of our laboratory using lentiviral transduction of canine 
OECs such that they constitutively express chABC, and we have demonstrated expression of chABC in 
vitro237 and digestion of CSPGs and increased axonal sprouting in vivo after xenotransplant into 
athymic rats at the time of dorsal column crush injury238. Investigation of functional recovery after 
transplant of these cells is one of the focusses of investigation of this thesis and will be discussed in 
chapters 3 and 4.  
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1.5.3 Mechanism of action of chondroitinase ABC 
The above delivery methods have all been tested in animal models leading to a wide literature on the 
efficacy of chABC after SCI and its potential mechanisms of action.  
 
Initial studies of in vivo application of chABC in SCI reported axonal regeneration after unilateral 
thoracolumbar210 and cervical239 hemisection, thoracolumbar contusion240 and cervical dorsal column 
crush injuries209. In chABC treated animals in this final study, growth cone tips were noted on axons 
indicating regeneration, axons were seen 4mm past the lesion site, and electrophysiological recording 
showed functional reconnection. All these studies applied chABC in the acute phase of injury.  
 
Despite this evidence, questions have since been raised about both whether ‘true’ axon regeneration 
is seen with chABC, and what the relevance of this regeneration might be to functional recovery given 
regenerating axons rarely extend more than a few millimetres past the lesion and are rarely shown to 
make functional connections241. Accurate detection of regeneration is controversial, and it has been 
suggested that collateral sprouting of spared axons around incomplete lesions could be mistaken for 
axons regenerating through the lesion. This sprouting and altered plasticity may allow functional 
recovery in its own right through the generation of alternate long-tract or propriospinal pathways242 
(see Figure 1-4).  
 
Sprouting and increased plasticity might arise due to chABC degradation of CSPG GAGs which are 
upregulated after SCI and known to be inhibitory to axon growth, i.e. their degradation allows the 
return of the limited regeneration potential of CNS neurons. Additionally however, chABC degrades 
the PNNs that surround neurons in the adult CNS (see section 1.2.2.2) and this may return axons to a 
more plastic, developmental state243.  
 
There is certainly significant evidence that sprouting occurs with chABC. In normal and injured (dorsal 
column crush) spinal cord, sprouting of 5HT and CST tracts respectively was seen after chABC 
administration244. This sprouting has also been related to functional recovery, for example in a mouse 
pyramidotomy model, chABC restored forepaw function accompanied by sprouting across the midline 
in brainstem and spinal cord245. In a rat dorsal column crush injury, repeated bolus administration of 
chABC and rehabilitation was shown to improve forepaw reaching and grasping, and increased 
sprouting of the CST was seen246. Sprouting after chABC has also been noted in a large animal model 
after hemisection injury in cats where functional recovery was seen111. More direct evidence linking 
sprouting and functional recovery was seen in rats after dorsal column transection where anatomical 
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axon tracing and electrophysiology receptive field mapping showed increased areas of innervation to 
the brain in the presence of chABC247. In a rat dorsal root rhizotomy model where only the C7 root is 
spared alongside rhizotomy to the rest of the C5-T1 roots, chABC restored forepaw sensation with no 
regeneration of afferents through rhizotomised roots, only spinal sprouting and reorganisation at 
C7248. Finally, and most recently, application of chABC in the chronic phase of injury was able to restore 




Figure 1-4. A diagrammatic representation of sprouting and regeneration of axons after an incomplete 
injury   
(Blesch and Tuszynski 2009242) 
 
It is important to note that this increased sprouting and plasticity could potentially cause neuropathic 
pain or hyperalgesia through maladaptive remodelling, although this has not been seen in numerous 
rodent models including over long-term (3-month) expression211,244 nor in the canine trial where it was 
specifically tested for with von Frey filaments over 6 months208. 
 
In addition to the mechanisms described above, chABC has been shown to modulate the immune 
system,  specifically by macrophage type conversion to favour M2 macrophages, increased anti-
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inflammatory cytokine IL-10 expression and reduced pro-inflammatory cytokine IL-12ß expression250. 
Additionally, the disaccharide digestion products of CSPGs have been shown to have anti-
inflammatory properties, albeit in an experimental autoimmune uveitis model251. Chondroitinase ABC 
has also been shown to have neuroprotective effects reducing retrograde axonal die-back in the acute 
phase after injury in mice252, an effect also seen in stroke models253, and there is a suggestion that the 
disaccharide digestion products may also be neuroprotective in vitro and in vivo albeit it again in eye 
models254.   
 
1.5.4 Dose and timing of chondroitinase ABC 
Although there is no meta-analysis of chABC for SCI, the majority of evidence suggests chABC leads to 
functional improvements, particularly in incomplete injuries111,209,210,213,228 (also see Bartus et al. 
2014211), including in the chronic phase213,249. The evidence is more mixed for larger or contusion 
injuries where chABC has less reliably shown functional improvements255,256. Indeed, one study 
directly compared the same treatment protocol (single intra-spinal injection of chABC) in two injury 
types, demonstrating axonal regrowth in hemisection but not contusion injuries110.  
 
However, these studies used more limited delivery of chABC by injection. By comparison, viral delivery 
of chABC that leads to widespread and long term chABC expression led to subsequent functional 
improvement even after thoracolumbar contusion injury211, which has been taken as evidence that a 
higher dose, longer time-period and possibly more widespread delivery of chABC is required to see 
changes in these types of injury.  
 
The dose of chABC and time period over which it should be administered for optimal regenerative 
outcomes has certainly not yet been fully established, but there is other evidence that longer delivery 
is required. The study with doxycycline inducible chABC used a cervical contusion injury and showed 
that longer-term (8 week) expression of chABC was required to see improvement in forepaw reaching, 
and 2 weeks was not sufficient235. Similarly, in cats after hemisection injury, longer (4 week) duration 
of chABC delivered by injection through a surgically placed port at the lesion led to greater 
improvements in fine motor tasks than 2 week delivery of chABC, again suggesting longer delivery 
may improve outcomes216. 
 
There is only one study directly assessing dose of chABC. In this study a single parenchymal injection 
of low dose (1U) chABC at 2 weeks after transection was not sufficient to see BBB improvement, 
whereas a higher dose (50U) was257. Notably, neither dose was sufficient to show BBB improvement 
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in a contusion model, consistent with the suggestion above that longer-term delivery is required. This 
study broadly suggests that a high dose of chABC is therefore required, but caution is needed as this 
dose caused sub-arachnoid haemorrhage and death when given within 48 hours after injury.  
 
In summary, higher doses and longer-duration of chABC administration may facilitate greater 
functional recovery, but to what degree this is required for each injury type is not clear.  
 
1.5.5 Combination therapy with chABC 
These multiple effects of chABC, which mostly do not overlap with other treatments, make chABC very 
amenable to combination therapy. There are a large number of recent studies using chABC in 
combination with other therapies (for a review see Muir et al. 2019232). 
 
It is worth noting the particular relevance of rehabilitation with chABC treatment, in the context of a 
means of directing plasticity and reorganisation after SCI towards functional synaptic connections and 
recovery. One clear example of this is a study conducted in rats with dorsal column crush injuries, 
where staircase reaching was improved only by combination of chABC (10 days bolus intrathecal 
injection) and rehabilitation specific to forepaw reaching, and not by either alone246. A more recent 
study after thoracolumbar contusion injury, with similar delivery of chABC at 6 weeks after injury and 
treadmill training also showed a small combined improvement in BBB score258. However, the timing, 
type and quantity of rehabilitation appropriate needs to be further explored256.  
 
Of particular relevance to this thesis is combination of chABC with OECs. In a combination treatment 
of OECs, Schwann cells, matrigel hydrogel and chABC after thoracolumbar transection injury, chABC 
increased BBB scores at 9 weeks compared to cell graft alone259. This combination therapy also 
showed some prevention of deterioration in bladder function after the same injury260, giving evidence 
that these two treatments could provide synergistic effects.  
 
As briefly mentioned previously, chABC and cell therapy have been used in combination with hydrogel 
biomaterials, both as a delivery method of chABC and to increase cell survival. Given the evidence 
discussed that longer-term administration of chABC may be important to functional outcomes, 
survival of OECs expressing chABC after transplant is likely to be an important issue, and hydrogel 
delivery is therefore another major focus of this thesis.  
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1.6 Hydrogel Biomaterials 
Hydrogels are a group of materials defined as three-dimensional networks of hydrophilic polymer 
chains, held together by covalent, ionic or hydrogen bonds, and capable of swelling to contain up to 
95% water (weight/volume) without being dissolved261,262. Most hydrogels are synthesised in 
monomeric form and then gel under certain conditions (e.g. pH, temperature). As such, although the 
more common approach is to transplant hydrogels en bloc once formed, some hydrogels are able to 
be injected directly into the lesion where they can then polymerise and ‘set’ in vivo, conforming to 
irregular lesion morphologies263.  The ability to inject a hydrogel rather than implant it is clinically 
desirable264 and this is discussed further in chapter 6. Due to their high water content, hydrogels are 
mechanically soft and flexible, minimising mechanical stress to the surrounding tissue after implant265. 
The mechanical characteristics of a hydrogel (e.g. it’s stiffness or elasticity) can be adjusted by 
changing the constituents of the gel, cross-linking, or adjusting gelling conditions7,266.  
 
Hydrogels can be synthesised from natural or synthetic polymers, with advantages and disadvantages 
to both sources. Naturally derived polymers (e.g. collagen, fibrin, hyaluronic acid) tend to be more 
biocompatible being more similar to native ECM, with fewer concerns around immune stimulation, 
toxicity or degradation, and they more readily form a porous structure similar to biological ECM 
allowing compatibility with transplant cell populations and in vivo axon growth. Synthetically derived 
polymers (e.g. poly-hydroxyethylmethacrylate, poly-ethylene-glycol (PEG)) tend to be simpler to 
manufacture and modify, for example when adjusting mechanical properties, porosity, degradation 
rates, or functionalising a hydrogel with additional beneficial molecules261–263. 
 
Some of the most commonly used hydrogels in SCI experiments are collagen, fibrin and Matrigel. 
Collagen and fibrin are both naturally derived polymers and highly biocompatible (collagen makes up 
a large part of the ECM throughout the body) and they can be injected to gel in situ267. As such, both 
have been used clinically in the nervous system39,268,269, although collagen has only been used as an 
implantable construct requiring scar resection rather than as an injectable, conforming gel. By 
contrast, although Matrigel consists of a mixture of laminin, collagen and enactin it is derived from 
Englebreth-Holm-Swarm sarcoma tissue in mice270,271 and while it is useful for proof of concept studies 
is unlikely to be translatable to clinics272.  
 
1.6.1 Hydrogels in spinal cord injury 
Hydrogels are attractive as a tissue engineering and regenerative approach to SCI repair. They are of 
particular interest for combination therapy, providing: (i) cell encapsulation and protected cell 
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delivery; (ii) an ECM-like structure to support axon growth; (iii) capacity for ‘functionalisation’ with 
growth promoting factors, drugs, antibodies or gene therapies; (iv) immunomodulatory effects; and 
(v) tuneable and biocompatible mechanical properties262.  
 
In rat models of injury,  hydrogel transplant has been shown to increase regeneration of axons through 
the lesion after transection injuries with collagen hydrogel273–275, as well as fibrin267, PEG276, agarose277 
and decellularised bladder and spinal cord constructs278. Regenerating axons have been shown to align 
with channels in implanted hydrogels273 which integrate well in the spinal cord to bridge the lesion 
cavity277,278 and reduce immunological reaction as determined by reduced GFAP intensity compared 
to saline controls278. A functional improvement in locomotion as determined by BBB score has also 
been demonstrated after hydrogel transplant alone276,278 including with collagen-based hydrogels273. 
There is also some evidence for long-tract axon regeneration correlated to functional improvement276, 
where re-transection at the cranial part of the lesion also abolished improvements seen in BBB score.   
 
Hydrogels have also been tested in large animal models of SCI, notably aligned fibrin increased axon 
regeneration as measured by MRI tractography after hemisection in experimental dogs112 and 
collagen hydrogel (as “Neuroregen”) improved locomotor score and sensation recovery after 
transection in experimental dogs279. This Neuroregen collagen-based hydrogel has also been tested in 
phase 1 human trials demonstrating safety268. 
 
1.6.2 Hydrogels for cell delivery in spinal cord injury 
1.6.2.1 Cell survival after transplant in spinal cord injury 
Cell survival after transplantation is one of the main problems seen with cell therapy for SCI280 and as 
mentioned earlier OECs show particularly poor survival by comparison to other cell types205,206. There 
are a number of reasons for the poor cell survival seen. Firstly, cells tend to integrate poorly in lesion 
sites due to cavitation and lack of anchorage sites281 and they tend to be washed out282; a rodent study 
transplanting OECs 1 week after thoracic contusion injury showed that around 30% of OECs (and 20% 
of Schwann cells) had already been ‘lost’ by 3 days after transplant205.  
 
Part of this initial cell loss may be due to shear forces damaging cells during injection. The flow rate 
and needle bore size and length have all been shown to affect fibroblast and MSC viability 6-24 hours 
after injection in vitro283,284.  Perhaps unintuitively, slower flow rates do not result in higher cell 
viability, with 50-300µl/min flow rates resulting in higher viability than 20µl/min flow (although there 
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is still potentially a ceiling speed not reached in this experiment). Also, in these experiments longer 
and narrower needles reduced viability (51mm vs 20mm and 34G vs 30G).  
 
In addition, the inflammatory environment at the site of injury is inhospitable to cell survival48. 
Interestingly this effect seems to be most pronounced after the immediate transplant period. In the 
cell survival study mentioned above, survival of OECs delivered into the lesion was compared to 
survival in more normal surrounding cord (4mm cranial and caudal to lesion). At 3 days, survival of 
OECs at the injury site and surrounding area was similar (71.1 ±11.9% and 68.9 ±10.1% respectively) 
but by 3 weeks there was a 16-fold difference in survival (3.1 ±1.4% at injury site, 48.4 ±6.3% in 
surrounding cord).  
 
It is important to note that any cell death of a transplant population may also cause further damage 
to the cord by triggering inflammatory pathways and worsening the local environment285. It is 
therefore clear that the method of cell delivery is important and requires addressing.  
 
1.6.2.2 Use of hydrogels to improve cell survival in spinal cord injury 
Hydrogels have been shown to protect cell delivery. In the experiments above investigating the effect 
of injection parameters in vitro283,284, delivery of cells in alginate hydrogel to increase viscosity of 
injection (and reduce shear forces) increased viability. After transplant, having a supportive ECM 
structure in place with cell delivery increases the chance of adhesion and reduces washout, 
particularly when transplanting into a cystic lesion cavity280.  
 
Cell encapsulation and delivery by injectable hydrogels has been shown to increase cell survival after 
transplant in vivo in a number of rodent models. In rat spinal cord, survival of induced pluripotent 
stem cell (iPSC) derived oligodendrocytes transplanted into sub-acute (1 week) clip compression 
injuries by injection in hyaluronan and methyl cellulose (HAMC) hydrogel increased survival at 1 week 
by ~50% compared to injection in media286. Approximately double the number of surviving neural 
progenitor cells were seen 2 weeks after injection into ischaemic rat brain in a hyaluronan-heparin-
collagen hydrogel compared to cells alone287, and HAMC hydrogel also improved survival of both 
retinal stem cells injected into retina and neural stem cells (NSCs) injected into both normal and 
injured brain in mice288. 
 
This increase in transplanted cell survival correlates to improved BBB locomotor outcomes in one 
study286, where transplant in hydrogel also reduced cavitation and increased migration of iPSCs 
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compared to transplant in media. In another study, increased NSC survival after transplant in HAMC 
into a T2 compression injury reduced foot falls on a ladder test but did not improve BBB scores289. 
Other studies have shown axon regeneration290,291, reduced inflammatory reaction291 and a locomotor 
benefit of hydrogel and combined adipose derived MSC and OEC transplant290 or MSC transplant291 
after SCI in rodents, despite not quantifying cell survival and so not being able to demonstrate a direct 
correlation between hydrogel transplant, cell number and functional outcomes.  
 
Studies assessing the effect of hydrogel and cell transplant after SCI have also been performed in 
experimental dogs, demonstrating an improved outcome after combination therapy. In one study, 
Matrigel alone was compared to Matrigel encapsulating adipose-derived MSCs differentiated into 
neurons after injection into the spinal cord during laminectomy at 1 week after balloon compression 
injury292. A significantly improved BBB score for Matrigel and MSCs compared to Matrigel alone was 
shown from 1-8 weeks after injury, while Matrigel alone showed a non-significant increase in BBB 
score compared to control. In another study, NeuroRegen collagen scaffold was implanted  en bloc 
with or without human umbilical cord-derived MSCs into a chronic (2 month) transection injury after 
resection of scar tissue293. Similarly, the combination therapy showed a significantly improved BBB 
score, this time from 3-12 months, while scaffold alone was not significantly different to control.  
 
Delivery of OECs using hydrogels has had little investigation. OECs have been shown to survive and 
proliferate in three synthetic hydrogels in vitro294–296 including in poly-lactic-coglycolic acid (PLGA) 
where the combination was also shown to enhance axon regeneration in vivo and improve BBB score 
after a T9-10 transection296. However, in alginate hydrogel OEC survival was shown to be poor and 
their morphology noted to be altered297. Survival of OECs within hydrogel after transplantation into 
SCI has not been specifically addressed, and this is explored further in chapter 6.  
 
1.6.3 Hydrogel stiffness and implant stiffness matching 
There are clear benefits to hydrogel-cell combination therapy. However, there is clinical concern that 
implantation or injection of a hydrogel that is too stiff could risk iatrogenic damage to the spinal 
cord7,265 or increased pressures within the spinal cord264. This is of particular importance in the central 
nervous system due to its comparatively soft nature compared to other tissues7 and the increased risk 
of inflammatory and immunological responses to stiffer implants, as reported after electrode 
implant298 and in a direct comparison of soft (100Pa) and stiff (30kPa) polyacrylamide implantation 
into rat brain299. Indeed, hydrogels reported to be of similar stiffness to spinal cord reduce 
inflammatory cell number after transplant in rodents300,301. Of course, if the hydrogel-cell construct is 
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too liquid, any benefits of hydrogel transplant including increased cell survival may be lost. As 
mentioned, the stiffness of hydrogels can be modified and therefore to take advantage of the benefits 
of hydrogels on clinics the mechanical properties of a hydrogel construct and host tissue must be 
matched.  
 
Alongside the necessity to match stiffness of the hydrogel-cell construct to the implanted tissue there 
is an interesting relationship between cellular behaviour and substrate stiffness. Namely, NSCs tend 
to differentiate to neurons in soft substrates (~1kPa) but to glial cells in stiffer substrates (~10kPa)302–
304. Additionally, neurites may preferentially grow on softer substrates; DRG neurites extend further 
on softer agarose gels305 and do not cross into stiffer substrates when grown in a gradient306, while 
mouse spinal cord primary neuronal cells show increased branching on softer substrates307. However, 
this is not a consistent finding with a neuron-like cell line308 and cortical neuron cultures309 insensitive 
to stiffness. Dendrites may also respond differently to axons with the number of primary culture 
dendrites increasing in stiffer gels310. The picture becomes further complicated when considering 
different hydrogel materials. Neurite outgrowth was decreased with increasing stiffness of agarose305 
and fibrin311 gels, but was maximal with intermediate stiffness collagen312 (~0.8mg/ml collagen in this 
experiment). It seems that whether axon outgrowth is increased by more or less stiff substrates is 
therefore highly dependent on neuron and substrate type as well as absolute stiffness (for reviews 
see313,314).  
 
This evidence may be relevant in deciding on the appropriate stiffness of implant to use to drive 
regenerative outcomes, and fits with the classical view of the glial scar forming a stiff, structural barrier 
to axon regeneration after SCI. However, more recent evidence from rodents suggests that the glial 
scar is in fact softer than surrounding spinal cord tissue315,316. This will be discussed further in chapter 
5.   
 
1.6.3.1 Measurement of stiffness 
To match stiffness of implant and tissue, comparable measures of both are clearly required. Stiffness 
is quantified as a modulus of elasticity in Pascals (Pa), however, determination of a single defined 
modulus of elasticity for a given material is technically challenging317. There are a wide variety of 
possible measurement techniques including: mechanical compressive, tensile and shear (rheology) 
measures; macro, micro and nano (Atomic Force Microscopy) indentation; and ultrasound or MR 
based elastography techniques. Each of these measurement techniques will measure a subtly 
different component of a material’s global elasticity, and hence give different values describing 
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different individual moduli of elasticity (e.g. bulk modulus, Young’s modulus, shear modulus)318. 
Mathematical conversion between these moduli can be possible depending on the information 
reported (see methods for example conversions) but even if possible is likely to introduce some error 
or variation in comparison based on constants and values used in conversion. Further, for all the 
measurement techniques above apart from the imaging-based techniques, invasive deformation of 
tissue is required to obtain a measure which would clearly not be feasible to use in the clinical 
environment. 
 
Several of these measurement techniques have been applied to spinal cord in experimental conditions 
across a number of species (for a review see Aurand et al. 20127). The values obtained for spinal cord 
elasticity in ex vivo studies cover a wide range even within species: in rats values vary from 0.3 – 1.3kPa 
measured by Atomic Force Microscopy (AFM) and microindentation respectively315; in cows from 
~100kPa – 1MPa319,320 using tensile measures; and in humans from 1 – 1.4MPa using tensile 
measures321,322. Measures of a spinal cord preparation in anaesthetised experimental puppies and cats 
using mechanical tensile methods323,324 reported a stiffness  for normal canine cord of 265kPa with 
low strain324, higher than that reported for canine cadaver spinal cord, 11.9-16.8kPa, under similar 
conditions7,325. 
 
Some of this variation can be explained by differences in sample preparation; e.g. removal of dura and 
pia mater, time post-mortem (see below), or measurement of grey or white matter. Some studies 
show a difference between the elasticity of grey and white matter316 but this is not consistently 
reported319,326. However, perhaps more importantly, spinal cord is known to be a viscoelastic material, 
meaning that when a force is applied it responds with components of liquid (visco-) and solid (elastic) 
properties322,327. This means that there is a non-linear relationship between deformation and 
elasticity, and the modulus of elasticity measured will be related to the stress-strain relationship, 
increasing with increasing strain and strain-rate320 (for a review see Bartlett et al. 2016328). Therefore, 
the value determined for the modulus of elasticity of spinal cord (its stiffness) can only be interpreted 
in light of the strain (e.g. tension) applied, making comparison between studies challenging.  
 
Additionally, the values listed above are determined from in vitro or ex vivo samples as sample 
preparation is required (e.g. dissection of the spinal cord and/or physical attachment to mechanical 
apparatus). As such the measures of spinal cord stiffness above are subject to tissue degradation post-
mortem, changed perfusion pressure, temperature and hydration status which are likely to affect 
measurements such that they may not accurately reflect in vivo stiffness329,330.  
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There are mixed reports in the literature of how tissue modulus of elasticity changes post 
mortem320,322–324,330,331, and few studies directly compare in vivo and post-mortem elasticity. One 
recent study showed that spinal cord had a higher elasticity post-mortem compared to in vivo in 
pigs330, although different breeds of pig and ambient temperatures (body temperature in vivo, room 
temperature post-mortem) were used. Two earlier studies also found an increased elasticity following 
death in a cat323 and dog324, but only one animal was tested in each study. The latter study also found 
that decreased temperature increased elasticity. Increasing time post-mortem raised spinal cord 
elasticity in one study320 but a trend to decreasing elasticity was seen in another322. In liver tissue 
measured by ultrasound elastography elasticity post-mortem elasticity was decreased compared to in 
vivo, attributed to reduced tissue perfusion and changed boundary conditions331.  
 
This all serves to highlight the necessity of a direct in vivo measurement of stiffness that can be applied 
to SCI. Ultrasound elastography is a clinically available method to non-invasively measure tissue 
stiffness and as such one aim of this thesis was to investigate using this approach to obtain in vivo 
measures of (canine) spinal cord intraoperatively and to explore means of comparing hydrogel implant 




1.7 Rationale for thesis 
The poor innate regenerative capacity of adult CNS, established for over 90 years332, means that even 
after removal of inhibitory cues, axon regeneration may not take place61.  However, it is also clear that 
when provided with the correct environment, CNS axons are capable of regenerating; when peripheral 
nerve grafts were placed into rat spinal cord after injury, where CNS axons were not growing, these 
same CNS axons extended into the peripheral nerve graft333–335. Manipulating the environment within 
SCI is therefore likely to be key to a successful regenerative therapy. It is now widely accepted that 
given the degree and complexity of the pathological changes seen after SCI, a combination of 
approaches will be required to achieve this.  
 
This thesis is aimed at further developing OECs as a therapy in the chronic phase after SCI (with 
particular reference to canine SCI and canine OECs). It builds on previous work in the laboratory 
showing OECs can be modified to express chABC, thereby providing combination therapy and novel 
delivery of chABC237,238. We first tested the functional benefit of this combinatorial intervention in two 
models of rodent SCI. As high cell death is known to reduce regenerative outcomes40 and is a limitation 
of OEC transplant35,123,205, our second goal was to improve OEC survival in vivo by encapsulation within 
a protective hydrogel biomaterial. In order to facilitate the use of hydrogel transplant on clinics, we 
tested a clinically relevant ultrasound elastography based approach to developing implants matched 
to host tissue stiffness.  
 
Combining OECs, chABC and hydrogel may provide a synergy of: (i) the regenerative properties of 
OECs, including their secretion of pro-regenerative factors and potential ability to provide a gateway 
to enable reconnection with remaining spinal cord axons; (ii) a reduction in inhibitory environment 
and increased axonal sprouting and plasticity from chABC; and (iii) protected OEC delivery and a 
structurally supportive matrix for repair and axonal growth in situ from hydrogel, with consideration 
of stiffness of the environment for both clinical safety and optimal regenerative outcomes.  
 
Our longer-term goal is to test these modifications of OEC transplant in companion dogs with chronic 
naturally occurring SCI. To facilitate direct translation of findings in this pre-clinical rodent model to 




1.7.1 Overall hypothesis 
Modifying OECs to express chABC and encapsulating these within a hydrogel of matched stiffness to 
the spinal cord will improve regenerative outcomes after SCI compared to OEC transplant alone.  
 
1.7.2 Overall aims 
1. Determine whether OECs expressing chABC provide a functional benefit in rodent models of 
SCI (chapter 3 and 4). 
2. Establish the feasibility of using ultrasound elastography to obtain intraoperative measures of 
spinal cord stiffness on clinics using the canine translational model (chapter 5). 
3. Investigate if hydrogel-OEC constructs can be made to match in vivo canine spinal cord 
stiffness (chapter 5).  
4. Determine if hydrogel delivery can improve OEC survival in rodent SCI and thereby improve 
regenerative outcomes (chapter 6).   
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Chapter 2  
 




Methods common to the whole thesis only are described in this chapter, more specific methods are 
provided in individual results chapters.  
 
2.1 Cell culture 
Canine mucosal OECs were obtained from a cell bank formed as part of a previous clinical trial123, and 
retrieved from -80oC storage. Cells were cultured as per previously published methods123,152,237 on 
poly-l-lysine (PLL, P8954, Sigma) coated flasks in growth medium consisting of low glucose Dulbecco’s 
Modified Eagle’s Media (DMEM, Sigma 6046), 10% foetal bovine serum (Gibco), 1% gentamycin or 
penicillin and streptomycin (Sigma) and growth factors neuregulin-1 (20ng/ml, R&D Systems) and 
forskolin (2µM, Sigma).  
 
Once confluent, cells were passaged by using 1% trypsin in PBS (Sigma) to detach cells, centrifuging at 
1000 rpm for 5 minutes to create a cell pellet, and resuspending in appropriate volume of growth 
medium for splitting into further PLL flasks. Cells were quantified using a haemocytometer and dead 
cells were determined using 1:1 dilution with 0.4% Trypan blue solution (Sigma). Cells were seeded at 
20,000 – 50,000 cells/cm2 depending on experiment.  
 
Passage and expansion were repeated until sufficient cells were obtained, then split for each 
experiment into well plates or flasks as described in each chapter. Where necessary, OECs were 
preferentially selected for over fibroblasts in culture by tapping the flask after 1 minute of trypsin to 
detach the less adherent OECs, then plating this supernatant separately – a modification of previously 
published methods151.  
 
2.2 Collagen hydrogel synthesis and cell encapsulation 
For a number of experiments OECs were encapsulated within collagen hydrogels. Type 1 high 
concentration rat tail collagen (Scientific Laboratory Supplies Ltd) is supplied dissolved in acetic acid 
at batch dependent concentrations and is monomeric at 4ᵒC. To polymerise and gel this needs to be 
neutralised and warmed above room temperature. Collagen hydrogels were therefore synthesised, as 
described previously336, by dissolving stock collagen in 0.02M acetic acid to provide a range of 
concentrations for testing. Minimum essential media α (Gibco, with nucleosides) at 10x concentration 
was added before neutralisation with 1M sodium hydroxide. Calculation for dilutions were performed 
in an Excel spreadsheet with formulas as in (Table 2-1), adapted from Dr Adams (collaborator at Keele 
University). All reagents were kept on ice throughout. After neutralisation, the hydrogel was 
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transferred to wells (see each chapter for details of experimental plan) and incubated in a cell culture 
incubator for 20 minutes (at 37°C and 5% carbon dioxide).  
 
Reagent Volume calculation 
10x Minimum Essential Media  VM = VT * 0.1 
Collagen (batch dependent concentration, mg/ml) VC = (VT * CR) / CS 
Acetic Acid (0.02M) VA = VT – VC – VM  
Sodium hydroxide (1M) VS = (VA + VC) * 0.023 
Table 2-1. Calculations for collagen hydrogel synthesis 
Where total volume required (VT), stock collagen concentration (CS) and required collagen concentration (CR) are 
pre-specified, and values used in calculation are; VM = volume of minimum essential media, VC = volume of 
collagen, VA = volume of acetic acid, VS = volume of sodium hydroxide.  
 
Where cells were encapsulated throughout collagen hydrogels, the hydrogel was made as above then 
a cell pellet containing the desired number of cells (calculated based on total volume of gel and desired 
cell concentration) triturated through the gel before pipetting into wells for gelling.  
 
2.3 Lentiviral preparation and cell transduction 
The Proteus vulgaris chABC gene was previously modified to produce active chABC in mammalian cells 
by optimisation of the Kozak sequence and removal of N-glycosylation sites234. This chABC gene was 
further codon optimised by Dr Liang-Fong Wong for use in this project. As previously published the 
transgene was subcloned into a third-generation self-inactivating non-replicating lentiviral plasmid: 
pRRL-SFFV-GFP-CMV-chABC (LV-chABC)237, hence expressing chABC under a CMV (cytomegalovirus) 
promotor and GFP under the SFFV (spleen focus forming virus) promotor. A lentiviral plasmid 
expressing just GFP under a CMV promotor (pRRL-CMV-GFP; LV-GFP) was used for control 
transduction and to identify transplanted cells in relevant experiments. The transfer plasmids were 
generated by Dr Wong, both additionally contained WPRE (woodchuck hepatitis post-transcriptional 
regulatory element) and cPPT (central polypurine tract) to increase expression of the transgene and 
improve transduction efficiency, as well the AmpR gene providing ampicillin resistance and allowing 
selective growth in E. coli.  
 
Lentiviral vectors were produced by, or with direct assistance from, Dr Wong or Dr Mahmoud Khazim 
using a 4 plasmid co-transfection system in HEK293T cells337. HEK293T cells were expanded in defined 
medium (DMEM with 10% FBS, 2mM glutamine and non-essential amino acids (Gibco, 11140-050)) 
then plated at 8x106 cells per 15cm2 plate. At 24 hours, the 4 plasmids were co-transfected; the 
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packaging plasmids Gag/Pol (10µg) and Rev (2µg), vesicular stomatitis virus envelope (VSVG, 3.4µg) 
and LV-chABC or LV-GFP (10µg) were mixed in 1.125ml of sterile distilled water before addition of 
140µl 2M calcium chloride, then 1.125ml 2x HEPES buffered saline (Sigma) was added dropwise. The 
mixture was incubated for 30 minutes at room temperature to precipitate DNA before dropwise 
addition spread across each 15cm2 plate for transfection. The next day, media was replaced with fresh 
media supplemented with 10mM sodium butyrate to increase DNA release into the cytoplasm. After 
6 hours, media was harvested and cell debris removed by centrifugation (1000rpm for 5 minutes). 
Supernatant was filtered (0.45µm filter bottle system, Corning) then filtrate further centrifuged at 
6000g for 16 hours at 4oC using a JLA10.5 rotor (Beckman Coulter). Supernatant was removed and the 
viral pellet resuspended in cold PBS and centrifuged at 20,000rpm for 90 minutes at 4oC in a SW40Ti 
rotor (Beckman Coulter). Again, supernatant was removed and the pellet resuspended in a total 
volume of 192µl TSSM (20mM Tris pH 7.3, 100mM sodium chloride, 10mg/ml sucrose and 10mg/ml 
mannitol) for 2 hours before aliquoting and storage at -80oC.  
 
Lentiviral titres were determined by flow cytometry. Briefly, HEK293T cells were cultured as above 
then seeded in a 12-well plate at 75,000 cells/well. The following day cells were transduced with 
lentivirus at serial dilutions of 103 - 106 (n=2 per concentration). An additional well was trypsinised and 
counted to determine cell number at transduction time point.  After 2 days, cells in each well were 
individually trypsinised, centrifuged at 1000rpm for 2 minutes, washed with PBS and re-centrifuged, 
then re-suspended and fixed in 1ml 4% paraformaldehyde for 15 minutes at room temperature. Cells 
were re-centrifuged a final time to obtain a cell pellet, washed and re-suspended in 1ml of PBS. Flow 
cytometry using the FACS Canto II (BS Bioscience) performed by Dr Lorena Sueiro Ballesteros (a 
member of the Flow Cytometry Facility, Cellular and Molecular Medicine, University of Bristol) gave a 







An average viral titre for each lentivirus was calculated by averaging each dilution. Viral tires were in 
the range 4.1x108 to 1.5x109.  
 
For transduction of OECs, cells were split onto PLL-coated 24-well plates at 20,000 cells/cm2 in a small 
volume of GM (300µL). 24 hours after plating cells were transduced with LV-GFP or LV-chABC at 
multiplicity of infection (MOI) 10. GM was topped up with an additional 300µL 6 hours later. 
Transduction of canine OECs using this process has previously been demonstrated in our lab237,238. 
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2.4 Morgan Elson assay for chondroitinase ABC activity 
This assay was used to detect the presence of breakdown products of CSPG digestion by chABC, and 
hence the presence of chABC in media. N-acetylation of the products of CSPG digestion results in a 
colour change which can be quantified using a spectrophotometer. Briefly, 50µL of sample media was 
mixed with 100µL of 40mM sodium acetate, 40mM Tris-Cl and 10mg/mL chondroitin-6-sulphate and 
incubated to 20 minutes at 37oC. N-acetyl-galactosamine (NacGal) was used as a positive control. The 
reaction was stopped by boiling for 1 minute, followed by boiling for 7 minutes with 100µL 0.8M 
potassium tetraborate tetrahydrate then cooling on ice. Samples were centrifuged for 33 minutes at 
10,000 rpm after addition of 1mL glacial acetic acid, and the resulting supernatant added to 0.4mL 
Morgan Elson reagent (10g paradimethylaminobenzaldehyde in 100mL glacial acetic acid containing 
12.5% hydrochloric acid) and incubated for 20 minutes at 37oC. Colour change from yellow to purple 
was quantified by measuring absorbance at 560nm and enzyme units calculated by referencing 














2.5 Immunocytochemistry  
Cells, prepared on glass coverslips in wells or plastic chamber slides (Nunc Lab-Tek, ThermoFisher), 
were fixed with 4% paraformaldehyde (PFA) for 10 minutes. Cell membranes were permeabilised by 
washing with 0.3% Triton in PBS 3 times for 5 minutes each before being blocked with 10% normal 
goat serum (NGS, Vector Laboratories) for 1 hour then incubated with primary antibody in 10% NGS 
overnight at 4oC or for 1 hour at room temperature. Primary antibodies included mouse anti-nerve 
growth factor receptor (p75) (MAB5364, Millipore) at 1:200, rabbit anti-fibronectin (AO245, DAKO) at 
1:400, chicken anti-GFP (AB16667, Abcam) at 1:2000. Appropriate complementary secondary 
antibodies were used including anti-mouse 546 (Abcam) at 1:500, anti-rabbit 660 (Abcam) at 1:400 
and anti-chicken 488 (Abcam) at 1:500. Coverslips were mounted using hard-set mounting media with 
DAPI (Vectashield).  
 
LIVE/DEAD staining was performed on hydrogels encapsulating cells by placing gels in 4µM calcein AM 
(VWR 80011) and 6µM ethidium homodimer-1 (Thermo Fisher Scientific E1903) in DMEM for 1 hour 
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at 37°C before washing in PBS 3 times for 5 minutes each. Gels were imaged using confocal microscopy 
(see below).  
 
2.6 Dorsal column crush surgery and cell transplantation 
All procedures were licensed under the Animal Scientific Procedures Act (1996), reviewed by the 
University of Bristol Ethical Review Board, and performed in line with Home Office guidelines and 
regulations. Animals were housed in a temperature controlled specific-pathogen free facility with a 
12:12 hour light:dark cycle in cages of minimum size 315mm x 420mm x 200mm (width x length x 
height) on wood shavings with additional paper nesting material in groups of up to 4. Rats had ad lib 
access to water and food apart from where specified for behavioural testing. 
 
For cell transplantation, animals were immunosuppressed with 15mg/kg cyclosporine (Sandimmune, 
Novartis), initially by daily intraperitoneal injection from 24 hours before cell transplant for 7 days, 
then by oral administration (Neoral, Novartis) in drinking water until termination. This protocol avoids 
the need for long term injection or oral gavage for the rats and has been shown to produce similar cell 
survival after xenotransplant into the CNS compared to continued daily injection338. Oral cyclosporine 
was diluted in drinking water such that animals received 15mg/kg/day based on a water consumption 
rate of 10mL/100g/day339.  
 
Animals were anaesthetised with intraperitoneal ketamine (60mg/kg) and medetomidine (250µg/kg), 
pain relief was provided by 0.02mg/kg buprenorphine. A dorsal column crush lesion to the CST was 
performed as previously described by performing a dorsal laminectomy at cervical vertebrae 3 (C3), 
placing 5 drops of lidocaine solution (2%) on the surface of the spinal cord, then  inserting marked 
forceps to a depth of 2mm within the dorsal columns and crushing for 10 seconds340. Sham animals 
received laminectomy but no injury to the spinal cord. Body temperature was maintained by use of a 
heat mat throughout surgery. Sedation was reversed with atipamezole after routine tissue and skin 
closure. 
 
Cells were trypsinised in batches from 24-well plates, washed in Hank’s Balanced Salt Solution (HBSS), 
resuspended at a concentration of 90,000 cells per µL and kept on ice until transplant. Cells were 
transplanted immediately after injury and within 90 minutes of trypsinisation.  Cells were injected at 
a rate of 250nL/minute in 2 injections of 1µL, cranial and caudal to the lesion, in the midline giving a 
total number of cells transplanted per rat of 180,000 cells. Media transplant animals received the 
same injections and volume of HBSS.  
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2.7 Tissue processing 
Rats were culled by terminal anaesthesia with pentobarbitone (1ml/kg) and transcardially perfused 
with phosphate buffered saline (PBS) followed by 4% PFA. The relevant (cervical or thoracic) spinal 
cord was dissected and removed and the cord directly surrounding the lesion (distances specified in 
each chapter) was isolated and mounted in 10% w/v gelatin (Sigma) in PBS then fixed in PFA overnight. 
An additional 3mm of spinal cord taken immediately cranial and caudal to the central lesion section 
was also mounted in gelatin and post-fixed in the same manner. Cords and gelatin were transferred 
to 30% sucrose in PBS for 48 hours or until equilibrated with samples sunk to the bottom, then 
transferred to optimised cutting complex (OCT, TissueTek) and snap frozen at -80oC. Samples were 
sectioned free floating on a cryotome at 30-40µm; the central area around the lesion was sectioned 
dorsally while the cranial and caudal segments were sectioned transversely.  
 
2.8 Immunohistochemistry 
Sections were immunostained free-floating in 4 or 24-well plates. For fluorescent 
immunohistochemistry, the same protocol as immunocytochemistry above was followed. Additional 
immunostaining used on sections included the following primary antibodies: rabbit anti-GFAP (Dako 
Z0334, 1:1000) to label astrocytes; mouse anti-TUJ1 (Biolegend 801202, 1:1000) as a pan-neuronal 
marker; rabbit anti-5HT (Immunostar 20080, 1:10000) to label serotonergic neuronal fibers; rabbit 
anti-vGlut1 (Synaptic Systems 135303, 1:500) to label pre-synaptic glutamatergic proprioceptive 
afferents; PKCƔ (Santa Cruz sc-211, 1:1000) to visualise the CST and verify injuries were consistent and 
completely disrupted the CST in dorsal column crush lesions.   
 
Additional specific immunostaining is described in each chapter. After final the final wash step, 
sections were mounted on SuperFrost slides (Thermofisher) in hard-set mounting media with or 
without DAPI (Vectashield) or in Mowiol (6ml glycerol, 2.4g Mowiol 4-88 (Calbiochem 475904 in 12ml 
200mM pH8.5 Tris-HCl and 6ml distilled water).  
 
Chromogenic immunohistochemistry using 3-3’ diaminobenzidine (DAB) staining was performed 
similarly to above with an additional 30 minute incubation in 30% hydrogen peroxide in PBS-Triton 
step before washing in PBS-Triton and subsequent blocking in 10% NGS in 0.3% PBS-Trition. Primary 
antibodies were incubated overnight at 4oC and included: mouse anti-C4S (MP Biomedicals 6365111, 
1:5000) to label digested stubs of CSPG degradation by chABC; mouse anti-neurocan (DSHB IFC-c, 
1:50) to label a CSPG; goat anti-IBA1 (Abcam ab107159, 1:1000) to label microglia. Primaries were 
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then removed and sections washed in PBS-Triton 3 times for 5 minutes, and incubated with 
appropriate species biotinylated secondary antibody for 1 hour (VectorLabs), washed 3 times in PBS-
Triton then incubated for a further 30 minutes with avidin-biotin (Vectastain Elite ABC Reagent, 
VectorLabs). Sections were washed 3 times in PBS-Triton then immersed in DAB (Vectastain) for a set 
period of time for each antibody then washed in PBS, mounted on slides and dehydrated overnight. 
Slides were further serially dehydrated in 70, 90 and 95% ethanol for 1 minute each followed by 2 
minutes in xylene before coverslips were mounted using DPX mounting media (Sigma 06522).  
 
2.9 Microscopy 
Immunocytochemistry images were obtained using Leica DMRB fluorescence microscope with Leica 
DFC340FX digital camera. Widefield whole section images were obtained at 10x or 20x on a Leica 
DMI6000 inverted epifluorescence microscope with a motorised stage with either Leica DFC365FX 
monochrome digital camera or Photometrics Prime 95B sCMOS camera and Leica LAS-X acquisition 
software for multi-site imaging. The same camera system was used for each immunostain.  Confocal 
imaging was performed using a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica 
DM I6000 inverted epifluorescence microscope.  
 
2.10 Image analysis 
Image analysis specific to each experiment is described further in each chapter. Analysis used widely 
throughout the thesis is described here as a single reference point.  
 
2.10.1 Quantification of cell population from immunocytochemistry 
Unless otherwise stated, proportion of p75 expressing (p75+) and GFP expressing (GFP+) cells were 
determined by counting all DAPI, p75 and GFP cells within five 10x magnification fields of view from 
each of 4 wells using ImageJ341 and expressing p75+ and GFP+ cells as a percentage of DAPI stained 
cells.  
 
2.10.2 Quantification of cell survival in vivo 
Serial sections (1 in 10) were processed for p75 and GFP as per immunohistochemistry and 
transplanted cells were identified by GFP. Given the relatively small number of surviving cells, all 
transplanted cells in a section were counted manually by an observer blind to transplant group. Total 
cell count was multiplied by 10 to give an estimate of total surviving transplanted cells in the cord, 
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and this was expressed as a percentage of transduced (GFP+) cells transplanted as previously 
reported238.  
 
2.10.3 Quantification of immunostaining 
In several chapters level of immunostaining (particularly GFAP, IBA1, TUJ1) has been quantified. GFAP 
is used to identify astrocytes, IBA1 to identify microglial cells or macrophages, and TUJ1 to identify 
neurons. In each case merge tilescan images were imported into Fiji ImageJ341 and a semi-automated 
system of quantification using custom macros was performed. Regions of interest (defined in each 
chapter) were specified for each image and saved in the ROI manager. Images were then automatically 
processed to manually threshold all images at a pre-set level (consistent for each antibody within each 
experiment). The pixel count above this threshold was determined and expressed as a percentage of 
the total number of pixels in the region of interest, giving pixel ‘density’342,343.  
 
2.10.4 Quantification of vGlut1 and 5HT immunostaining in transverse sections 
Five transverse sections were immunostained as above for vGlut1 (to assess excitatory glutamatergic 
innervation) and 5HT (to assess serotonergic fibres). Due to their size, sections were sometimes 
damaged during the staining process so 3-5 sections per animal were analysed. Merge whole section 
tilescan images were imported into Fiji ImageJ341 and staining above a set manual threshold was 
quantified within regions corresponding to grey matter laminae or white matter. Number of positive 
pixels was expressed as a percentage of total pixels in a region (due to differing region sizes). Regions 
were defined by custom made templates, produced by tracing several example transverse sections 
from the same segment of cord using InkScape (The Inkscape Project, v0.92) and creating an average 
scaled vector graphic template. Regions were identified by filling with different pixel colour values. 
Reference points at clear landmarks (e.g. central canal, dorsal and ventral points of grey matter, 12-
18 points per image) were added in Fiji ImageJ to both the template and all transverse section merge 
images. A custom macro using the Bristol Wolfson Imaging Modular Image Analysis Plugin344, written 
by Dr Stephen Cross, was used to transform each section image onto the template and produce a 
spreadsheet of percentage positive pixels for each region of each image. Spreadsheet data for each 
set of staining was collated by cord, region and transplant group using a custom Python and R script 




2.11 Statistical analysis 
Statistical analysis is reported in more detail in each chapter. Averages are reported as mean ± 
standard deviation unless otherwise stated. Normality of data was tested using Shapiro Wilk test, non-
parametric data was analysed by Mann Whitney U or Kruskall-Wallis, parametric data by Student’s t 
test or ANOVA. Data with repeated measures was analysed as such; with complete data sets repeated 
measures ANOVA (or ANCOVA if a baseline measure was available) was used, data with incomplete 
data sets was analysed using mixed models. Statistical packages GraphPad Prism v7 or 8 for MacOS 
(GraphPad Software, La Jolla California USA), SPSS v23 or 24 (IBM SPSS Statistics for MacOS, IBM 
Corporation, Armonk New York), inVivoStat345 and RStudio (v 1.1.463)346. 
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Chapter 3  
 
Functional effect of canine olfactory ensheathing 
cells expressing chondroitinase ABC after transplant 






The pathophysiology of SCI is complex and multifaceted, and therefore a combination of therapies is 
likely to be required to facilitate regeneration of the spinal cord. Olfactory ensheathing cells (OECs) 
and chondroitinase ABC (chABC) represent two of the most promising individual therapies for SCI. 
OECs have been shown to increase axonal regeneration170 and remyelination180, and improve 
locomotor outcomes after transplant into sites of SCI as established by two recent meta-analyses of 
animal models104,126. The easily accessible biopsy site, the olfactory mucosa, means autologous 
transplant can be readily used on clinics; phase 1 trials in humans have demonstrated safety42 and a 
phase 2 randomised controlled trial in pet dogs demonstrated some improvements in fore-hindlimb 
coordination123. Chondroitinase ABC can also lead to increased axonal regeneration and 
plasticity209,210,247, and has been shown to improve locomotion and skilled voluntary movements 
across multiple rodent models209,213,240,246,347, in experimental cats111,215 and non-human 
primates113,217. It has also shown a similar degree of benefit to OECs in a phase 2 randomised 
controlled trial in pet dogs208.  
 
Chondroitinase ABC provides one of the best options for combination therapy because it has 
pleiotropic effects which can augment other therapies232,348. Combination of intra-spinal OEC 
transplant and chABC injection in rodent models has shown an improvement in outcomes over and 
above OECs alone both in preventing deterioration of bladder function260 and improving locomotor 
score after spinal cord transection in rats259. 
 
Despite the evidence for chABC as a treatment for SCI it has not advanced to human testing, in large 
part due to its rapid degradation within 3 days at body temperature226. The consensus opinion is that 
clinical treatment with chABC would require longer-term delivery than single injection of chABC 
provides227, which would necessitate repeated spinal injection or implantation of delivery pumps that 
is clinically undesirable. There is therefore a need for new delivery methods of chABC appropriate for 
clinical use. Other approaches are discussed in greater detail in the thesis introduction but include 
chemical thermostabilisation of chABC229,230 or gene therapy using a viral vector containing chABC – 
either by injection directly into the spinal cord211,212,235 or by ex vivo modification of transplanted 
cells236,237.  
 
We have previously reported that canine OECs can be genetically modified by lentiviral transduction 
to stably express chABC237. We have also shown that these OECs modified to express chABC (OEC-
chABC) can successfully digest CSPGs in vivo after SCI in athymic rats and increase axonal branching238. 
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Survival of transplanted OEC-chABCs was seen up to 4 weeks after transplant, implying expression of 
chABC until 4 weeks. Genetic modification of cells ex vivo is considered safer than widespread viral 
modification of host cells and is therefore more likely to be clinically translatable349,350.  
 
The next step in testing of these OEC-chABCs is to determine whether the reported CSPG digestion 
and axon sprouting can induce a functional behavioural change in a pre-clinical rodent model of SCI. 
The typical human SCI today is an incomplete cervical injury without associated fracture or 
dislocation351. To model this injury, we chose to use a cervical dorsal column crush model of SCI in rats 
that selectively destroys the dorsal CST tracts, one of the main tracts responsible for control of 
voluntary movements in rats and humans352. In humans the CST is responsible for almost all aspects 
of voluntary motor control, so if motor function is to be improved after SCI then regeneration of this 
tract is crucial242. In rodents, the CST controls fine movements of the limbs and dorsal CST injury results 
in a relatively mild injury with forepaw reaching and grasping deficits. High levels of homology in 
rodent forepaw and human hand movements during reaching and grasping add weight to this being 
a good model of hand function353, which is reported as the most desired function by tetraplegics354. 
These specific deficits in the rats can be tested with highly sensitive measures348 such as the Montoya 
staircase96 and Whishaw reaching task355 (described in methods).  
 
The evidence for OEC transplant effect in cervical SCI is mixed. There is some evidence OECs improve 
forepaw reaching162,163,169,356,357 but only one of these five studies had blinded behaviour testing and 
robust controls357. None of the remaining four studies had blinding, one study had no direct control 
group169, and the remaining three studies had poor control groups who received no intervention to 
control for the effects of second surgery and spinal injection which OEC transplanted animals 
received162,163,356. There are three further, robustly controlled, studies of OEC transplant in cervical rat 
SCI which show no benefit of transplant193,194,358, however two of these studies use a more severe 
model of injury which also affects the rubrospinal tract. Determining the efficacy of OECs in improving 
forepaw reaching after cervical SCI from the literature is therefore challenging.  
 
The existing literature regarding the efficacy of chABC after cervical SCI more consistently shows a 
benefit to forepaw reaching. A series of three studies investigated the effect of directly injected chABC 
active enzyme on forepaw reaching alongside variation in rehabilitation, two of these studies 
administered chABC in the acute phase after dorsal column crush injury228,246 and one in the chronic 
phase213. All studies reported improvements in staircase forepaw reaching after chABC administration, 
however, blinding of surgery and behavioural testing, randomisation and allocation concealment was 
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not specified in any of these studies. A further study assessed forepaw reaching after injection of a 
lentiviral vector delivering doxycycline regulatable chABC into the spinal cord at time of C5 dorsal 
contusion235, and also showed a benefit to forepaw reaching. This study had blinded behavioural 
testing and randomisation of groups. Additional studies using similar cervical injury and delivery 
paradigms have also shown improvements after chABC on ladder crossing and gait analysis209,212.   
 
Rehabilitation was used in several of these forepaw reaching studies with chABC213,246, and forms an 
integral part of the clinical management of clinical SCI14. A synergy is seen between chABC 
administration and rehabilitation246 that is likely due to rehabilitation driving the reorganisation of 
new connections formed from the axonal sprouting and plasticity seen due to chABC359.  
 
It has been suggested that migration is important to the regenerative effects of OECs, for example 
through their release of trophic factors (e.g. GDNF) ahead of regenerating axons202,360. Improving the 
migration of OECs is therefore of interest as it may enhance their regenerative capacity. A study 
examining the migration of OECs in vitro demonstrated that migration is mainly inhibited by CSPGs 
and that this effect can be mitigated by chABC361. We therefore wanted to explore whether we see 
the same effect with OEC-chABC and began development of an in vitro assay of OEC proliferation and 
migration using time-lapse imaging. 
 
3.1.1 Aims and hypotheses 
It is clear that many studies reporting behavioural results after cervical SCI in rodents are obtained 
without allocation concealment of treatment group, some without blinding, and even a number 
without robust controls362. Given the variability inherent in SCI lesions and subsequent variation in 
functional outcomes, this introduces crucial potential bias in experimental design. This sort of 
unintended bias is held to be one of the main causes of lack of replication and conflicting results that 
are reported throughout SCI research35,363. It is of particular concern with injury models which are 
produced by hand in a relatively subjective manner and in the CST where it has been reported that 
functional forepaw reaching can recover with only 1% surviving CST axons162.  
 
Our aims in this experiment were therefore to: 
1. Conduct a blinded, randomised, robustly controlled experiment to determine efficacy of 
canine OEC and OEC-chABC transplant in a cervical dorsal column crush model of SCI in rats.   
2. Determine if OEC-chABC can be used as a functionally relevant delivery system of chABC.  
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We hypothesised that the greatest improvements in forepaw reaching would be seen after OEC-chABC 
transplant and that these animals, but not OEC-GFP or media animals, would show histological 
changes consistent with presence of chABC (e.g. digestion of CSPGs, increased axonal sprouting). An 





Figure 3-1. Experimental timeline and summary in vivo behavioural methods. 





3.2.1 Cell culture, genetic modification, and pre-transplant characterisation 
Cell culture and transduction was performed as described in thesis methods, with canine OECs derived 
from one dog (‘Bethan’) retrieved from -80oC storage from a previous canine clinical trial123. 
Transduction with LV-GFP or LV-chABC was performed 10 days prior to transplant as per thesis 
methods. A sample of cells was also split onto PLL-coated glass coverslips in 4 well plates for 
immunocytochemistry and transduced in the same manner. 
 
A Morgan Elson reaction to determine chABC activity in vitro was performed as described in thesis 
methods on 50µl samples of media from 4 wells of OEC-chABC and OEC-GFP cells at day 5 after 
transduction. Immunocytochemistry of cell cultures was performed as per thesis methods for p75 and 
GFP.  
 
3.2.2 Experimental groups and power calculations 
Animals were transplanted with either OEC-chABCs to test combination therapy, OEC-GFPs to control 
for transduction and to test OECs alone, or media to control for injection. Sham animals receiving 
cervical laminectomy surgery but not SCI were included to confirm the specific effect of dorsal column 
crush lesion in our lab and control for the effect of surgery.  
 
Previously reported data for staircase retrieval after dorsal column crush injury and acute 
administration of chABC with forepaw rehabilitation show that at 6 weeks after injury, chABC treated 
animals retrieved 10 pellets compared to 3.5 retrieved by controls, with a standard deviation ~3.5246. 
Power calculations (power at 0.8 and significance at 0.05) therefore predicted n=5 required for each 
group to see a similar difference. As such we planned to use n=6 per transplant group to allow for 
losses, although 2 ‘batches’ with the same experimental protocol were eventually performed (see 
results).  
 
3.2.3 Behavioural training (Montoya staircase and ladder crossing) 
Male Wistar rats (Charles River) were housed in groups of up to four in enriched cages under standard 
conditions as detailed in thesis methods. We pre-specified pellet retrieval on Montoya staircase96 as 
our primary outcome measure and all animals were trained on this apparatus pre-surgery for 3 weeks, 
5 days a week, once a day for 15 minutes. For this task, animals must reach down from a raised 
horizontal platform to retrieve reward pellets placed on 7 ‘steps’ at increasing distances below them 
on each side, thus testing proprioception and grasping (for images of behavioural testing see Figure 
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3-1B). Number of pellets retrieved and accuracy of pellet retrieval (i.e. number of pellets retrieved as 
a percentage of total pellets displaced) can be determined.  
 
For initial training, reward pellets were replaced in the highest ‘steps’ during each session as rats 
retrieved them to encourage learning. Once rats were doing this consistently, and for later testing, 2 
pellets were placed on each ‘step’ bilaterally (giving a total number available of 28). Animals were 
habituated to reward pellets (cocoa pops) prior to training and were trained without feed restriction 
but were tested twice a week after overnight starvation. Animals which were able to retrieve a 
minimum of 12 pellets in the final two tests were used for behaviour analysis, remaining animals were 
used for histological analysis at earlier time points. All animals also received training in ladder crossing, 
crossing a 1 metre, regularly spaced ladder 3 times daily for 5 days for reward pellets.  
 
3.2.4 Surgical procedures, OEC transplant and immunosuppression 
Rats weighed between 225-250g at time of surgery. Dorsal column crush spinal cord lesion surgery 
and cell transplant was performed as described in thesis methods with a total of 180,000 cells injected 
split between two 1µl injections immediately cranial and caudal to the lesion in the midline. All animals 
received cyclosporine immunosuppression throughout the experiment as per thesis methods.  
 
3.2.5 Blinding, randomisation and allocation concealment 
Animals reaching the 12 pellet threshold on staircase retrieval were randomly assigned into each of 
the three transplant groups used for the behavioural study. Animals retrieving more than 8 pellets 
were used as shams. Surgical order (including sham surgeries) was determined using random number 
generation in Excel. One surgeon conducted all approaches and injuries (Jon Prager), another all cell 
transplants (Dr Darren Carwardine in batch 1, Dr Wong in batch 2). All surgeons were blinded to 
transplant group (though not sham surgeries); only the person preparing cells (Dr Wong in batch 1, Dr 
Ito in batch 2) had access to this information but they had no control over order of transplant to 
maintain allocation concealment. Cells or media were delivered to surgeons in Eppendorf tubes 
labelled with each animal’s reference number only and could not be distinguished. This reference 
number was used throughout the experiment to maintain blinding of transplant group.  
 
3.2.6 Behaviour testing 
All behavioural testing was performed by the same person blinded to treatment group. Weekly 
behavioural testing of staircase and ladder ability after overnight starvation was performed twice 
weekly in the morning. The number of pellets retrieved and displaced in the staircase was recorded. 
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Animals were videoed crossing the ladder and number of foot slips, defined as complete or partial 
miss of a rung, per crossing was later counted. For each week, an average value of these two trials 
was used in analysis.  
 
Whishaw reaching was performed using an apparatus as previously described355 requiring animals to 
reach through a 1.5cm slit onto a raised platform to retrieve reward pellets (see Figure 3-1B for image). 
This was conducted once, at 6 weeks after injury, without prior training. Animals were initially placed 
in the box for 10 minutes with reward pellets placed at the opening to habituate them, then the 
number of pellets retrieved and displaced over a subsequent 5 minute period was recorded246. Gait 
analysis was performed by dipping each animal’s forepaws in ink, then allowing them to walk along a 
1m paper covered runway. Paw width was measured between the outside edges of the 2nd and 5th 
digits of the first distinguishable print. Stride length and base of support was measured from the 
middle back of each print and averaged over the first 5 consecutively distinguishable prints. Base of 
support is the perpendicular lateral distance between consecutive prints and a measure of lateral 
stability.  
 
All animals received rehabilitation specific for forepaw reaching as previously described246. Briefly, 
grids with apertures 1.7x1.7cm wide and 2.2cm deep were filled with seeds and other rewards and 
placed in home cages 5 days a week for 1 hour a day from 1 week after injury. Animals could only 
reach rewards with their forepaws, and cages were intermittently monitored during the hour to 
confirm all animals were reaching for pellets.  
 
3.2.7 BDA axon tracer injection surgery 
After week 6 behavioural testing all transplanted animals (not sham animals) received a second 
surgery to inject biotinylated dextran amine (BDA) into the sensorimotor cortex. Animals were 
anaesthetised and received pain relief as per previous surgery (see thesis methods), placed in a 
stereotactic frame and a midline incision was made over the skull. Six stereotactic injections were 
made bilaterally with reference to bregma as previously reported238, after drilling through the skull, 
at: (rostro-caudal/lateral in mm) -1.5/2.5, -0.5/3.5, +0.5/3.5, +1/1.5, +1.5/2.5, +2/3.5. All injections 
were made 2mm deep to the brain surface. Skin was closed and animals recovered routinely.  
 
3.2.8 Immunohistochemistry 
Rats were culled after final behaviour at 9 weeks after injury and transplant (3 weeks after BDA 
injection) and perfuse-fixed as described in thesis methods. The central (dorsal sectioned) region was 
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taken from 10mm cranial to 10mm caudal to the lesion and processed as described in thesis methods. 
Rats which did not reach the required threshold of pellet retrieval during staircase training were used 
to investigate OEC survival and chABC activity in vivo at 2 weeks after both OEC-GFP (n=4) and OEC-
chABC (n=4) transplantation under the same conditions as animals used for behavioural testing; these 
animals were therefore culled at 2 weeks after transplant and processed in the same manner as above.  
 
Dorsal sections were immunostained for cell quantification as per thesis methods (1 in 10 sections 
through the cord stained for p75 and GFP) as well as for C4S, neurocan, and BDA. Transverse sections 
were immunostained for vGlut1, 5HT and PKCƔ and analysed as per thesis methods. 
 
3.2.8.1 BDA axon imaging and analysis 
BDA axons were imaged and processed as previously reported in our lab238. Three serial (1 in 10) dorsal 
sections though the lesion incorporating the CST were incubated overnight at 4oC with Avidin-
Neutravadin Texas Red (Thermofisher, 1:500) to fluorescently label BDA stained axons. Whole dorsal 
sections were imaged at 20x using a motorised stage and tilescan software (Leica DMI6000 inverted 
epifluorescence microscope with Leica DFC365FX monochrome digital camera and Leica LAS-X 
acquisition software). Images were then processed using the FeatureJ plugin364 of imageJ to selectively 
segment and threshold linear structures using Hessian-based edge detection342. Three defined regions 
of interest were traced manually within ImageJ for each section; white matter and grey matter cranial 
to the lesion edge, and white matter caudal to the lesion edge. All regions of interest were of length 
1mm from the lesion. The percentage of BDA positive pixels within each region of interest was 
quantified (referred to as BDA pixel density) for each region. Cranial grey matter and caudal white 
matter pixel densities were expressed as a ratio to the cranial white matter pixel density (to normalise 
for variation in BDA staining between animals and sections342) and compared between transplant 
groups.  
 
3.2.9 Quantitative PCR for chABC in vivo 
To test for chABC gene expression using quantitative polymerase chain reaction (qPCR) we used 
methods similar to those previously reported after viral delivery235. Fresh frozen spinal cord samples 
were obtained from other animals not reaching the required threshold for behavioural testing, these 
animals (n=4 OEC-chABC and n=3 OEC-GFP) were culled at 2 weeks after transplant and injury by 
intraperitoneal injection of pentobarbitone without perfusion. The cervical cord 1cm around the 
injury was rapidly dissected, cut transversely into 4 equal pieces and frozen on dry ice. Samples were 
stored at -80oC until RNA was isolated using mirVana miRNA isolation kit (ThermoFisher). Tissue was 
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initially disrupted by passing samples 10 times through a 21G needle in denaturing lysis buffer, 
followed by mixing with Acid-Phenol:Chloroform and subsequent centrifugation (5 minutes at 
10,000g) to extract RNA into the aqueous phase. RNA was isolated by washing and filtering with 
100% ethanol before eluting with nuclease-free water. A spectrophotometer was used to confirm 
RNA:protein ratio of ~2.0. Isolated RNA was stored at -80oC and converted to cDNA using 
SuperScript III Reverse Transcriptase kit (Invitrogen) with 2µg of isolated RNA and random primers. 
cDNA  product was diluted 1:5 with nuclease-free water and stored at -20oC until qPCR. This was 
performed using Power SYBR Green (ThermoFisher), with primers against the chABC gene designed 
by Dr Wong and using GAPDH as a housekeeping gene on a Step-One RealTime PCR System (Applied 
Biosystems). The same primers were tested on RNA isolated from LV-chABC and LV-GFP transduced 
HeLa cells (100,000 cells/well) by the same technique to act as positive control for the primers. Cycle 
threshold (Ct) values were converted to relative fold change by 2-∆∆Ct (where ∆Ct = Ct gene of 
interest – Ct GAPDH housekeeping, ∆∆Ct = ∆Ct sample – average control ∆Ct).  
 
3.2.10 Proliferation and migration of OEC-GFP and OEC-chABC in vitro 
Proliferation, attachment and migration of OECs in vitro and the effect of chABC was explored using 
an Incucyte Zoom microscope (Essen Biosciences) which allows time lapse imaging during culture. 
OEC-GFP and OEC-chABC were plated at 50,000 cells per well on a 24-well plate and imaged hourly at 
4x magnification for 5 days. Images were exported and processed in ImageJ to segment and count cell 
bodies using a custom macro (which used the Log3D plugin to increase contrast of phase images, 
followed by “otsu” auto-threshold, inversion of black/white, watershed segmentation and finally Fiji 
ImageJ in-built “analyse particles” function to quantify cell number). Process extension was used as 
an indication of OEC attachment (OECs appear circular when floating and put out processes once 
attached). Process length was determined using proprietary Incucyte ‘NeuroTrak’ software to identify 
and quantify the total length of processes in each image. Migration distance of cells was analysed 
using manual tracking with the in-built Fiji ImageJ plug-in by randomly selecting 5 attached cells per 
well and manually tracing them over the final 12 hours of images.  
 
3.2.11 Statistical analysis 
All data was tested for normal distribution using Shapiro-Wilk. Parametric data was analysed using t-
tests or one-way ANOVA with post-hoc Tukey test unless otherwise specified. Non-parametric data 
was analysed by Mann-Whitney U or Kruskall-Wallis. Behavioural tests where repeated measures 
were taken (staircase and ladder testing) were analysed using linear mixed effects model analysis. This 
was used to account for individual variation between animals and to avoid violating the assumptions 
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of repeated measures ANOVA, specifically that there are no missing values e.g. due to animal drop 
out during the course of the experiment365. Linear mixed effects models were constructed in R366 to 
test the relationship between transplant group and number of pellets retrieved on staircase, accuracy 
of this pellet retrieval and number of ladder foot slips. Fixed effects were defined as transplant group 
and time, individual animal was assigned as a random effect. Post-hoc Tukey multiple comparison test 







A total of 60 rats were used (45 for the behavioural study and 15 for histology or gene expression 
analysis which did not reach the threshold on staircase training). Seven animals (3 OEC-chABC, 1 OEC-
GFP and 3 media transplanted) were culled three days after injury in the first experiment as they had 
persistent limb deficits impeding movement. As such we repeated the experiment (‘batch 2’) with the 
same group sizes (n=6). Data from both batches was combined as the experimental protocol was 
identical, to give final group sizes of n=9 for OEC-chABC and media, and n=11 for OEC-GFP.  
 
3.3.1 Characterisation of transplanted canine OEC population 
The canine OEC population used in this experiment was prepared to minimise differences between 
batches of experiments and transduced populations. The same passage of cells from the same dog 
was used as a starting point for both experiments, transduction conditions were identical, and the 
same passage of cells was transplanted.  
 
The population of cells was characterised before transplantation by immunofluorescence staining 
(Figure 3-2A) to determine proportion of cells transduced (cells which were GFP+) and proportion of 
cells p75+ (considered to be OECs). Quantification of GFP+ and p75+ proportion (Figure 3-2B and C 
respectively) from both experimental batches and both OEC-chABC and OEC-GFP transduction show 
no statistically significant differences (one-way ANOVA). The overall average transduction rate was 
49.0±5.9% and p75+ proportion was 99.3±0.39%.  
 
As previously demonstrated237, OECs transduced with the lentivirus for chABC (LV-chABC) produce 
chABC in vitro. We confirmed that the OEC-chABCs transduced for this series of experiments were 
producing chABC before transplant and that there was no statistically significant difference between 





Figure 3-2. Transplanted OEC characterisation 
Canine OEC population was characterised before transplant by immunofluorescence staining. An example image 
(A, OEC-GFP cells in “expt 2”) illustrates the proportion of cells which are p75+ (red) and which have been 
transduced (GFP+, green) for OEC-GFP cells in experiment 2. There was no significant difference in the proportion 
of GFP+ cells (B, one-way ANOVA) or p75+ cells (C, Kruskall-Wallis) between OEC-chABC and OEC-GFP or between 
experiment 1 and 2. OEC-chABC produce active chABC, determined by Morgan Elson reaction, with no significant 
difference between the amount produced in experiment 1 and 2 (D). In both experiment 1 and 2 the enzyme 
actvity of OEC-chABC is significantly greater than that of OEC-GFP (****p<0.0001 and ***p=0.0007 respectively, 
one-way ANOVA with post hoc Tukey test), with activity of OEC-GFP measuring a negligible enzyme activity 




3.3.2  OEC survival and chABC action in vivo 
In animals culled at 2 weeks both OEC-GFP and OEC-chABC could be identified by immunofluorescent 
staining for GFP (Figure 3-3A). Quantification of surviving cell number, expressed as a percentage of 
transplanted GFP+ cells, showed no significant difference (unpaired t-test) between OEC-GFP and 
OEC-chABC survival (Figure 3-3B). A possible trend towards increased OEC-chABC survival was seen 
with twice the average number of OEC-chABC (0.95±0.73%) as OEC-GFP (0.45±0.27%) surviving at 2 
weeks). 
  
Immunohistochemistry for C4S at 2 weeks shows the presence of digested stubs of CSPGs localised 
around the cystic lesion and area of OEC transplant in OEC-chABC animals. A similar, but inverse, 
distribution is seen in neurocan immunostaining showing digestion of CSPGs in this area (Figure 3-3C). 
Staining for C4S is still seen at 9 weeks after OEC-chABC transplant (Figure 3-3D) but loss of neurocan 
staining around the lesion is not consistently seen at this time point. No comparable C4S staining is 
seen in OEC-GFP transplanted animals (Figure 3-3E). Cell survival was not quantified at the final time 
point as only occasional scarce cells were seen.  
 
No significant difference in relative chABC or GFP expression levels on quantitative PCR were seen in 
a segment of cervical cord at 2 weeks after transplant of OEC-chABC compared to OEC-GFP (Figure 
3-3F, G).  Although there is one outlier showing comparatively increased chABC expression in the OEC-
chABC group, and one outlier showing increased GFP expression in the OEC-GFP group. Relative chABC 
expression was considerably higher in LV-chABC transduced compared to LV-GFP transduced HeLa 





Figure 3-3. Cell quantification and presence of chondroitinase ABC after transplant 
Animals which did not meet the threshold for pellet retrieval on the staircase task still received OEC-chABC (n=4) 
or OEC-GFP transplant (n=4) which was used to determine cell survival and CSPG digestion at 2 weeks after 
transplant. An example image of a group of transplanted OEC-GFPs is shown, along with a higher magnification 
image used to quantify cell number (A). There was no significant difference between OEC-GFP and OEC-chABC 
survival (unpaired t-test) (B). Immunohistochemistry at this 2 week time point shows digested stubs of CSPGs 
(C4S, black) around the lesion (marked † in all images) and reduction of normal neurocan (black) across a similar 
area in a serial section (C). Immunohistochemistry for C4S at the end-point of the trial (9 weeks after injury) 
shows C4S staining still present in OEC-chABC transplanted animals (D). An example image of OEC-GFP showing 
no comparable C4S staining is also shown (E). No difference in chABC (F) or GFP (G) expression was detected 
between OEC-GFP and OEC-chABC groups by quantitative PCR on a small section of flash frozen spinal cord 




3.3.3 Montoya staircase (primary behavioural outcome) 
All animals receiving dorsal column crush injury (all animals except sham animals) showed a consistent 
decrease in number of pellets retrieved and accuracy of pellet retrieval at week 1 after injury 
compared to baseline (pre-injury) levels (Figure 3-4A,B). Sham animals showed a non-significant 
increase from baseline to week 1.  
 
For number of pellets retrieved (Figure 3-4A) there was a significant effect of group [F(3,34)=9.67, 
p<0.0001)] and time [F(7, 237)=10.5, p<0.0001] but no significant difference was seen between 
transplant groups (p>0.05 on post-hoc Tukey test). All transplant groups were significantly different 
to sham animals (p=0.033 for OEC-chABC, p=0.0005 for OEC-GFP and p=0.0002 for media animals).  
 
For accuracy of pellet retrieval (Figure 3-4B) a similar picture was seen with a significant effect of group 
[F(3,34)=5.4, p<0.0038)] and time [F(4.7, 159)=10.6, p<0.0001] but no significant difference was seen 
between transplant groups (p>0.05 on post-hoc Tukey test). All transplant groups were significantly 
different to sham animals (p<0.0001 for OEC-chABC, p<0.0001 for OEC-GFP and p<0.0001 for media 
animals).  
 
The number of pellets retrieved (Figure 3-4A) by OEC-chABC transplanted animals increased (from an 
average at week 1 of 6.11±3.49 to 9.69±3.56 at week 8) more than the OEC-GFP group (which 
increased from 5.86±4.83 at week 1 to 7.00±6.42 at week 8) and media group (which did not increase, 
remaining at 5.44±3.45 at week 1 and 5.50±4.54 at week 8). The accuracy of pellet retrieval (Figure 
3-4B) by OEC-chABC transplanted animals also increased (from an average at week 1 of 33.7±17.1% 
to 59.2±13.6% at week 8) more than the OEC-GFP group (which increased from 29.0±22.6% at week 
1 to 41.8±30.0% at week 8) and media group (which increased from 34.1±19.3% at week 1 to 
48.7±24.1% at week 8). As stated above, these changes were not significantly different between 
groups.  
 
Looking at the number of pellet retrievals by individual animals Figure 3-4C) shows more OEC-chABC 
animals improved over the 8 weeks of the experiment (6 of 8, 75%), compared to OEC-GFP (5 of 11, 
45%) and media (4 of 9, 44%) transplanted animals. One OEC-chABC treated animal died under 
anaesthesia during BDA tracer injection surgery after week 6 behaviour data collection hence the OEC-





Figure 3-4. Primary behaviour outcome; Montoya staircase 
Rats had weekly staircase testing. Line graphs displaying average number of pellets retrieved (A) and average 
accuracy of pellet retrieval (B) are shown for OEC-chABC (red, n=9), OEC-GFP (green, n=11) and media (blue, n=9) 
transplanted animals, as well as sham animals (black, n=9). Data points are mean±SEM. No significant difference 
was seen between  transplanted groups for either measure, but in both measures sham animals were 
significantly different from all transplanted groups. [F(3,34)=9.67, p<0.0001 mixed effects analysis, *p<0.05, 
***p<0.001 post-hoc Tukey], [F(3,34)=5.4, p<0.0038 mixed effects analysis, ****p<0.0001 post-hoc Tukey], 
mean±SEM].  
The number of pellets retrieved on staircase testing for each animal in each transplant group is displayed giving 
an overview of individual animal improvement or deterioration between week 1 and 8 after injury and transplant 
(C, each coloured line is one animal). One animal in OEC-chABC group died under anaesthesia during BDA 





3.3.4 Secondary behavioural outcomes 
3.3.4.1 Whishaw testing 
Forepaw retrieval was secondarily tested using the Whishaw reaching task performed at 6 weeks after 
surgery without training. Not all animals completed the task with only some animals in each group 
attempting to reach for pellets, numbers that performed the task were: n=4 for OEC-chABC, n=5 for 
OEC-GFP, n=6 for media transplanted animals and n=8 for sham animals.  
 
The number of pellets retrieved by sham animals (29.3±16) was significantly greater than media 
(10.0±4.1; F(3,19)=5.0, p=0.0104 one-way ANOVA, p=0.014 post-hoc Tukey test) and OEC-GFP 
(12±4.5, p=0.042) transplanted animals (Figure 3-5A). There was no significant difference between 
OEC-chABC transplanted animals (14.8±2.2) and any other group.  
 
The accuracy of pellet retrieval (Figure 3-5B) for OEC-chABC transplanted animals (61.7±9.2%) was 
greater than OEC-GFP (39.1±7.3%; F(3,19)=14.8, p<0.0001 one-way ANOVA, p=0.01 post-hoc Tukey 
test) and media (34.2±9.9%, p=0.0013) transplanted animals, and similar to sham animals 
(62.9±10.2%). Sham animals also showed greater accuracy than media (p=0.0001) and OEC-GFP 
(p=0.0015) transplanted animals. 
 
3.3.4.2 Ladder testing 
The number of foot slips while crossing horizontal rungs of a ladder was tested weekly. Sham animals 
and animals at baseline (before receiving a dorsal column crush injury) showed virtually no foot slips 
when crossing. All animals receiving injury showed an increased number of foot slips which then 
decreased over the 8 weeks of testing (Figure 3-5C). A significant effect of group [F(3,32)=28.1, 
p<0.0001)] and time [F(7, 185)=41.0, p<0.0001] was seen but there was no significant difference 
between transplant groups (p>0.05 on post-hoc Tukey test). All transplant groups were significantly 
different to sham animals (p<0.0001 for all groups). 
 
OEC-chABC transplanted animals had the largest reduction in foot slips (8.47: from 15.8±6.4 at week 
1 to 7.33±3.4 at week 8), OEC-GFP animals had less reduction (5.20: from 11.2±3.4 at week 1 to 




3.3.4.3 Gait analysis 
Gait analysis at the final behaviour testing time-point 8 weeks after surgery (Figure 3-5D) shows no 
differences in paw print width between transplant groups (Figure 3-5E) but significant differences 
were seen in stride length [F(3,33)=4.9, p=0.0062] and base of support [F(3,33)=4.1, p=0.015 one-way 
ANOVAs].  
 
Both OEC-chABC (277±29mm) and sham (280±44mm) animals had a longer fore-limb stride length 
than media transplanted animals (213±63mm, p=0.03 and p=0.023 respectively on post-hoc Tukey 
test), but there was no significant difference between OEC-chABC and OEC-GFP transplanted animals 
(226±45mm) or OEC-GFP and media transplanted animals (Figure 3-5F).  
 
Base of support in the fore-limbs (Figure 3-5G) was narrower in OEC-chaBC animals (13.4±5.9mm) 
than OEC-GFP (22.1±7.1mm, p=0.019; post-hoc Tukey test) and media (21.6±5.8mm, p=0.041) 





Figure 3-5. Secondary behaviour outcomes; Whishaw reaching task, ladder crossing, gait analysis 
Fore-paw reaching ability was assessed at 6 weeks, without training, using the Whishaw task. The number of 
pellets retrieved (A) in 5 minutes and accuracy of this retrieval (B) was recorded. Not all animals completed this 
task, group sizes were therefore as follows; cOEC-chABC n=4, cOEC-GFP n=5, media n=6, Sham n=8. Sham animals 
retrieved more pellets than OEC-GFP and media transplanted animals (p=0.042 and 0.014 respectively), but were 
not significantly different to OEC-chABC transplanted animals. OEC-chABC transplanted animals showed a higher 
accuracy of retrieval than both OEC-GFP (p=0.010) and media (p=0.0013) transplanted animals (B). There was 
no significant difference between sham animals and OEC-chABC transplanted animals but sham animals 
performed significantly better than OEC-GFP (p=0.0015) and media (p=0.0001) transplanted animals.  
Ladder crossing was tested weekly, line graph shows number of foot slips for each group (C, mean±SEM). There 
was no significant difference between transplant groups, but sham animals were significantly different to all 
other groups and showed virtually no foot slips [F(3,32)=28.1, p<0.0001 mixed effects analysis; ****p<0.0001 
post-hoc Tukey) 
Gait analysis was performed by ink tracing of forepaws as animals walked along a 1m runway, example traces 
for media and OEC-chABC transplanted animals are shown (D) illustrating example stride length (i) and base of 
support (ii) measures. No difference was seen in paw print width between groups (E). Both OEC-chABC and sham 
animals showed longer fore-limb stride length than media transplanted animals (p=0.03 and 0.023 respectively), 
with no significant difference between OEC-chABC, OEC-GFP and sham animals (F). OEC-chABC transplanted 
animals showed a significantly narrower fore-limb base of support than OEC-GFP and media transplanted 
animals (p=0.019 and 0.041 respectively), which was not significantly different to sham animals (G).  
[Unless otherwise stated displayed values are mean±SD, statistical analysis is by one-way ANOVA followed by 
Tukey post-hoc comparisons, *=p<0.05, **=p<0.01, ***p<0.001.] 
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3.3.5 BDA axon tracing 
Example immunofluorescent (Figure 3-6A) and processed (Figure 3-6B) images for analysis of BDA 
positive axons in dorsal sections of spinal cords at 8 weeks after transplant are shown for media and 
OEC-chABC transplanted animals.  An increased number of axons sprouting into grey matter cranial 
to the lesion can be seen in the OEC-chABC transplanted group in higher magnification images (Figure 
3-6B’). This is reflected when quantified with the ratio of BDA positive pixel density in cranial 
grey:white matter significantly greater in this OEC-chABC group compared to media [F(2,25)=12.9, 
p=0.0001 one-way ANOVA, p=0.0004 post-hoc Tukey test] and OEC-GFP (p=0.0005 post-hoc Tukey) 
transplanted animals (Figure 6C). There is no difference in the amount of BDA staining caudal to the 
lesion between groups (Figure 3-6D) (Kruskal-Wallis).  
 
3.3.6 Cranial and caudal vGlut1 and 5HT immunostaining 
Immunostaining for vGlut1 in serial transverse ends taken 1cm cranial and caudal to the lesion were 
quantified for groups of lamina within the grey matter (Figure 3-7, Figure 3-8). No significant 
difference was seen between groups in any region cranial or caudal to the lesion (Kruskal-Wallis for 
each region).  
 
Immunostaining for 5HT in similar transverse ends caudal to the lesion was quantified for dorsal and 
ventral grey and white matter regions. A significant increase in 5HT staining was seen in OEC-chABC 
compared to media transplanted animals in middle (p=0.025 Kruskall-Wallis, p=0.036 Dunn’s post-hoc 
test) and ventral grey matter (p=0.0093 Kruskall-Wallis, p=0.021 Dunn’s post-hoc). A significant 
increase in 5HT staining in OEC-chABC transplanted animals compared to all other groups was also 
seen in ventral white matter [F(3,12)=8.0, p=0.0035 one-way ANOVA, post-hoc Tukey test p=0.005 
compared to media, p=0.009 compared to OEC-GFP, p=0.016 compared to sham]. A similar trend, not 
reaching significance, was seen in middle white matter (Figure 3-9).  
 
3.3.7 Confirmation of complete CST lesions 
PKCƔ staining of all cords showed complete CST lesions in all animals in this study. Example images of 






Figure 3-6. BDA axon tracing analysis 
Media, OEC-GFP and OEC-chABC transplanted animals were culled 2 weeks after BDA injection into the motor 
cortex. Example images of spinal cord dorsal sections through the lesion (†) for media and OEC-chABC transplants 
show immunostained BDA (A) and thresholded images (B) for quantification. White dashed lines show regions of 
interest for cranial white (i) and grey (ii) matter and caudal white matter (iii). Corresponding inset images (A’, B’) 
show white/grey matter border (yellow dashed line, grey matter top) at a point cranial to the lesion illustrating 
axon sprouting. Quantified, there is a significant increase in the amount of BDA staining in the cranial grey matter 
in the OEC-chABC transplanted group compared to both media and OEC-GFP transplants (C) determined by the 
difference in BDA+ pixel density within grey matter compared to white matter regions of interest cranial to the 
lesion (one-way ANOVA, post-hoc Tukey test, ***p<0.001). There is no significant difference between 





Figure 3-7. Quantification of vGlut1 immunostaining cranial to the dorsal column crush lesion 
Transverse sections taken 10mm cranial to the lesion were immunostained for vGlut1 and threshold images were 
analysed for positive staining within sections of grey matter lamina by automated reference to a pre-specified 
template (A). White lower-case letters correspond to lamina regions quantified in upper-case figure panels; 
lamina 1 (b/B), lamina 2 (c/C), lamina 3 (d/D), lamina 4 and 5 (e/E), lamina 6-9 (f/F). No significant difference 






Figure 3-8. Quantification of vGlut1 immunostaining caudal to the dorsal column crush lesion 
Transverse sections taken 10mm caudal to the lesion were immunostained for vGlut1 and threshold images were 
analysed for positive staining within sections of grey matter lamina by automated reference to a pre-specified 
template (A). White lower-case letters correspond to lamina regions quantified in upper-case figure panels; 
lamina 1 and 2 (b/B), lamina 3 (c/C), lamina 4 and 5 (d/D), lamina 6-9 (e/E). No significant difference was seen 




Figure 3-9. Quantification of 5HT immunostaining caudal to the dorsal column crush lesion 
Transverse sections taken 10mm caudal to the lesion were immunostained for 5HT and threshold images were 
analysed for positive staining regions of spinal cord by automated reference to a pre-specified template (A). 
White lower-case letters correspond to regions quantified in upper-case figure panels; dorsal grey matter (b/B), 
middle grey matter (c/C), ventral grey matter (d/D), middle lateral white matter (e/E), ventral white matter (f/F). 
A significant difference was seen between media and OEC-chABC groups in middle and ventral grey matter 
sections (C,D) and between OEC-chABC and all other groups for ventral white matter (F). A similar trend was seen 
in middle white matter (E) but did not reach significance. [Kruskal-Wallis with post-hoc Dunn’s test, mean ±SD, 




Figure 3-10. Establishing complete CST lesions with PKCƔ staining 
Immunofluorescence labelling with PKCƔ for intact CST axons (*) on transverse sections of spinal cord cranial and 
caudal to the lesion. Complete lesions show no PKCƔ labelling in the caudal sections, incomplete injuries show 
some remaining intact staining (white arrow). All animals in this study had complete injuries (image above of 




3.3.8 Migration of OEC-GFP and OEC-chABC 
Example images are shown (Figure 3-11A) of segmentation and image processing used in automated 
cell counting of OEC-GFP and OEC-chABC grown on control PLL or inhibitory CSPG. Quantification 
(Figure 3-11B) shows that both OEC-GFP and OEC-chABC proliferate on PLL with no significant 
difference in proliferation [F(3,8)=28.0, p=0.0001 two-way repeated measure ANOVA, p>0.05 post-
hoc Tukey test]. Only OEC-chABC are able to proliferate on CSPG substrates, OEC-GFP cell count 
decreases throughout the 5 days of culture and has a significantly reduced cell count compared to all 
other groups (p<0.0001 post-hoc Tukey). OEC-chABC cell count is also significantly reduced compared 
to both types of OECs grown on PLL (p<0.0001) but do increase from the starting value and have a 
markedly higher cell count (p<0.0001) than OEC-GFP.  
 
Automated image analysis was also used to identify OEC processes and example images are shown 
(Figure 3-11C). Quantification (Figure 3-11D) shows that OEC-GFP on PLL put out the longest processes 
compared to all other groups [F(3,8)=377, p<0.0001 two-way repeated measures ANOVA, p<0.0001 
post-hoc Tukey test). OEC-chABC process length is slightly less, and not significantly different between 
PLL and CSPG substrates, while OEC-GFP process length on CSPG is markedly lower than all other 
groups (p<0.0001).  
 
Cell tracking to determine distance migrated was performed manually, example traces are shown for 
each condition (Figure 3-11E). Migration distance is similar between OEC-GFP and OEC-chABC on PLL 
and OEC-chABC on CSPG, but OEC-GFP migration is significantly reduced on CSPG compared to all 
other groups [F(1,8)=27.8, p=0.0008 for transduction type and F(1,8)=47.0, p=0.001 for substrate on 
two-way ANOVA; post-hoc Tukey test: p=0.0007 compared to OEC-chABC on CSPG, p=0.0001 





Figure 3-11. In vitro comparison of proliferation, attachment and migration characteristics of OEC-chABC and 
OEC-GFP on CSPG substrate 
OEC-chABC and OEC-GFP were cultured on CSPGs or PLL (control) substrates and imaged every hour over 5 days 
using an Incucyte Zoom microscope. Incucyte images were batch processed in ImageJ to create a segmented, 
binary, inverted image isolating cell bodies – example images are shown for each condition (A) – allowing 
automated and objective quantification of cell number for each image (B). OEC-GFP were unable to proliferate 
on inhibitory CSPG while OEC-chABC were able to proliferate significantly better; significant differences are seen 
in cell count over time between all conditions (p<0.0001 two-way repeated measures ANOVA, post-hoc Tukey 
test) except between OEC-GFP and OEC-chABC on PLL (marked ‘ns’). Proprietary IncuCyte ‘NeuroTrak’ software 
was used to identify OEC processes and quantify the total length of these processes in each image (C, processes 
recognised and quantified by software are highlighed yellow). Quantification (D) shows OEC-GFP are unable to 
extend processes on CSPG, while OEC-chABC extend processes equally well on PLL or inhibitory substrates but 
these are both less than OEC-GFP on PLL; significant differences between all groups (p<0.0001, two-way repeated 
measures ANOVa, post-hoc Tukey test) except between OEC-chABC on PLL and CSPG. Manual migration tracking 
produces example tracks of cell movement, shown for each condition (E). OEC-GFP and OEC-chABC migrate 
similar distances on PLL, but OEC-GFP migrate significantly less far on CSPG compared to all other conditions 





The results presented here are the first behavioural results reported after spinal cord transplant of 
OECs modified to express chABC. They are also the first behavioural data obtained for canine OEC 
transplant in rodent SCI, and the first fore-paw reaching results for OEC transplant following dorsal 
column crush injury. The results presented are obtained after randomisation of surgeries and 
concealed allocation of groups, with blinded surgery, cell transplant and collection of behaviour data.  
 
The data shows evidence of OEC-chABC benefit over OEC-GFP and media controls in terms of 
improved accuracy of fore-paw reaching in Whishaw testing and improvements in fore-limb gait, along 
with supportive histological evidence of axon sprouting (BDA) and possible regeneration (5HT). Any 
impact of transplantation did not, however, reach significance in our primary outcome measure of 
reaching in the Montoya staircase. We show no evidence that canine OEC transplant alone (OEC-GFP 
transplant group) provides functional benefit after dorsal column crush injury in rats.  
 
3.4.1 OEC survival and duration of chABC administration 
In previous studies of chABC after cervical SCI, chABC was administered at different time-points after 
injury for variable periods of time, with varying forepaw reaching outcomes seen213,228,235. For 
example, a study using doxycycline regulatable viral vector delivery of chABC injected immediately 
after dorsal contusion injury to the CST at C4 only saw significant increases in Whishaw reaching after 
8 weeks (not 2 weeks) of chABC expression235. In our study, the time-period over which chABC would 
be administered is dependent on transplanted OEC survival. This is likely to be variable and potentially 
unpredictable, but we have demonstrated that transplanted OECs (OEC-GFP and OEC-chABC) survive 
a minimum of 2 weeks, and that OEC-chABCs digest CSPGs in this time (Figure 3-3). Presence of OECs 
expressing GFP at 2 weeks implies expression of active chABC until this time point as chABC is under 
the same promotor in OEC-chABC as GFP is in OEC-GFP237. This is a similar time-point to studies using 
direct administration of chABC and reporting recovery of forepaw reaching213,228,246. It is possible that 
OEC-chABCs survive and deliver chABC over a slightly longer time-period than this; further 
experiments with animals culled at serial time points would be required to determine this, although 
by 8 weeks we see only occasional sparse cells. 
 
The cell survival reported here (0.95±0.73% at 2 weeks for OEC-chABC) is low, but of a similar order 
to that seen for previous OEC transplant in rats where 3.1±1.4% of transplanted OECs were seen 
surviving at 3 weeks after T8/9 contusion injury205. This was with allogenic rat OECs transplanted into 
rat SCI and it is intuitive that xenotransplanted cells as used in this study will survive for less time than 
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autologous or allograft cells. However, the precise effect of immunosuppressive treatment is hard to 
predict. In a previous xenotransplant of canine OECs into rat spinal cord, considerably more OECs 
(number not quantified) were seen surviving in athymic ‘nude’ rats at 2 weeks than cyclosporine 
immunosuppressed ‘immunocompetent’ rats, while no transplanted cells were found in 
immunocompetent rats not given immunosuppression367. This corresponds to data from our own lab; 
we recently showed ~6% survival of OECs in athymic rats at 4 weeks238, considerably higher than the 
survival seen at 2 weeks in this study in cyclosporine immunosuppressed Wistar rats. Cyclosporine 
only attenuates T-cell responses368, the dominant response seen after allografts369, but after 
xenografts there is additional involvement of the innate immune system (e.g. natural killer cells) which 
may explain the lower survival for xenotransplanted cells despite immunosuppression. 
 
Given the presence of normal morphology OEC-chABC at 2 weeks still expressing GFP on histology, it 
is perhaps surprising that we do not detect chABC expression by qPCR at 2 weeks. It is possible this is 
due to migration of OECs and the way the cord was segmented for analysis. It is also possible that 
chABC and GFP were at levels too low to detect due to the low cell survival. The qPCR methodology 
has been reported in experimental guidelines to be sensitive to down to 3 copies of a target gene370 
(the “limit of detection”), however this does not take into account RNA isolation and losses at other 
steps in the process (e.g. efficiency of conversion of mRNA to cDNA), or the signal:background ratio in 
tissue. The actual limit of detection in tissue is likely to be considerably higher than this, standards for 
detection of microbiological contamination (e.g. C. jejuni in milk) suggest 1500 cells is the limit of 
detection371. This is around the number of GFP+ OECs we see surviving in the spinal cord based on 
immunohistochemistry, and we would see less than this number in a given segment tested by PCR. 
Further work to optimise the PCR analysis could check for PCR detection of chABC expression on lower 
numbers of cells in vitro to determine the limit of detection, on removal the spinal cord could be 
further segmented or segmented differently (e.g. to remove the ventral cord), or direct injection of 
the virus into the spinal cord could be tested as a positive control for qPCR detection.  
 
Positive C4S staining and loss of neurocan staining at 2 weeks does confirm CSPG digestion has 
occurred during the first 2 weeks after transplant of OEC-chABC, and therefore that active chABC was 
present over this time period. Neurocan levels are known to peak at 2 weeks after dorsal column crush 
injury73.  C4S staining is still present at 8 weeks but inverse loss of neurocan is no longer seen 
suggesting CSPGs have re-formed and chABC is no longer active (or is active only at very low levels) at 
this time-point. C4S stubs have been shown to persist for up to 10 weeks after very high (100U) doses 
of chABC and for 4 weeks with a lower dose (50U) after transection SCI257. In a separate experiment 
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C4S was also shown to persist for 4 weeks in uninjured rat brain after injection of 0.15U chABC372. 
Neurocan begins to return 7 days after single injection of chABC (0.15U) as determined by western 
blot on rat brain after injury225. These data points imply that chABC is likely to have been present up 
to 4 weeks after transplant in this study, although further experiments to look for surviving cells at 
intervening time-points, and/or optimisation of qPCR for gene expression would be required to 
determine this.  
 
3.4.2 Forepaw reaching  
We saw no significant effect of OEC (OEC-GFP group) or OEC-chABC transplant on our primary 
outcome measure of Montoya staircase forepaw reaching, despite a trend towards this and an 
indication that more OEC-chABC transplanted animals improved compared to other groups when 
looking at individual animal responses to treatment. We did however see an improvement after OEC-
chABC transplant on forepaw reaching compared to both OEC transplant and media controls on one 
of our secondary outcome measures, Whishaw testing, at 6 weeks after injury. 
 
That our olfactory mucosa canine OEC xenotransplant had no effect on forepaw reaching in our study 
is perhaps consistent with previous literature162,163,169,193,194,356–358. Although one previous study using 
xenotransplant (of mouse OECs transplanted into rats in the chronic phase) showed improvement, 
this study was not blinded, had weaker controls, and used olfactory bulb OECs356. In contrast, two 
better controlled xenotransplant studies using olfactory mucosa OECs (with mouse OECs transplanted 
into rats at time of injury), do not show an improvement of OECs on forepaw reaching193,358. However, 
these two studies use a more severe model of SCI which also affects the dorsolateral rubrospinal tracts 
making comparison difficult; it has been shown that injury to either the corticospinal or rubrospinal 
tract can be partially compensated for by the remaining one373. 
 
There are too many variables to draw out from these different studies firm conclusions about whether 
xenotransplant, source of OECs, type of lesion, or timing of transplant might be affecting efficacy, but 
it is interesting to note that of five studies with olfactory bulb OECs (one xenograft356 and the 
remainder allograft162,169,194,357), four, including the xenotransplant, report improvements in forepaw 
reaching after transplant162,169,356,357. Although only one of these has blinded behaviour testing and 
robust controls357. By comparison, of three studies with olfactory mucosa cells only one (allograft) 
transplant in the chronic phase reported improvement163 while two better controlled studies 
transplanting at the time of injury report no improvement193,358. However, these two studies are also 
xenotransplants and (as mentioned above) use more severe models of SCI. Our study increases this 
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number to three out of four studies using olfactory mucosa OECs not showing improvement, but all 
studies not showing improvement use xenotransplantation. A tentative suggestion can be made that 
mucosal OECs and xenotransplant of OECs are negative factors in OEC efficacy after cervical SCI in rats. 
This would be partially supported by work in a dorsal root avulsion model. Comparing two studies by 
the same group using the same methods; transplant of olfactory bulb OECs showed  an improvement 
in forepaw reaching374 while transplant of olfactory mucosa OECs did not375. However, although these 
studies use the same paradigm, they were published 5 years apart and obviously do not provide a 
direct comparison.  
 
Aligned with the more convincing literature for chABC improving forepaw reaching212,213,228,235,246, our 
results show an improvement in forepaw reaching after OEC-chABC transplant as determined by 
Whishaw testing. Not all animals attempted to retrieve pellets in this task, likely because they had not 
been habituated to the testing or trained to perform it previously, therefore reducing the numbers in 
each group. Power analysis (ß=0.8, a=0.05) based on previously reported data for Whishaw reaching 
after cervical contusion injury and doxycycline regulatable viral delivery of chABC235 suggests 4 animals 
per group would be sufficient to detect a similar difference between chABC treated animals and 
controls at the final time point (reported accuracy of retrieval of 43.4% for chABC treated and 11.9% 
for GFP controls with a standard deviation of 15.3). Similar power analysis based on data reported for 
Whisaw reaching after dorsal column crush injury with 10 days of injected chABC and rehabilitation246 
suggests a similar ‘n’ of 3 per group is sufficient (based on number of pellets retrieved for chABC of 23 
and control 14 with SD 3.6). This suggests our Whishaw reaching results remain appropriately 
powered, and provides evidence that OEC-chABC are able to deliver functionally relevant quantities 
of chABC.  
 
3.4.3 Quantity of chABC administered 
The exact quantity of chABC delivered by the OECs is not known. Morgan Elson reaction provides a 
value for chABC activity in vitro (Figure 3-2), which is repeatable across different transductions and 
cell cultures (data not shown). Determining how much chABC is delivered in vivo, however, will be 
highly dependent on cell survival. Further discussion of chABC quantification and comparison to 
standard commercial concentrations is explored further in the next chapter. 
 
Quantity of chABC delivered is also not clear for direct viral delivery of chABC. A study using a non-
temporally controlled lentiviral vector to deliver chABC in thoracic contusion lesions demonstrated 
higher levels of CSPG digestion at 3 days and 2 weeks after viral injection compared to single injection 
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of active chABC using western blot analysis211, implying more chABC was delivered by viral injection 
compared to direct chABC injection. However, this is not comparable to the repeated chABC injection 
protocol used in the functional studies of active chABC administration.  Quantity of chABC delivered 
by OEC-chABC in vivo is explored further in the next chapter.  
 
3.4.4 Ladder crossing  
Here we report no difference between transplant groups in ladder crossing ability. In the only previous 
report of OEC transplantation after dorsal column crush injury in rats, using the TEG3 clonal cell line 
of OECs originating from rat olfactory bulb192,  the authors reported a clear reduction in number of 
foot slips crossing a horizontal beam after OEC transplantation compared to vehicle alone. The 
number of foot slips walking across a beam and crossing rungs of a ladder test require similar 
combined proprioceptive and motor functions376 but our study does not see a similar significant effect 
on ladder foot slips of either OEC-GFP or OEC-chABC. Whether this is due to the difference in specific 
behavioural test, the difference between allo- or xenotransplant of cells (and presumed lower OEC 
survival), or between olfactory bulb cells and olfactory mucosa cells is not possible to determine. 
Notably although behavioural testing was reported to be blinded in the above study, blinding of 
surgeries and transplants are not specified, and nor is randomisation or allocation concealment. 
 
The first report of behavioural improvement after SCI due to chABC administration showed a 
reduction in number of foot slips during beam and grid walking following C4 dorsal column crush 
injury209. More recent studies using viral delivery of chABC also showed a decrease in foot slips on 
ladder crossing212,235. In all of these studies rats received only chABC and no rehabilitation after injury. 
By comparison, in a study testing types of rehabilitation in combination with chABC administration 
immediately after injury, ladder foot slips were only reduced by general rehabilitation, with no effect 
of specific rehabilitation for forepaw reaching or chABC administration itself246.  
 
This finding regarding specific rehabilitation having no, or possibly a negative, effect on ‘untrained’ 
behaviours was also seen in another report. Rats which received rehabilitation training for reaching 
improved reaching ability after SCI without any other treatment, but this specific rehabilitation 
increased foot slips on ladder testing compared to animals receiving no rehabilitation377. All animals 
in our study received specific forepaw reaching rehabilitation, which may explain why we do not see 
a significant effect of transplant group on ladder crossing here, and re-iterates the importance of both 
rehabilitation after SCI and ensuring training is designed for the desired outcome377,378. 
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3.4.5 Gait analysis 
In this study, OEC-chABC transplant but not OECs alone modified gait after injury. Stride length was 
increased, and base of support was decreased. Base of support gives an indication of the balance of 
an animal, and has been shown to be a sensitive measure after cervical SCI365. Both of these changes 
are consistent with those reported after chABC administration in previous literature, with direct 
administration of chABC at time of injury being shown to similarly affect stride length in two 
studies209,228 and base of support in one of these209. This provides additional supportive evidence that 
OEC-chABC are able to deliver functionally relevant quantities of chABC.  
 
3.4.6 Axon sprouting and regeneration 
Axon sprouting following chABC administration after SCI is a consistent finding with both direct 
injection of chABC209,228,246 and viral delivery211,235, and we also see clear increased sprouting of BDA 
stained axons cranial to the lesion with OEC-chABC transplant here. Despite improvements in forepaw 
reaching, we see no significant difference in BDA positive axons caudal to the lesion. The BDA labelled 
axons are specific to the CST, a tract that is known to be particularly refractory to treatment242,379. It is 
possible that the improved forepaw reaching and gait we see is a result of plasticity and compensatory 
re-organisation of neighbouring tracts not labelled with BDA. Indeed this compensation has previously 
been suggested in the rubrospinal215,373 and reticulospinal380 tracts. Increased levels of 5HT caudal to 
the lesion has previously been reported after injected enzyme244,246,381 and viral delivery of chABC211. 
 
We see no changes in vGlut1 expression cranial or caudal to the lesion in any group. Increased 
expression in certain laminae was reported after doxycycline regulated viral delivery of chABC after 
dorsal cervical contusion235. Changing expression could be reflective of plastic changes in a number of 
pathways relevant to reaching and grasping control; vGlut1 is indicative of excitatory input from the 
CST382,383, primary myelinated sensory afferents from muscle mechanoreceptors384,385, or 
proprioceptive afferents386. We may not see changes in vGlut1 expression in this experiment because 
the transverse sections we took were 1cm from the lesion (further than the 1 vertebral body reported 
in that study). The area of CSPG digestion (C4S staining) we see is also smaller so any plastic changes 
occurring are likely to be seen closer to the lesion within this area with reduced CSPGs and perineuonal 
nets. Plasticity of the CST after chABC has previously been reported to be very localised to the lesion 
site (within the vertebral segment only)246. Transverse sections closer to the lesion would allow us to 
test this theory, but due to the laminae distribution dorsal sections at this level would not allow 
accurate comparisons to be made between animals and transplant groups.  
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3.4.7 Proliferation, attachment and migration of OECs and OEC-chABC on CSPGs 
Although a difference in cell number between OEC-GFP and OEC-chABC on CSPG substrate is seen in 
vitro over 5 days, we do not see a comparable difference in cell number 2 weeks after transplant in 
vivo (despite a trend to increased OEC-chABC number) (Figure 3-3). If chABC improves the ability of 
OECs to attach to substrate, as implied by the process extension data in vitro, it is possible that there 
may be more of a difference in OEC number at earlier time-points in vivo not examined here. Future 
work could examine the survival of cells in vivo at earlier or more frequent time points.  
 
Our data on reduced migration of OECs on CSPG and subsequent increased migration with chABC in 
vitro is consistent with a previous report361, although in this report migration speed was not returned 
to normal levels with commercial chABC added to media as it was by OEC-chABC here.  
 
Manual tracking of migration is time consuming. Further work (performed as part of a Masters project 
by Mr Robert Howe and so not reported here) has gone on to show that fluorescent imaging (using 
GFP) of these OECs and increasing imaging frequency to every 10 minutes allows for better 
segmentation of cells and automated migration tracking using the TrackMate plugin387 for Fiji ImageJ. 
Automated tracking of cells allows more objective measurements to be taken and can more feasibly 
be applied to all cells in a field over a longer period of time, giving more robust data for migration. In 
future work it would be interesting to repeat the experiments reported here with automated 
migration. Using this technique, it would be fairly straightforward to perform further experiments that 
could explore the mechanisms underlying the reduced migration of OECs on CSPGs. For example, 
migration in vitro and in vivo of OECs towards activated  TNFa has been reported to be dependent on 
ERK signalling388. Proliferation, process extension and migration measured using these automated 
techniques could also be used as measures to compare chABC delivery systems in vitro, e.g. OEC-
chABC compared to commercial chABC or chemically stabilised (sucrose or trehalose) chABC. This 
would be most interesting in co-culture with neuronal cells where neurite length could also be 
assessed. 
 
We do not see long-distance migration of either type of OECs away from the lesion, as observed 
previously in our lab after transplanting canine OEC-GFP and OEC-chABC into athymic rats in acute 
dorsal column crush injury238. Migration in vivo of both cell types was not formally assessed in this 
experiment, in part due to the low cell survival, but this would be interesting to establish in future 
experiments. Some possible methods that could be applied to tracking OECs in vivo are discussed in 




Rats receiving canine OEC-chABC show an improvement in our secondary outcome measure of 
forepaw reaching (Whishaw testing), but do not show an improvement in ‘untrained’ ladder crossing. 
Changes in gait after OEC-chABC provide additional supportive evidence that OEC-chABC express 
sufficient chABC to drive functional improvements in combination with rehabilitation, and we see 
sprouting of CST axons in the presence of OEC-chABC. These modified OECs may therefore represent 
a novel delivery method of chABC and combination therapy for SCI.  
 
We do not show any evidence for the benefit of canine OEC transplant alone in this xenotransplant 
model of dorsal column crush cervical injury where OEC survival is limited. The evidence for OEC 
transplant in cervical injury is weaker than that for thoracolumbar injury126,362 and indeed a recent 
meta-analysis of animal models of SCI showed the greatest effect of OEC transplant after thoracic 
injuries104. The next chapter therefore sets out to test OEC and OEC-chABC transplant in a rodent 




Chapter 4  
 
Functional effect of canine olfactory ensheathing 
cells expressing chondroitinase ABC after transplant 





Given the proof of concept evidence presented in the previous chapter that OEC-chABC can deliver 
sufficient chABC to improve functional outcomes (forepaw reaching and gait), we extended this work 
to investigate OEC-chABC efficacy transplanted in chronic thoracic contusion injuries. This model more 
closely reflects the type of injury seen in pet dogs with SCI, where OEC transplant123 and chABC 
administration208 have both, in separate phase 2 trials, been shown to improve walking co-ordination. 
However, recovery was limited and not all patients responded – combination therapy may increase 
efficacy.  
 
Contusion injuries are also the most common type of SCI in humans, representing around 50% of 
injuries107,389, and are therefore arguably the most important type of injury in which to demonstrate 
efficacy before translation to human clinics106. Additionally, testing an intervention in the chronic 
phase of injury is an important step before translation; stimulating axon regeneration in the chronic 
environment is considered more challenging than in the acute phase390 and is more likely to be the 
phase in which experimental therapies are trialled clinically.  
 
It has been suggested that OEC transplant has differential effects on different tracts and types of 
injury, providing a greater effect in thoracolumbar injuries compared to cervical injuries126,362. 
Thoracolumbar injury provides an opportunity to test effect of an intervention on walking, obviously 
of more direct relevance to pet dogs than reaching ability. Behavioural testing of walking can be 
performed in many ways but the most standard and commonly performed test is using the BBB score 
to grade open field locomotion based on joint movement, weight support and coordination98.  
 
The evidence for OEC efficacy in improving BBB score after experimental thoracic contusion injuries is 
mixed, with 4167,176,391,392 out of 8205,206,393,394 studies showing improvements in BBB score. However, 
the evidence is generally of higher quality than that for OEC transplant in cervical injury. All studies 
have appropriate controls that received a surgical intervention and injection of media (or fibroblasts) 
controlling for surgical transplant of OECs and received these interventions contemporaneously (or 
within a randomised block design).  
 
There is therefore some good evidence for OEC efficacy in thoracic contusion injury, but clearly this is 
not consistently seen. This inconsistency is difficult to attribute to one specific factor, but there are a 
number of variables which may have an impact, for example injury severity (e.g. weight and height of 
contusion injury for weight drop models), thoracic level of injury, number of OECs transplanted, 
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degree of OEC survival, number of injections, passage of OECs at transplant198,204, time between cell 
preparation and transplant, strain of rat. As previously discussed, meta-analyses of large numbers of 
studies have attempted to dissect these variables126.  
 
There are only a few studies of chABC used alone in experimental sub-acute or chronic thoracic 
contusion injury models. Many studies use combination treatments with chABC, for example with 
neural progenitor cells and growth factors395 or peripheral nerve graft and growth factors396, and these 
studies do not have a single therapy chABC group (for a review see Muir et al. 2019232). However, 
there are 5 studies229,257,258,397,398 which use chABC single therapy and four of these studies showed 
improvements in BBB score with chABC treatment229,258,397,398.  
 
The consistency of findings gives some confidence in the efficacy of chABC in thoracic contusion injury, 
although improvements with chABC alone are small in the chronic phase229,258. Combination of OEC 
transplant and chABC, therefore, may provide greater and more consistent improvement than either 
OECs or chABC alone as seen with combined delivery in acute thoracic transection259,260 and sub-acute 
(1 week) thoracic crush399 injuries.  
 
4.1.1 Aims and hypotheses 
The aim of this experiment was to evaluate recovery of locomotion with canine OECs and OEC-chABCs 
transplanted 3 weeks after thoracic contusion SCI in rats. We hypothesised that the greatest recovery 
would be with OEC-chABC transplant, and that a greater effect of OECs alone might be seen in this 
thoracic model compared to the cervical model in the previous chapter.  
 
The in vivo part of the work in this chapter was kindly hosted by Dr Ito’s laboratory in Nihon University 
(Japan) and additional funding provided as part of a British Council and Japan Society for the 
Promotion of Science programme. The in vivo work was therefore time-limited to the duration of this 










4.2.1 OEC culture and genetic modification  
Cell culture and genetic modification was performed as described in thesis methods and the previous 
chapter. Cells were transduced with LV-GFP or LV-chABC in a 24 well plate, grown to confluence and 
frozen into 1ml vials. These transduced cells were shipped frozen on dry ice to Nihon University, Japan 
where culture was re-established. Cells from the same dog (Bethan) and same original vial as reported 
in the previous chapter were used.  
 
4.2.2 Morgan Elson 
Morgan Elson reaction for chABC activity was performed as described in thesis methods. In addition, 
commercial chABC (0.01, 0.05 and 0.1 U) was tested in the same reaction to give a direct comparison 
with OEC-chABC produced enzyme for quantification.  
 
4.2.3 Immunocytochemistry 
Immunocytochemical staining was performed for p75, fibronectin and GFP as per thesis methods. A 
sample of OEC-GFP and OEC-chABC were seeded onto slides for immunostaining before being shipped 
to Japan.  
 
Quantification of number of GFP positive cells was determined in Japan 3 days before transplantation 
using phase and fluorescent imaging (Keyence BZ-X700 microscope with 10x objective) of 3 fields in 
each of 3 wells of OEC-GFP and OEC-chABC (>100 cells per field). Automated thresholding and 
segmentation in Fiji ImageJ of phase and green fluorescent fields provided cell counts for phase and 
GFP+ cells.    
 
4.2.4 Surgeries and cell transplantation 
A total of 24 adult male Wistar rats (Charles River, Japan) were used, weighing 175-200g at time of 
first surgery, housed as described in thesis methods. All surgical procedures had ethical permission 
from the animal experiment committee of Nihon University (AP13B057) and were performed in 
accordance with UK Home Office guidelines and regulations.  
 
For surgery, animals were premedicated with medetomidine (250µg/kg) and buprenorphine 
(0.02mg/kg) by intraperitoneal injection and received carprofen pain relief (5mg/kg) sub-cutaneously. 
Animals were induced in an induction chamber and maintained on isoflurane in oxygen. Skin over the 
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dorsal thoracolumbar area was shaved and surgically prepared before a dorsal laminectomy was 
performed at T10. Vertebrae T9 and T11 were stabilised using clamped forceps and a 250kdyn 
impactor contusion injury (velocity 1mm/s, dwell time 0s) performed midline at T10 (Infinite Horizon 
Impactor, Precision Systems and Instrumentation)400. Synthetic replacement dura (Gore Preclude PDX) 
was placed above the injury site to facilitate lesion localisation for the repeat ‘transplant’ surgery. 
Injury surgeries were performed by Dr Daisuke Ito, Mr Naoki Sekiguchi and me. Body temperature was 
maintained on a heat mat throughout surgery and animals recovered in individual cages after routine 
tissue and skin closure. Bladder size was checked twice daily in the immediate post-operative period 
and the bladder was manually emptied if necessary.  
 
Three weeks later, animals were re-anaesthetised as above and the spinal cord at T10 exposed for 
transplantation. OECs were prepared and transplanted as described in thesis methods; briefly a total 
of 180,000 OEC-GFP or OEC-chABC were transplanted in 2 injections of 1µl, immediately cranial and 
caudal to the lesion at a depth of 1mm in the midline, injected at 250nl per minute. Cell transplants 
were performed by Dr Ito and Mr Sekiguchi.  
 
Animals received immunosuppression as described in thesis methods with 15mg/kg cyclosporine 
(Sandimmune, Novartis), initially by daily intraperitoneal injection from 24 hours before cell transplant 
for 7 days, then by oral administration (Neoral, Novartis) in drinking water until termination338. 
 
4.2.5 Groups, blinding and randomisation  
Power calculations indicated 7 animals would be required per group to detect a difference in our 
primary outcome measure (BBB score) with a power of 80% and alpha = 0.05 based on BBB scores of 
4±1.5 for OECs and 6.6±1.6 for OECs with chABC mini-pump delivery in a prior transection SCI 
experiment259.  
 
Rats received either media control (HBSS), OECs expressing GFP only for cell tracking (OEC-GFP) or 
OECs expressing chABC and GFP (OEC-chABC). Rats were randomly allocated to groups and the order 
of surgery randomised using Excel random number generation. Surgeons were blinded to transplant 
group and all analysis of behavioural testing was performed by observers blinded to treatment group.  
 
4.2.6 Behavioural measures 
Our pre-defined primary outcome measure was BBB score98. Animals were habituated to a 60cm 
circular arena pre-surgery, then placed in this area and videoed for 3 minutes weekly from injury 
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surgery. Two observers blinded to treatment scored each animal from video and these scores were 
averaged.  
 
Number of foot slip errors crossing rungs of a horizontal ladder was also determined. Animals were 
trained to cross a 1m ladder with 18 unevenly spaced rungs pre-injury. After transplant surgery, ladder 
crossing was performed weekly with two runs videoed per rat. Number of hind limb foot slips (defined 
by paw slipping off or below the plane of rungs) per run was determined by 2 observers from slow 
motion video replay. Run and observer scores were averaged per rat.  
 
Gait analysis was performed at 6 weeks after cell transplant by placing hind-paws in black ink and 
allowing rats to walk down a narrow channel on paper (the ladder frame was used without rungs as 
rats were already habituated to this). Stride length and base of support (perpendicular distance 
between right and left paw prints) was calculated based on measurements of the first 5 clear prints 
for each rat.  
 
4.2.7 Immunohistochemistry and quantification analysis 
Animals were culled and perfuse-fixed after final behavioural testing at 6 weeks as per thesis methods. 
A segment of spinal cord 1cm cranial and caudal to the lesion at T10 was dissected and shipped to the 
Bristol lab for staining and analysis. This was kindly performed by Dr Ito and Mr Sekiguchi after I left 
Japan. The central (dorsal sectioned) region was taken from 5mm cranial to 5mm caudal to the lesion. 
Further processing, sectioning and immunostaining was performed as per thesis methods.  
 
Transverse sections were immunostained for vGlut1 and 5HT, imaged and analysed as described in 
thesis methods. Dorsal sections (1 in 10) were stained for TUJ1, GFAP and GFP, and sample sections 
were stained for C4S as per thesis methods. For TUJ1 analysis, region ‘lesion’ was defined as the area 
between GFAP staining (after threshold) marking cranial and caudal extent of the lesion. Region 
‘caudal’ was defined as the area from caudal edge of the lesion defined by GFAP for 500µm caudal. 
Distance of TUJ1 positive staining (above threshold) closest to the cranial edge of the lesion401 was 
measured in each section above and averaged for every cord. Distance was measured in pixels using 
Fiji ImageJ and converted to microns (1 pixel = 1.1 microns). For GFAP analysis, two regions were 
measured from each dorsal section, encompassing an area 500µm cranial or caudal from the lesion 




4.2.8 Statistical Analysis 
The experimental unit is the rat. Averages are reported as mean ± standard deviation unless otherwise 
stated. Normality of data was tested using Shapiro Wilk test, non-parametric data was analysed by 
Mann Whitney U or Kruskall-Wallis, parametric data by Student’s t test, ANOVA or ANCOVA. Data with 
repeated measures was analysed as such with repeated measures ANOVA. Repeated measures 






4.3.1 Characterisation of transplanted OEC population 
No significant difference was seen in percentage GFP positive cells between OEC-GFP and OEC-chABC 
cells in culture (mean = 48.9 ±7.7% and 47.2 ±10.5% respectively) (Figure 4-2A,B). A representative 
image of OECs immunostained for Hoescht, p75 and GFP (Figure 4-2C) shows all cells remain p75 
positive as reported in the previous chapter.   
 
Morgan Elson reaction demonstrates presence of active chABC in vitro in OEC cultures (significantly 
different from OEC-GFP, p<0.0001 unpaired t-test; mean OEC-chABC = 0.0034 ±0005 U/ml, OEC-GFP 
= 0.00011 ±0.000077 U/ml) (Figure 4-2D). Morgan Elson values for activity of chABC in vitro derived 
from OEC-chABC are shown alongside activity of commercial chABC of varying concentrations to 
provide a direct comparison. Commercial chABC with a concentration of 0.05U was determined by 
this Morgan Elson in our hands to have an activity of 0.00234 ±0.00016 U/ml and a concentration of 
0.1U to have an activity of 0.00486 ±0.000093 U/ml. Hence, the equivalent concentration of OEC-







Figure 4-2. Characterisation of transplanted cells and expression of chABC in vitro 
Three 10x fields in each of three wells (n>100 cells per field) were imaged under phase and fluorescence 
microscopy for OEC-GFP and OEC-chABC cell culture groups. A representative composite image is shown (A). 
Phase and fluorescent images were automatically thresholded and counted separately in Fiji to obtain 
percentage of GFP positive cells directly before transplantation (B). No significant difference in percentage of 
cells GFP positive was seen between OEC-GFP and OEC-chABC (unpaired t-test). A sample of OEC-GFP and OEC-
chABC cells were seeded onto slides and stained with Hoescht (blue), p75 (red) and GFP (green) to confirm all 
cells expressed p75 (C). Morgan Elson reaction confirms OEC-chABC express active chABC in vitro while OEC-
GFP do not (p<0.0001, unpaired t-test; mean OEC-chABC = 0.0034 ±0005 U/ml, OEC-GFP = 0.00011 ±0.000077 
U/ml) (D). Also shown is a comparison of OEC-chABC and OEC-GFP expressed chABC activity with commercially 




4.3.2 Behavioural outcome measures 
In the 3 weeks following SCI surgery 3 animals were euthanised due to autotomy. A further 3 animals 
died under anaesthesia during cell transplant surgery leaving remaining group numbers as media n=5, 
OEC-GFP n=6, OEC-chABC n=7. Measurements of contusion injury force showed no difference 
between groups confirming equal severity and similar variability of injury (one-way ANOVA; media = 
303.6 ±70.8, OEC-GFP 296.7 ±52.94, OEC-chABC 281.9 ±60.0 kdyn) (Figure 4-3A).  
 
Our primary outcome measure was BBB score. No significant difference was seen between groups 
across the 6 weeks tested, however there was a general trend for OEC-GFP and OEC-chABC animals 
to improve over the period (from 11.4 ±3.1 pre-transplant to 15.0 ±2.5 at week 6 for OEC-GFP, n=6, 
and from 11.8 ±2.2 to 15.9 ±2.9 for OEC-chABC, n=7) while media animals showed relatively little 
improvement potentially improving only after week 5 (11.65 ±3.3 pre-transplant, 12.2 ±4.0 at week 5, 
13.1 ±4.6 at week 6, n=5) (Figure 4-3B). This is reflected in statistical analysis; there is a significant 
effect of time and an interaction effect of time and group [F(2.6,37)=3.37, p=0.034 and F(5.2,37)=3.57, 
p=0.009 respectively] but no significant effect of transplant group on whole model or posthoc analysis 
(two-way repeated measures ANCOVA, pre-transplant score as covariate; Mauchly’s test of sphericity 
significant [χ2(14)=32.6, p=0.004 so Greenhouse-Geisser correction used and reported above]).  
 
On ladder crossing, similarly, no significant difference was seen in number of foot slips between 
groups (two-way repeated measures ANOVA). There is a reduction in foot slips for OEC-GFP and 
additional reduction in OEC-chABC animals (from 3.3 ±1.8 at week 1 to 2.8 ±1.1 at week 6 for OEC-GFP 
and 3.5 ±1.6 to 2.1 ±1.2 for OEC-chABC) (Figure 4-3C). Media animals show less reduction (3.2 ±1.6 to 
3.4 ±1.4). One media control animal refused to cross the ladder or run along gait runway giving n=4 
for media on these tasks (OEC-GFP n=6, OEC-chaBC n=7 as above).  
 
Gait analysis at week 6 showed no difference in stride length or base of support between groups (one-





Figure 4-3. Behaviour outcomes after OEC-GFP and OEC-chABC transplant in chronic contusion injury 
There is no significant difference in contusion injury force between groups (one-way ANOVA; media = 303.6 
±70.8, OEC-GFP 296.7 ±52.94, OEC-chABC 281.9 ±60.0 kdyn) (A). Average BBB score for each group (media n=5, 
OEC-GFP n=6, OEC-chABC n=7) is plotted over the 6 weeks of the experiment along with pre-transplant scores at 
3 weeks after injury (B). There is a trend for OEC-GFP and OEC-chABC groups to improve over time while control 
media animal average score remains virtually the same until week 6. There is a significant effect of time and an 
interaction effect of time and group [F(2.6,37)=3.37, p=0.034 and F(5.2,37)=3.56, p=0.009 respectively] but no 
significant effect of transplant group on whole model or posthoc analysis (two-way repeated measures ANCOVA, 
pre-transplant score as covariate). Average number of foot slips crossing a ladder is shown for each week after 
transplant (C). A trend to OEC-chABC treated animals reducing number of slips is seen but there is no significant 
difference between groups (two-way repeated measures ANOVA; media n=4, OEC-GFP n=6, OEC-chaBC n=7). 
Gait analysis of stride length (D) and base of support (E) at week 6 shows no significant differences between 
groups (one- way ANOVA). [A,D,E mean ±SD. B,C mean ±SEM] 
 96 
 
4.3.3 Chondroitinase ABC activity in vivo and OEC survival 
Immunohistochemistry for C4S at 6 weeks after transplant (9 weeks after injury) show presence of 
these digestion stubs of CSPGs in OEC-chABC animals but not OEC-GFP animals, indicating chABC 
activity after transplantation (Figure 4-4). Digestion is seen centred around the large injury site (up to 
1mm in length) with some sign of digestion spreading more caudal than cranial.  
 
No surviving OECs (GFP+ cells) were seen at 6 weeks after transplant, with presence only of GFP debris 







Figure 4-4. Digestion of chondroitin sulphate proteoglycans 
Immunohistochemistry showing C4S (black) digestion products of CSPGs in OEC-chABC (A) but not OEC-GFP (B) 
transplanted animals. The C4S staining is centred around the lesion in the centre of the section but spreads 
further caudal (right of page). Note the more irregular and wider cystic areas of the lesion compared to the more 





4.3.4 Quantification of TUJ1 and GFAP immunostaining 
TUJ1 labelled neurons were seen within the lesion area and caudal to it. Quantification of TUJ1 staining 
density (the number of TUJ1 positive pixels within measured area) was performed for within the lesion 
and in a region 500µm caudal to the lesion within spinal cord parenchyma, as defined by GFAP staining 
(Figure 4-5A). No significant difference was seen between groups in either caudal (one-way ANOVA) 
of lesion (Kruskall-Wallis) regions (Figure 4-5B,C). More OEC-GFP and OEC-chABC animals were seen 
with TUJ1 positive staining >0.1% in the lesion region (4/6 [66%] OEC-GFP and 4/7 [57%] OEC-chABC) 
than media control animals (1/4 [25%]).  
 
The average distance between the cranial extent of the lesion (defined by GFAP) and the closest TUJ1 
positive staining (after threshold) was determined (Figure 4-6A). Animals transplanted with OEC-
chABC had TUJ1 staining significantly closer to the lesion edge compared to media control animals 
(one-way ANOVA F(2,17)=6.46, p=0.0095 and posthoc Tukey p=0.0073) (Figure 4-6B).  
 





Figure 4-5. Quantification of TUJ1 neuronal staining in and caudal to lesion 
 A representative dorsal section immunofluorescent image through the lesion from an OEC-chABC transplanted 
animal is shown stained for TUJ1 (red) and GFAP (blue) (A). White arrows mark dorsal root nerve parallel to the 
cord in this section. Regions demarcated by dotted lines enclosing label ‘i’ and ‘ii’ denote the ‘lesion’ and ‘caudal’ 
regions of interest as determined by GFAP staining. The number of TUJ1 positive pixels (pixels above threshold in 
TUJ1 channel) is quantified as a percentage of total pixels in region of interest (“TUJ1+ density”) and an average 
of serial sections 300µm apart (n=5-7 per animal) is shown for lesion (B) and caudal (C). No significant difference 
was seen between groups in either area (one-way ANOVA caudal, Kruskall-Wallis lesion), but there is a trend 
towards more TUJ1 staining in the lesion for OEC-GFP and OEC-chABC transplanted groups. [media n=5, OEC-






Figure 4-6. Distance of TUJ1 staining from cranial edge of lesion and GFAP staining 
A representative dorsal section fluorescent image from the cranial edge of the lesion in an OEC-GFP transplanted 
animal after TUJ1 (red) and GFAP (blue) thresholding is shown (A). Dotted white arrow marks the distance from 
cranial extent of the lesion (as defined by GFAP) to closest TUJ1 staining, dotted white line encloses region of 
GFAP quantification. TUJ1 staining is seen significantly closer to the cranial edge of the lesion in OEC-chABC 
transplanted animals compared to media control animals [one-way ANOVA F(2,17)=6.46, p=0.0095 and posthoc 
Tukey p=0.0073] (B). Quantification of GFAP positive density (percentage of pixels positive after GFAP channel 
threshold within a region) shows no significant difference between groups (C). [Average of serial sections 300µm 
apart (n=5-7 per animal), media n=5, OEC-GFP n=6, OEC-chABC n=7, mean ±SD, ** p<0.01]  
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4.3.5 Quantification of vGlut1 immunostaining 
Immunostaining for vGlut1 in serial transverse ends taken 500µm cranial and caudal to the lesion were 
quantified for groups of lamina within the grey matter. No significant difference was seen between 
groups in any region cranial or caudal to the lesion (one-way ANOVAs for each region) (Figure 4-7, 
Figure 4-8). 
 
4.3.6 Quantification of 5HT immunostaining  
Immunostaining for 5HT in similar transverse ends was quantified for dorsal and ventral grey and 
white matter regions (see Figure 4-9, Figure 4-10). No significant difference was seen between groups 
cranial or caudal in any region (one-way ANOVAs); 5HT in caudal dorsal grey matter (laminae 1-5) 
showed significance on ANOVA but not on posthoc tests, although the OEC-chABC was close to 
significance compared to media and OEC-GFP (one way ANOVA F(2,13)=8.955, p=0.040 Tukey posthoc 




Figure 4-7. Cranial vGlut1 quantification after transplant in chronic contusion injury 
Transverse sections taken 5mm cranial to the lesion were immunostained for vGlut1 and threshold images were 
analysed for positive staining within sections of grey matter lamina by automated reference to a pre-specified 
template (A). White lower-case letters correspond to lamina regions quantified in upper-case figure panels; 
lamina 1 (b/B), lamina 2 (c/C), lamina 3 (d/D), lamina 4 and 5 (e/E), lamina 6-9 (f/F). No significant difference 




Figure 4-8. Caudal vGlut1 quantification after transplant in chronic contusion injury 
Transverse sections taken 5mm caudal to the lesion were immunostained for vGlut1 and threshold images were 
analysed for positive staining within sections of grey matter lamina by automated reference to a pre-specified 
template (A). White lower-case letters correspond to lamina regions quantified in upper-case figure panels; 
lamina 1+2 (b/B), lamina 3 (c/C), lamina 4+5 (d/D), lamina 6-9 (e/E). No significant difference was seen between 




Figure 4-9. Cranial 5HT quantification after transplant in chronic contusion injury 
Transverse sections taken 5mm cranial to the lesion were immunostained for 5HT and threshold images were 
analysed for positive staining by automated reference to a pre-specified template (A). White lower-case letters 
correspond to regions quantified in upper-case figure panels; lamina 1-2 (b/B), lamina 3-5 (c/C), middle white 
matter (d/D), laminae 6-9 (e/E), ventral white matter (f/F). No significant difference was seen between groups 




Figure 4-10. Caudal 5HT quantification after transplant in chronic contusion injury 
Transverse sections taken 5mm cranial to the lesion were immunostained for 5HT and threshold images were 
analysed for positive staining by automated reference to a pre-specified template (A). White lower-case letters 
correspond to regions quantified in upper-case figure panels; dorsal white matter (b/B), lamina 1-5 (c/C), lamina 
6-9 (d/D), ventral white matter (e/E). There was a trend to increased 5HT immunostaining in lamina 1-5 (c/C) but 
this was not significant (one way ANOVA F(2,13)=8.955, p=0.040 Tukey posthoc between Media and OEC-chABC 
p=0.0712, and OEC-GFP and OEC-chABC p=0.051). No other ANOVAs reached significance [one-way ANOVAs, 





Digestion of CSPGs was seen after transplant of OEC-chABC, however despite a trend to improvement, 
the results presented here show no significant effect on locomotor outcomes of canine OECs (OEC-
GFP group) or OEC-chABC transplanted 3 weeks after chronic thoracic contusion injury in rats. There 
is a small amount of histological evidence for a regenerative effect of OECs or OEC-chABC in this 
model; OEC-chABC transplanted animals had increased axon regeneration or sprouting cranial to the 
lesion (Figure 4-6A).  
 
There is also a non-significant trend that more TUJ1 positive axons are present within the lesion in 
OEC-GFP and OEC-chABC groups and a suggestion (though also non-significant) that 5HT innervation 
caudal to the lesion is increased in OEC-chABC transplanted animals (Figure 4-10), as was seen after 
dorsal column crush injury (see previous chapter).  
 
4.4.1 Type and chronicity of lesion 
As discussed, inducing regeneration and functional improvements after SCI with interventions in the 
chronic phase of injury is more challenging than in the acute phase, and more challenging in contusion 
injuries than other injuries such as transections106,390. Indeed administration of the same amount of 
chABC, in the same lab, has been shown to lead to BBB improvement in rats after thoracic transection 
but not contusion257, and axonal regrowth after hemisection but not contusion110. Our results show 
similar trends; transplant of the same population of OEC-chABC leads to a functional improvement in 
acute cervical crush injury but not chronic thoracic contusion injury.  
 
The effect of time of intervention is also seen in the literature with OEC transplant. Seven studies 
report OEC transplant in the sub-acute167,176,205,391–394 phase after injury (transplant 1-2 weeks after 
injury), with 4 reporting improvement in BBB score after OEC transplant167,176,391,392. The only 
transplant of OECs found in the chronic phase206 (8 weeks after injury) showed no BBB improvement. 
All but one study used an allogenic transplant of rat OECs derived from OB; the remaining study used 
human OECs derived from OM (reporting an improvement)167, so this is less of a confound than for 
OEC transplant in cervical injury. Additionally, in the studies showing a BBB improvement 3 (of 4) 
reported blinding to treatment group for behavioural assessment167,176,391; notably only 1 (of 4) studies 
showing no improvement reported blinding for behaviour. No studies reported blinding of surgeon to 
treatment group at time of transplant. Interestingly, no studies reporting BBB recovery reported 
randomisation of group assignment, while all 4 studies reporting no BBB improvement did205,206,393,394.  
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This chronic compared to acute effect is less clear cut with chABC studies in thoracic contusion injuries. 
Of the 5 studies which use chABC single therapy there are 3 in the sub-acute phase with delivery at 1 
week397, 9 days398 or 2 weeks257 after injury, and 2 in the chronic phase with delivery at 4229 and 6258 
weeks. Four of these studies229,258,397,398, including both in the chronic phase, showed improvements 
in BBB score with chABC treatment. 
 
However, the degree of improvement seen with chABC in chronic injuries was less than that seen in 
sub-acute injuries and required longer delivery of chABC. The 2 studies in the chronic phase show only 
small effects on BBB score at the final time point (6-8 weeks after administration), despite continuous 
delivery of chABC over a period of 1 week by sub-arachnoid mini-pump258 and thermal stabilisation of 
chABC for 2 weeks in sucrose229, alongside fairly intensive treadmill rehabilitation in both. Blinded 
analysis of BBB score is reported in the first study, but not the second, and randomisation of treatment 
is reported in the second study but not the first. 
 
By comparison, the 3 studies in the sub-acute phase all deliver chABC as a single injection without 
rehabilitation, and 2 report quite large changes in BBB score from early after administration. The first 
study shows a significant effect of chABC on BBB score from 1 week after injection until 8 weeks at 
the end of the study397. This study reports blinding of behavioural assessment and randomisation of 
transplant group. The second study sees a significant improvement in BBB by 3 weeks after chABC398. 
It is worth noting that in this study control untreated animals have a BBB score of 0 throughout the 
experiment, despite other reports using this same injury (2mm diameter 10g weight dropped from 
25mm) showing improvements even in untreated animals229. Blinding and randomisation is not 
reported. The third study saw no difference in BBB score after a more severe contusion (2mm 
diameter 10g weight dropped from 50mm), and again BBB scores for all groups increased from 2-10 
weeks257. Blinding of behaviour assessment and randomisation of groups was reported. This study also 
used much higher doses of chABC (50U and 100U) than the other studies (1U and 0.2U respectively). 
 
Studies with chABC in other SCI models have also shown that increased length of delivery of chABC 
may facilitate greater improvement in outcomes, specifically; a doxycycline inducible delivery of 
chABC improved forepaw reaching after cervical contusion injury with 8 weeks but not 2 weeks 
administration of chABC235, and 4 weeks administration of chABC through a sub-cutaneous port in cat 
T10 hemisection injury improved voluntary motor tasks more than 2 week administration216. It 
therefore seems reasonable that in a more severe injury (e.g. chronic contusion), longer delivery of 
chABC may be required to drive a functional improvement.  
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4.4.2 Cell survival after transplant and chABC quantity in vivo 
The low cell survival of OECs205, even in comparison to other cell types206, has been mentioned 
previously. Interestingly, in the studies above investigating OEC transplant in thoracic contusion 
injury167,176,205,206,391–394, OECs were seen to survive for quite long periods. Four (of 8) studies report 
seeing OECs still present at 3-5 weeks after transplant167,205,392,394, and a further 2 report surviving OECs 
at 3-4 months176,206. Most studies did not quantify survival but it is likely to be low, those that did 
quantify survival give a range of 0.01 – 3.1% of transplanted cells at 3 weeks205,394. Survival at 9 weeks 
after transplantation has been reported to be similar to survival at 3 weeks205 implying that in most of 
these studies OECs would have been present at 6 weeks (the termination time-point in our study). We 
see no clear OECs surviving at 6 weeks based on GFP immunofluorescence imaging, only GFP debris 
as also reported by the only paper using a xenograft transplant167. A lower cell survival of canine OECs 
in this study compared to the allogenic OECs in the above studies may in part explain why we do not 
see any significant functional effect of OECs here.  
 
The lack of survival we see is most likely related to graft rejection as discussed in the previous chapter. 
It would be interesting to repeat the experiment with a different immunosuppression regime or in 
athymic rats, where we saw comparatively higher cell survival238. It is perhaps a little surprising that 
we may see less survival in a chronic injury compared to acute transplant (no cells seen here at 6 
weeks after transplant compared to scant cells at 9 weeks in the previous chapter), despite using 
similar cells and the same transplant protocol. Cell survival has been reported to be better in chronic 
injuries402. However, differences in immune response between rat strain403 and even source404 have 
been reported, and this is a potential difference between the 2 studies as although the strain of rat 
used was the same (Charles River Wistar) the source colony was different (UK and Japan).  
 
This lack of OEC survival we see may have limited chABC delivery. Due to time-restraints on the in vivo 
part of this project additional animals were not transplanted for histological analysis and cell survival 
quantification at any interim time points, therefore we cannot say exactly how long the OECs survived 
for (and hence what duration chABC was delivered for). If cells were present at 2 weeks (as seen in 
the previous chapter) this would make delivery similar to the previously reported studies on chABC 
treatment in chronic thoracic contusion injury229,258. However, even in these studies only small 
changes in BBB scores were seen229,258. Limited duration of chABC due to limited OEC survival may 
therefore be part of the reason we saw no functional response to OEC-chABC transplant. This more 
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intransigent model of SCI may require longer delivery of chABC211 than the acute dorsal column crush 
model where we saw functional improvement.  
 
In these studies of chABC in chronic contusion injuries229,258, differences in BBB improvement were 
also only seen at 6229 and 8258 weeks after injury. Similarly, in a study of combined OEC transplant and 
subsequent repeated injection of chABC for 4 weeks after transection injury a difference in BBB 
improvement was only seen at 8-9 weeks after injury259. Extending the length of behaviour 
measurement in this study may therefore have given more chance of seeing an effect. These studies 
also used treadmill rehabilitation which was not available during our experiment. It has been reported 
that there is a degree of “self-training” of walking in quadrupeds as they move around with front-
limbs in their home cage to which additional training has no additive effect405. However, additional 
specific rehabilitation may have improved outcomes and could be considered in future studies.  
 
As discussed in the previous chapter the precise dose of chABC reaching the spinal cord is difficult to 
determine. In this study, a direct comparison of media between OEC-chABC and commercial chABC 
activity was conducted showing that 50,000 OEC-chABC produce ~0.075U chABC in vitro (Figure 4-2D). 
This may equate to ~0.27U for the 180,000 OEC-chABC transplanted but is obviously entirely 
dependent on cell survival. This dose would be comparable to one of the chronic contusion chABC 
studies (0.2U/hour from mini-pump)258. There is one study which indicates that a single higher dose 
of chABC (50U or 100U) improved BBB score by 10 weeks  whereas a lower dose (1U or 5U) did not 
given 2 weeks after thoracic transection injury257. These dosages are much higher but effective dosage 
is likely to be different in single and ongoing administration (as for mini-pump and OEC delivery). 
Direct lentiviral delivery of chABC into spinal cord parenchyma is likely to deliver a large ‘dose’ of 
chABC for a long period of time211,235, but this has also not been quantified in terms of chABC activity. 
More information about dose of chABC and the pharmacokinetics of chABC in the spinal cord is 
therefore needed to determine the required quantity of chABC which needs to be delivered, which is 
also likely to depend on the exact type of injury. 
 
There might be ways to titrate the delivery of chABC using OEC-chABC. Around 50% of cells were 
transduced in this study; increasing transduction rate, or sorting for GFP+ transduced cells and 
transplanting only these cells (this is performed in chapter 6), would increase delivery of chABC and 
may improve functional outcomes further. Additionally, delivering OECs within a hydrogel may 
increase cell survival and so increase chABC delivery (also explored in chapter 6). The neatest way to 
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control temporal delivery of chABC would of course be with a doxycycline regulatable vector which 
could also be integrated into OECs.  
 
4.4.3 Statistical power of experiment and detection of locomotor improvement 
Based on power calculations (see methods), 7 animals per group were required to detect a difference 
between transplants. Due to loss of animals the final numbers in media and OEC-GFP groups are less 
than this (n=5 and 6 respectively), meaning the experiment is underpowered for BBB analysis. More 
importantly, the variability of BBB scores is higher than anticipated (the standard deviation in our BBB 
scores is around double that of the study the power calculations were based on259). A source of this 
increased variation may be the wide range in contusion forces we recorded (~50-70kdyn). Previous 
studies using the same force-driven impactor systems have reported variation in contusion forces 
closer to ±5kdyn211,235.  
 
Power calculations based on week 6 BBB data from this experiment suggests 15 animals per group 
would be required to show a difference between media and OEC-chABC animals if this experiment 
were to be repeated.  
 
The BBB scoring system is the most widely used score of locomotor recovery in rats, but it has some 
limitations. For example, recovery is not linear through the scale, with the distribution of scores seen 
in one study highlighting threshold levels; notably at score 8 beyond which weight support is required, 
and at score 14 beyond which parallel paw position is required indicating improved trunk stability99. 
Interestingly, in our thoracic contusion transplant of OEC and OEC-chABC, the average scores of both 
transplant groups cross this ‘threshold’ at score 14 while media transplanted animals do not.  
 
The similar (non-significant) changes in BBB score we see for OEC and OEC-chABC animals is a different 
picture to that which we see in recovery after cervical injury (previous chapter) where only OEC-chABC 
show increased improvement. This could fit with the suggestion from meta-analyses that OECs have 
a greater effect in thoracic compared to cervical injuries126,362, however, the changes seen in this 





This study shows no evidence of functional recovery after canine OEC or OEC-chABC transplant in this 
chronic thoracic contusion model in rats. Some minimal histological evidence for axonal sprouting or 
regeneration is shown. This lack of functional improvement is considered likely to be due to poor OEC 
survival, and hence low chABC delivery, in this xenotransplant experiment. Given the trend seen in 
BBB and ladder outcomes it would be interesting to repeat this study with increased numbers so it is 
fully powered, and more importantly with less variation in contusion impact force (and therefore likely 
less variation in the BBB scores).  
 
Additionally, a model with higher OEC survival would be desirable. This could include using 
xenotransplant canine OECs in rats with additional immunosuppression (or athymic rats), or by using 
an allogenic transplant of OECs; either rat OECs transplanted into rats, or canine OECs could still be 
studied using the natural canine SCI model. Transplant of OECs within a biomaterial to improve OEC 






Chapter 5  
 
Intraoperative canine spinal cord ultrasound 
elastography and stiffness matching of collagen 




5.1 Introduction  
Cell survival after transplant is often low and is considered a limiting factor in translation of cell-based 
therapies to clinics40. This low cell survival is particularly the case after transplant into sites of injury205 
as has been seen in the previous two chapters. There are a number of reasons for this even in 
autologous transplant where immune reaction is less of a consideration. Shear forces damage cells 
during injection283, cells integrate poorly in lesion sites due to cavitation and lack of anchorage sites281 
and tend to be washed out282, and the environment in the chronic lesion scar is inhospitable to cell 
survival48. Transplanted cell death may also cause further damage to the cord by triggering 
inflammatory pathways and worsening the local environment285. It is therefore important that the 
method of cell delivery is addressed.  
 
Hydrogel biomaterials offer multiple benefits as for therapies for SCI. They form a substitute extra-
cellular-matrix and porous structure after intraspinal injection which can modify the injury 
environment promoting cell and axon infiltration262,280. They are widely used as a delivery vehicle for 
experimental molecular, drug or cell based therapies, provide a means to combine multiple 
treatments in one implant (for reviews see263,406–408), and have been reported to improve cell survival 
after transplant in rat CNS286–288. 
 
To take advantage of the benefits of hydrogels on clinics, the mechanical properties of a hydrogel 
construct and patient tissue need to be matched. Increased inflammatory and immunological 
responses are seen after implant of stiff materials into the CNS. One in vivo study demonstrated 
increased microglial activation and astrogliosis around polyacrylamide hydrogel implants 100 fold 
stiffer (10-30kPa) than their measures of tissue stiffness in rat brain (100Pa)299. Implant for 6 weeks of 
an electrode array onto lumbar spinal cord of ~10MPa stiffness (100 fold greater than this study’s 
spinal cord stiffness measurement of ~100kPa) caused astrogliosis, microgliosis and affected 
locomotion with an increase in the number of missed steps on ladder walking298. In rodent studies 
where stiffness-matched hydrogels are transplanted into sites of SCI, reduced inflammatory cell 
numbers after transplant are seen300,301. Clinically it is intuitive that if the implanted construct is too 
stiff there is a risk of iatrogenic damage to the spinal cord and that this risk is of particular concern in 
the central nervous system due to its comparatively soft nature compared to other tissues7. 
Conversely, if the implanted construct is too fluid, the benefits of hydrogel transplant, including 
increased cell survival, may be lost.  
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However, there is limited information available about stiffness of the spinal cord, particularly in vivo. 
Most previous studies have been conducted ex vivo and post-mortem where tissue degradation, 
absent perfusion pressure, reduced temperature and hydration all affect measurements329,330. In vivo 
studies, limited to normal spinal cord, have largely used mechanical measures requiring manipulation 
and dissection of the cord323–325,409 that would clearly be inappropriate for clinical patients. This 
knowledge gap represents a major obstacle to safe implantation of hydrogels into the central nervous 
system on clinics and precludes matching of a hydrogel implant to a patient’s specific requirements. 
The first goal of this chapter was therefore to establish a clinical method of determining the stiffness 
of spinal cord that could be used as a tool to generate stiffness measures in patients. 
 
Ultrasound elastography provides a clinically relevant method of determining the stiffness of a tissue, 
akin to ‘virtual palpation’. The technology has progressed rapidly in recent years, advancing from 
quasistatic elastography dependent on variable manual operator compression of tissue410 to acoustic 
radiation force impulse (ARFI) ultrasound elastography that allows for reliable quantitative 
measurements of tissue elasticity. Acoustic radiation force impulse ultrasound elastography uses an 
acoustic impulse generated from the ultrasound transducer to set up a wave of displacement in the 
target tissue whose speed varies with tissue stiffness411. This speed is detected as a ‘shear wave 
velocity’, which can be mathematically converted to modulus of elasticity412,413 allowing quantitative 
comparisons; materials with a higher elastic modulus will be stiffer. Acoustic radiation force impulse 
ultrasound elastography has been demonstrated to be reliable and repeatable in clinical use. It has 
compared favourably to gold-standard measures (i.e. histopathology) in the diagnosis and staging of 
liver fibrosis414,415, discrimination between malignant and benign thyroid masses416 and for ancillary 
diagnosis of mammary neoplasia417 in humans. 
 
The use of ultrasound elastography is growing in veterinary medicine too. Initial studies established 
normal values for tissue stiffnesses (or shear wave velocity) in healthy animals, largely focussed on 
the liver, spleen and kidneys in both dogs418,419 and cats420. Other groups used ultrasound elastography 
to discriminate between benign and malignant neoplasia in lymph nodes of dogs and cats421 and 
subcutaneous neoplasms in dogs422. Perhaps most successfully in mammary neoplasia, benign and 
malignant neoplasia have been shown to have significantly different stiffnesses423,424 and elastography 




The canine translational model of SCI, discussed in the thesis introduction, provides a useful platform 
to test the application of ultrasound elastography to the spinal cord in a clinical setting, specifically 
while these pet dogs undergo decompressive surgery after SCI and the cord is surgically exposed 
allowing ultrasound access. Ultrasound elastography has been successfully applied to the spinal cord 
of experimental dogs where large areas of the cord were exposed426, and standard (‘B-mode’) 
ultrasound of intraoperative canine spinal cord has been reported427. We therefore hypothesised that 
intraoperative ultrasound elastography could represent a non-invasive method to obtain quantifiable 
measures of spinal cord stiffness intraoperatively, providing a new clinically applicable tool and a 
target for biomaterial implant synthesis.     
 
This approach also provides an opportunity to investigate the effect of natural injury on spinal cord 
stiffness. In clinical practice it is appreciated that tissue stiffness is altered by disease pathology; 
fibrotic scar tissue feels stiffer than normal tissue, tumours often feel stiffer than surrounding tissue. 
However, there is minimal information about the stiffness of the spinal cord in vivo7, indeed the in 
vivo stiffness of injured spinal cord is unknown. Determining values for this characteristic may give 
information relevant to diagnosis or prognosis of the disease, and aid in understanding why the injured 
spinal cord environment is inhibitory to axon regeneration55,313.  
 
The glial scar that forms after SCI has previously been assumed to be stiffer than normal tissue, 
forming a physical as well as molecular barrier to axonal regeneration60. However, recent evidence 
from rodent experimental models of SCI suggests that the lesion area is in fact less stiff compared to 
normal cord, when measured by mechanical compression testing315 and atomic force microscopy316 
(AFM). These previous studies have been conducted ex vivo and in rats with experimental non-
contusive injuries. Determining if these findings are consistent in the mixed compressive-contusive 
clinical injuries seen in companion dogs (and most commonly seen in humans107,389) would be of value 
in extending understanding of the mechanical properties of SCI.  
 
In parallel to determining the in vivo stiffness of injured spinal cord by ultrasound elastography a 
further goal was to establish the comparative stiffness of collagen hydrogels, with or without 
encapsulation of OECs, to establish if matched-stiffness implants were possible with this simple 
hydrogel. Collagen was chosen because of: (i) work by collaborators in Keele showing OECs could be 
cultured within collagen428; (ii) its prior use in experimental SCI repair406,429, including for cell 
encapsulation430,431 and in experimental dogs279; (iii) its temperature-dependent gelling that would 
allow gelation after injection in its liquid form into spinal cord; and (iv)  its biocompatibility7,39. Indeed, 
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one of the few ‘negatives’ commonly cited about collagen in the context of tissue engineering is its 
relative lack of stiffness (particularly when considering other common biomaterial applications, e.g. 
for cartilage)264,432, but this might be appropriate for soft CNS tissues7; 
 
These hydrogel stiffness measures were conducted with ultrasound elastography to allow direct 
comparison to spinal cord measures, alongside comparative measures with widely used gold-standard 
laboratory mechanical (macro-)indentation and AFM techniques. The aim of this comparison between 
techniques was to try and corroborate ultrasound elastography measures and to establish if different 
techniques resulted in similar measures of stiffness in our hands, as well as to attempt to provide a 
comparative target reference using these more common lab-based techniques for laboratories 
working on biomaterial synthesis that may not have access to ultrasound elastography.  
 
5.1.1 Aims and hypotheses 
The aims of this chapter were therefore to:   
1. Determine the feasibility of using ultrasound elastography intraoperatively on clinics and 
obtain ‘target’ measures of spinal cord stiffness.  
2. Investigate the effect of natural, clinical injury on the stiffness of spinal cord. 
3. Establish if the stiffness of collagen hydrogels encapsulating OECs could match that of spinal 
cord measured in vivo.  
4. Compare ultrasound elastography stiffness measures with lab-based techniques.  
 
We therefore hypothesised that intraoperative ultrasound elastography could determine a target 
stiffness for in vivo spinal cord and that variation of collagen concentration and encapsulation of OECs 
would alter hydrogel construct stiffness such that it could match this target stiffness.   
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5.2 Methods 
5.2.1 OEC culture 
Canine OECs were cultured as per thesis methods. OECs were derived from ‘Bethan’ and ‘Roger’, used 
as a mixed culture to enable sufficient cells to be obtained for the large gels and high cell concentration 
(see below) required in these experiments.  
 
5.2.2 Collagen hydrogel synthesis and OEC encapsulation 
Collagen hydrogels were synthesised as per thesis methods, then gelled in 96-well plates for 
mechanical indentation or 48-well plates for ultrasound elastography with or without OEC 
encapsulation. For this series of experiments, OECs were encapsulated at the same concentration as 
used in clinical canine transplants at 12.5 million OECs per ml123.  
 
5.2.3 Immunocytochemistry and image analysis 
LIVE/DEAD staining and imaging by confocal microscopy was performed as per thesis methods. For 
each gel, 3-4 image stacks were obtained and number of LIVE and DEAD stained cells quantified for 
each z-plane using a custom Fiji/ImageJ macro running thresholding and segmentation followed by 
particle analysis. The number of LIVE cells out of total LIVE and DEAD stained cells was expressed as a 
percentage (% LIVE) and averaged for each image stack and gel.  
 
5.2.4 Case recruitment 
Dogs, 5-20kg, undergoing spinal cord decompressive surgery following acute thoracolumbar 
intervertebral disc extrusion were recruited at Langford Vets (Bristol Veterinary School Small Animal 
Hospital). Ethical approval (VIN/15/036) and informed owner consent was obtained. These dogs 
present with signs of transverse myelopathy such as back pain, pelvic limb ataxia, paresis, paralysis 
incontinence and loss of pain sensation in the worst cases. We aimed to recruit 15 dogs to detect a 
difference between injured and normal spinal cord stiffness based on a power of 80%, a previously 
reported spinal cord stiffness of 265kPa325, reduction to 55% as previously reported after experimental 
injury315, and a predicted standard deviation of 115kPa (44% of cord stiffness measure based on 
preliminary ultrasound elastography cadaver cord measurements – see results 5.3.2).  
 
On admission, all animals were scored for clinical severity in their pelvic limbs using the modified 
Frankel score20 where grade 1 = back pain with no neurological deficits, 2 = ambulatory paraparesis, 3 
= non-ambulatory paraparesis, 4 = paraplegia, and 5 = paraplegia with loss of conscious pain 
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perception in the pelvic limbs.  Recovery of pain perception at 3 weeks was recorded for grade 5 
animals.  
 
5.2.5 Ultrasound elastography  
Ultrasound elastography was performed using a Siemens Acuson S2000 (Siemens Healthcare, 
Erlangen, Germany) with “Virtual Touch Imaging Quantification” Acoustic Radiation Force Impulse 
imaging software using a 9L4 linear matrix array transducer operating at 8MHz; with this probe the 
region of interest measurement box size is 5x5mm. An error, depicted as ‘x.xx’ m/s, is returned if the 
confidence level between tracking beams is below 80%418. If ‘x.xx’ m/s was returned, the 
measurement was discounted and repeated. 
 
Recorded shear wave velocities (m/s) were converted to Young’s modulus of elasticity (kPa) using 
previously published methods412,413. Briefly, shear wave velocity can be converted to shear modulus 
by 𝐺 = 𝜌𝑐! [where G = shear modulus, ρ = density of material, c = shear wave velocity] and shear 
modulus can be converted to Young’s modulus by G = E / (2(1+ ν)) [where E = Young’s modulus, ν = 
Poisson’s ratio]. Young’s modulus was therefore calculated by E = (2(1+ ν))𝜌𝑐!. Poisson’s ratio and 
density are material dependent, and values used are reported in the relevant sections below. 
Calculated values reported as modulus of elasticity are therefore taken to be the Young’s modulus.  
 
5.2.5.1 Ultrasound elastography of elastography phantom 
To allow calibration of our ultrasound elastography set-up, as well as to determine the reliability and 
accuracy of elastography measures, an elastography phantom (Elasticity QA Phantom model 049A, 
Computerised Imaging Reference Systems, Norfolk, VA) was used. This contains background (27kPa) 
and four stepped diameter cylindrical ‘targets’ of known stiffness (10, 14, 46 and 86kPa) as certified 
by manufacturer’s mechanical testing giving 5 target elasticities.  
 
Ten measurements were taken from each of the four cylinders at a consistent point along their length 
(section of diameter 16.7mm). For background, measurements were taken at a consistent depth of 
3cm. Targets and background are made from ZerdineTM hydrogel; the manufacturer reports Zerdine 
to have a density of 1.04±0.01g/cm3 and a Poisson’s ratio of 0.5433.  
 
5.2.5.2 Ultrasound elastography of canine cadaver spinal cord 
Ultrasound elastography measurements were performed on spinal cords of canine cadaveric 
specimens from clinical cases undergoing post-mortem examination at Bristol Veterinary School, 
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having been euthanized at owners’ request for medical reasons unrelated to this study and for 
conditions not involving the spinal cord. Owner consent was obtained and ethical approval gained 
from the University of Bristol local ethical review panel (VIN/16/004).  Dogs were excluded if they had 
spinal cord pathology determined based on clinical signs or gross post-mortem examination.  
 
The spinal cord was removed from the vertebral column and meninges within 6 hours of euthanasia 
and placed in isotonic saline solution. Measurements were taken within 30 minutes of spinal cord 
removal. The spinal cord was transversely sectioned to obtain the C1-T2, T3-L3 and L4-S4 spinal 
segments. These segments were immobilised in plastic containers, still submerged in saline, and the 
ultrasound transducer positioned in contact with the saline longitudinally to the segment to view it in 
sagittal section, with the cord at a depth of 2cm (Figure 5-1A). The hyperechoic central canal was 
visualised along the length of the ultrasound window to ensure the probe was held parallel to the cord 
and repeat measurements (n = 3-5) of shear wave velocity were taken from 5 regions (cervical, cervical 






Figure 5-1. Example images for measurement techniques 
An example image (A) shows canine cadaver cord being measured by ultrasound elastography, with the cord 
(black arrow) suspended in saline at a depth of 3cm from the ultrasound probe. The resulting ultrasound image 
can be seen in (B). An example image of hydrogel measurement by ultrasound elastography is shown in (C). The 
ultrasound elastography mode allows measurement of the shear wave velocity of the tissue contained within the 
marked 0.5 x 0.5cm white window (region of interest), which can be mathematically converted to a standard 




5.2.5.3 Ultrasound elastography of intraoperative canine spinal cord 
The anaesthesia protocol for surgery was at the discretion of the attending veterinary anaesthetist; 
all animals received pre-medication, intravenous induction, tracheal intubation and maintenance on 
inhalational anaesthetic in oxygen, with appropriate monitoring and analgesia throughout surgery and 
recovery. The spinal cord was exposed by hemilaminectomy or mini-hemilaminectomy and the 
compressive disc material removed. The surgical field was then filled with sterile saline at 37oC and 
the ultrasound probe placed in contact with the saline as previously reported434. To maintain sterility, 
the probe, covered in ultrasound gel, was placed either in a sterile glove or a sterile sleeve (Safersonic 
Medizinprodukte, Austria) based on surgeon preference. A sterile endoscope sleeve was placed 
around the ultrasound cable, through the surgical field, to an operator at the ultrasound machine. The 
spinal cord was initially visualised in B-mode ultrasound before switching to the elastography mode. 
The cord was imaged in a sagittal plane, with orientation being confirmed by visualisation of the 
hyperechoic central canal between the hyperechoic dura. The region of interest box was positioned 
over the spinal cord at the lesion site (named ‘lesion epicentre’) and as far cranial and caudal to it as 
possible within the surgical window (approximately 1 to 2cm). Cranial and caudal measures of shear 
wave velocity were combined in one data set named ‘lesion periphery’. Three repeat measures were 
recorded at each location (lesion epicentre, cranial and caudal) where the cord could be reliably 
visualised.  
 
Poisson’s ratio can be assumed to be 0.5 for soft tissue413. The density of canine spinal cord is unknown 
but human spinal cord has been reported435 as 1.03g/cm3, so this value was used for calculations as 
an approximation. To normalise the difference in spinal cord modulus of elasticity between dogs and 
therefore allow comparison of the degree of change of lesion elasticity from periphery cord elasticity, 
the ratio of ‘lesion epicentre’ to ‘lesion periphery’ cord was calculated for each dog.  
 
5.2.5.4 Ultrasound elastography of hydrogels and hydrogel encapsulating OECs 
Collagen hydrogel and hydrogels encapsulating OECs intended for culture and stiffness measurement 
by ultrasound elastography were gelled in 48-well plates at a volume of 500µl per well. These were 
removed once gelled, submerged in growth media in 24-well plates and kept in a 37°C 5% CO2 
incubator (n=3 per gel). Ultrasound elastography measures were taken within 2 hours of cell 
encapsulation (day 0) then at day 1, 3, 5 and 7. For measurement, gels were moved with a spatula 
onto sterile 10% gelatin in a plastic container submerged in sterile 37°C PBS. Twenty measurements 
were recorded from the centre of each gel (Figure 5-1C) at a depth of 2cm at each time point before 
being moved back to growth medium in 24-well plates. Growth media was replaced after 
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measurement. Measurements of shear wave velocity were converted to Young’s modulus as 
described above based on a Poisson’s ratio of 0.5 and density436 of 1g/cm2. 
 
5.2.5.5 Ultrasound elastography of Zerdine 
Additional samples of ZerdineTM hydrogel at varying certified elasticities (similar to those in the 
ultrasound phantom), kindly provided by Computerised Imaging Reference Systems Inc., were used 
to provide a direct comparison between ultrasound elastography, mechanical indentation and atomic 
force microscopy measures. For ultrasound elastography measures Zerdine cylinders 12mm diameter 
and 10mm long were submerged to a depth of 2cm in PBS and 20 measures obtained from the centre 
of each sample.  
 
5.2.6 Indentation measurement of elasticity 
Mechanical compressive (macro-)indentation testing was conducted using a Universal Testing 
Machine 3367 (Instron) fitted with a 10N load cell and 2mm radius cylindrical indenter. Material 
(hydrogel or ZerdineTM) was deformed at a rate of 0.02mm/s up to a maximum of 5mm or 3N of force. 
The best-fit line forming the gradient of the linear section of the resulting force-extension graph 
(within 0-10% strain) was then used to obtain a measure of stiffness in N/mm. This value in N/mm was 
converted to Young’s modulus (Pa) using published methods437 assuming that gels behave as a thin 
elastic layer on a rigid surface336,436,438. Briefly, published finite element analysis was used to define 
the load-depth relationship for a given ratio of indenter radius:layer thickness, which can then be 






[where P = load, E = Young’s modulus, n = Poisson’s ratio, a = radius of indenter, h = indentation 
depth/extension, FEA = finite element analysis constant]. By rearranging for E and substituting the 
described N/mm gradient for the term ‘P/h’, Young’s modulus can be calculated. The value for ‘FEA’ 
is based on gel and indenter size and in our set-up = 1.48.   
 
Hydrogels for mechanical testing were synthesised to a volume of 300µl per gel (n=4) formed in wells 
of a 96-well plate, giving a gel depth of 9mm. Zerdine cores were cut to the same size using a biopsy 
punch and also measured in 96-well plates. Samples measured by indentation were measured only 
once to avoid any changes associated with potential deformation affecting further measures.  
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5.2.7 Atomic Force Microscopy measurement of elasticity 
To allow direct comparison between ultrasound elastography and Atomic Force Microscopy (AFM) 
measures the same samples were measured with both techniques within 24 hours. Hydrogel samples 
were synthesised as for ultrasound elastography measurement above with a volume of 500µl in 48-
well plates (n=1 per concentration). For measurement by AFM, samples were superglued to plastic 
petri dishes and measured with PBS in contact between hydrogel surface and AFM indenter. AFM 
measures were obtained every 1mm from 5x5mm grid overlaid within the diameter of the gel (n=25 
measures per gel). To compare hydrogel surface and interior elasticity measurement, one gel was 
embedded within 20% gelatin (pH 7 and <40°C), then sectioned on a vibrotome (Campden 
Instruments, 7000smz-2) to 500µm thickness slices at 85Hz immediately prior to AFM measurement. 
Zerdine samples were prepared as for ultrasound elastography and measured using the same grid 
system. A sample of PFA fixed canine cadaver cord was obtained (as above within 6 hours of death) 
from the lumbar region of a 2 year old male entire Labrador euthanased for unrelated reasons. A 1cm 
segment of the spinal cord was measured in transverse section by ultrasound elastography submerged 
in PBS as described above. For AFM, this segment was sectioned on a vibrotome as described and a 
section superglued to a petri dish before measurement by AFM in the grid pattern. 
 
AFM measurements were conducted by Miss Chloe Hall (PhD student at UCL under the supervision of 
Professor Emad Moeendarbary) using a JPK Nanowizard Cellhesion 200 (JPK Instruments AG, Berlin, 
Germany) machine mounted on an inverted microscope (Olympus GX53) with a motorised stage. A 
ball tip indenter of radius 25µm was attached to a MLCT cantilever (Bruker, nominal spring constant 
of 0.6N/m) using ultraviolet curing glue (Loctite). Actual spring constant was measured using the 
thermal noise method. Force-distance curves were taken using an approach speed of 10µm/s. Forces 
varied between 10nN and 180nN in order to give an indentation depth of at least 3µm, but no more 
than 10µm.  The contact point and indentation depth were determined using JPK data processing 
software, and elastic moduli calculated from the force-distance contact curve by fitting to a parabaloid 
Hertz-Sneddon contact model assuming a Poisson ratio of 0.5.  
 
5.2.8 Statistical analysis 
Data distribution was tested for normality using the Shapiro-Wilk test. Parametric data was 
summarised using mean ± standard deviation and coefficient of variation (ratio of standard deviation 
to the mean) and analysed by t-test, appropriate ANOVAs and Pearson correlation (correlation results 
presented are Pearson correlation coefficients unless otherwise stated). Non-parametric data was 
summarised by median and ranges and analysed with Wilcoxon-matched pairs, Mann-Whitney U or 
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Kruskall-Wallis tests and Spearman correlation. Statistical analysis was performed in RStudio346 or 
Graphpad Prism 7.0d.   
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5.3 Results 
5.3.1 Ultrasound elastography and certified phantom values are strongly correlated 
A strong, positive, linear correlation was seen between certified phantom elasticity values and 
ultrasound elastography measures (R2=0.995, p<0.0001) (Figure 5-2A).  The equation of the line of 
linear regression (y=0.663x, where ‘y’ is measured elastic modulus and ‘x’ is phantom elastic modulus) 
defines this relationship and allows calibration of the ultrasound measures in our set-up. Ultrasound 
elastography values of spinal cord and hydrogel constructs presented here are corrected by this 
calibration.  
 
5.3.2 Ultrasound elastography of cadaver canine spinal cord is feasible and shows no 
difference between spinal cord regions 
Three dogs were used for investigation of cadaver cord. Their ages ranged from 5 to 7 years; breeds 
included a Sprocker, Bull Mastiff cross and Flat Coat Retriever. Causes of death were haemolytic 
anaemia, left cerebral hemisphere glioma, and dilated cardiomyopathy respectively. 
 
No significant difference was seen between regions of spinal cord (one-way ANOVA) (Figure 5-2B) and 





Figure 5-2. Calibration of Ultrasound Elastography and cadaver spinal cord measures 
Scatter graph shows a strong correlation (R2=0.995, p<0.0001) between known, certified, phantom elasticity 
targets and elasticity obtained when measured by ultrasound elastography (A). All measures for each elasticity 
(open circles, n=10) and line of linear regression (dashed black line) ±95% confidence intervals (grey shading) are 
shown. The equation of the linear regression, allowing calibration of measured values, is y=0.663x. Measures, 
after conversion to Pa and calibration ‘correction’, for cadaver spinal cord (n=3) from each of 5 regions of the 
spinal cord are shown (B). No difference was seen between regions (one-way ANOVA), global average cadaver 




5.3.3 Intraoperative ultrasound elastography is feasible 
Fifteen dogs with injury between T3 and L3 spinal cord segments were recruited as planned. In 2 dogs, 
the spinal cord could not be reliably visualised through a mini-hemilaminectomy approach. For the 
remaining 13 animals: 4 had mini-hemilaminectomies and 9 had hemilaminectomies; ages ranged 
from 4 to 8 years; 9 animals were male and 4 female; breeds included six Dachshunds, two Cocker 
Spaniels, one Beagle, Basset Hound, Labrador, Jack Russel Terrier and Cavalier King Charles Spaniel 
cross Pug. All animals were in the acute or sub-acute phase of injury47, at less than 2 weeks from first 
onset of clinical signs, with the majority in the acute phase. They showed clinical signs ranging from 
paraparesis to paraplegia with loss of pain sensation in the pelvic limbs. For full details see Table 5-1. 
 
After visualisation of the spinal cord (Figure 5-3), areas of compression could be readily identified by: 
(i) visualisation of hyperechoic disc material ventral to the spinal cord; (ii) loss of visible hyperechoic 
central canal within spinal cord; (iii) narrowing and/or irregularity of hyperechoic dura mater dorsal 
and/or ventral to the spinal cord; (iv) direct surgeon visualisation. Intraoperative ultrasound 
elastography was feasible and measures of shear wave velocity could be obtained. In 3 animals, 







Table 5-1. Clinical details of dogs undergoing intraoperative ultrasound elastography 
 
All dogs suffered acute onset thoracolumbar disc injury to the spinal cord.  
Clinical grades of injury: 1 = pain only, 2 = ambulatory paraparesis, 3 = non-ambulatory paraparesis, 4 = 
paraplegia, 5 = lack of pain sensation.  








Figure 5-3. Intraoperative ultrasound image of the spinal cord 
Representative ultrasound image of the canine spinal cord scanned in sagittal section intraoperatively following 
acute disc injury (white arrow marks site of disc herniation). Note the hyperechoic central canal visible in the 
cranial and caudal spinal cord, and the loss of this central canal with compression of the cord at the site of injury. 





Variability of intraoperative ultrasound elastography measures was assessed by determining the 
coefficient of variation for peripheral and lesion epicentre measures for each dog (Figure 5-4A). The 
average coefficient of variation for peripheral and lesion epicentre spinal cord was similar at 32.0 ± 
12.1% and 31.0 ± 22.6% respectively.  
 
The median distance from transducer to spinal cord (i.e. measurement depth) was 19.5mm, with a 
range of 16-25mm (Figure 5-4B). No significant correlation was seen between depth and either 
peripheral or lesion epicentre stiffness measures across this relatively small range (r=-0.17, R2=0.056, 
p=0.66 and r=-0.54, R2=0.37, p=0.18 respectively, Spearman correlation).  
 
5.3.3.1 Stiffness of lesion epicentre and periphery spinal cord are significantly different 
Intraoperative ultrasound elastography measures of the spinal cord at the lesion epicentre had a 
significantly lower modulus of elasticity than at the lesion periphery (p=0.0056, Mann-Whitney U), 
with a median of 18.3 kPa (IQR: 11.6-31.1 kPa) and 47.9 kPa (IQR: 32.6-81.7 kPa) respectively (Figure 
5-4C). It was noted that the only 2 dogs in this cohort whose modulus of elasticity was not lower at 
the lesion compared to peripheral spinal cord were the only dogs in this cohort who did not recover 
sensation and motor function after injury. 
 
Comparison of intraoperative measures to earlier cadaver measures shows a significant difference 
between cadaver and intraoperative peripheral spinal cord stiffness (p=0.0254, Kruskall Wallis 
followed by Dunn’s multiple comparison test). There is no significant difference between cadaver and 
intraoperative lesion epicentre measures.  
 
5.3.3.2 Post-hoc analysis shows a preliminary association between injury stiffness and clinical severity 
A significant difference in the ratio of lesion to periphery modulus of elasticity (i.e. the degree of 
change of lesion modulus of elasticity from periphery modulus of elasticity) was seen between 
paraparetic and paraplegic dogs (p=0.019, two-tailed unpaired t-test) (Figure 5-5A). Within dogs which 
lost conscious pain perception (n=4), it was noted that the 2 dogs who recovered had a ratio <1 while 





Figure 5-4. Spinal Cord Stiffness measured by Intraoperative Ultrasound Elastography 
Average coefficient of variation for each location is shown for lesion epicenter (31.0%) and lesion periphery 
(32.0%) by dotted lines (black and grey respectively). Missing columns reflect missing measures (A). No significant 
correlation was seen between depth of measurement from transducer and modulus of elasticity for either lesion 
epicentre [r=-0.54, R2=0.37, p=0.18, Spearman correlation] or lesion periphery [r=-0.17, R2=0.056, p=0.66] (B). A 
significant difference was seen between periphery cord and lesion epicentre cord stiffness [**p=0.0056, Mann-
Whiney U, n=13] (C). Dots mark average measured values for each dog, grey lines denote comparison within 
same dog where this is possible (n=10). Grey arrows mark the only 2 dogs in this cohort who did not recover after 
injury. The coefficient of variation for intraoperative ultrasound elastography measures at the lesion epicenter 







Figure 5-5. Association with clinical severity 
Dogs were graded based on a simple observational score and grouped by clinical severity. The ratio between 
lesion and peripheral cord stiffness for each dog was calculated to normalise differences between dogs. A, Dot 
plot showing comparison of this ratio between paraparetic (n=6) and paraplegic (n=4) dogs shows a significant 
difference [*p=0.019, two-tailed unpaired t-test]. Grey dot and lines indicate Mean±SD. B, Within dogs which lost 
pain sensation (n=4), the 2 dogs which did not recover were the only dogs to have a ratio >1. These dogs are also 




5.3.4 Ultrasound elastography measures show collagen hydrogel stiffness increases with 
collagen concentration, OEC encapsulation and time in culture  
Stiffness measurement of collagen hydrogels by ultrasound elastography broadly shows an increase 
in modulus of elasticity with encapsulation of OECs at a concentration equivalent to canine clinical 
transplants (12.5 million OECs/ml) and with increasing collagen concentration (4.5, 6 and 7.5mg/ml 
collagen was tested) (Figure 5-6A). The 7.5mg/ml cellular gel is approximately similar in stiffness to 
lesion epicentre canine spinal cord (18.3kPa), with its modulus of elasticity becoming greater than that 
of the spinal cord after 1-3 days in culture (up to a maximum of 21.9 ±0.8kPa by day 7; dashed line 
marks spinal cord stiffness for comparison in Figure 5-6A).   
 
Statistical analysis shows modulus of elasticity of collagen hydrogels is significantly affected by 
collagen concentration [F(2,12)=863, p<0.0001], OEC encapsulation [F(1,12)=868, p<0.0001], time 
[F(4,48)=16.7, p<0.0001], and interaction effects; time*encapsulated [F(4,48)=6.11, p<0.0001], 
time*conc [F(8,48)=3.31, p=0.004] and encapsulated*conc [F(2,12)=184, p<0.0001] (repeated 
measures 3 way ANOVA). Post-hoc analysis shows that only hydrogels encapsulating OECs at collagen 
concentration 6 and 7.5mg/ml significantly change over time (from 7.92 ±1.0kPa on day 0 to 11.3 
±2.2kPa on day 7 for 6mg/ml and from 12.8 ±1.0 to 21.9 ±0.8kPa for 7.5mg/ml; p=0.012 and p<0.0001 
respectively, testing for linear trend – only a linear slope showed significance in 3 way ANOVA test of 
contrasts, p<0.01).  
 
Post-hoc analysis (Tukey HSD test) was further performed at the first time point (day 0, immediately 
after encapsulation of cells) as this is the time point at which OECs encapsulated in gel would be 
injected into the spinal cord in patients (Figure 5-6B). At this time point, no significant difference was 
seen after encapsulation for 4.5mg/ml gels (although modulus of elasticity increased from 2.67 ±0.22 
to 3.36 ±0.03kPa, factor of 1.26) but a significant increase in elasticity was seen for 6 and 7.5mg/ml 
gels (from 5.05 ±1.14 to 7.92 ±1.02 kPa, factor of 1.56, p<0.012 and 7.37 ±0.93  to 12.8 ±0.99 kPa, 
factor of 1.74 respectively, p<0.0001). There was also a significant increase in elasticity with increasing 
collagen concentration for cellular and acellular gels (p<0.001 and p<0.05 respectively). This increase 
in modulus of elasticity with increasing collagen concentration was linear for both acellular and 
cellular gels (linear regression showed r = 0.99, R2 = 1.00, p=0.0042 and r = 0.99, R2 = 0.99, p=0.012 
respectively) (Figure 5-6C). The equation of the line for acellular gels was y = 1.565x - 4.36 and for 
cellular gels was y = 3.14x - 10.8 (where y = modulus of elasticity and x = collagen concentration).  
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5.3.4.1 Encapsulated OEC viability decreases with time in culture in this experiment  
OEC culture population was characterised by immunofluorescence imaging with no contaminant 
fibroblasts seen (Figure 6D). Percentage of live cells was determined at each time point when stiffness 
was measured for similar gels cultured in parallel during this experiment (Figure 5-6E, F). There was 
no significant difference in live cells between concentrations of collagen but a significant, broadly 
linear, decrease was seen over the 7 days of the experiment [F(3,21)=123, p<0.0001 repeated 
measures two-way ANOVA]. Percentage live cells started high with 89.0 ±5.1, 92.9 ±6.5 and 91.4 ±7.1 
% for 4.5, 6, and 7.5mg/ml gels respectively but reduced to 10.8 ±3.4, 12.9 ±7.0 and 17.0 ±8.7 % by 





Figure 5-6. Stiffness of collagen hydrogels encapsulating OECs as measured by ultrasound elastography 
Stiffness of collagen hydrogels (collagen concentration 4.5, 6 and 7.5mg/ml) was measured repeatedly over 7 
days by ultrasound elastography with or without encapsulation and continued culture of OECs (termed cellular 
and acellular, respectively; n=3 hydrogels per condition) (A). There is a significant (p<0.0001, three-way repeated 
measures ANOVA) effect of encapsulation, collagen concentration, time, and interaction effects, but significance 
is not shown on this graph and is described in full in results. Orange dot-dash line indicates median modulus of 
elasticity of intraoperative lesion epicentre canine spinal cord (18.3kPa). Results for day 0 (i.e. immediately after 
OEC encapsulation) are displayed separately for clarity (B); a significant increase in modulus of elasticity was 
seen with encapsulation of cells at 6 and 7.5mg/ml, and with increasing collagen concentration for cellular and 
acellular gels. The increase in modulus of elasticity with collagen concentration is linear for acellular and cellular 
gels (C); r = 1, R2 = 1.00, p=0.0042 and r = 0.99, R2 = 0.99, p=0.012 respectively. OEC population was characterised 
by immunofluorescence for p75 and fibronectin before encapsulation in hydrogel and an example image is shown 
in (D). OECs were LIVE/DEAD stained and confocal imaged to determine % live cells every 2 days on additional 
gels kept in the same conditions (E). There is no significant difference between collagen concentrations but a 
significant effect of time (F(3,21)=123, p<0.0001 repeated measures two-way ANOVA; biological n=1, with 
mean±SD from 3-4 image stacks per gel). Example images from confocal imaging at day 1 and 7 are shown for 
4.5 mg/ml gel (F). [Mean±SD; *p<0.05, ***p<0.001, ****p<0.0001] 
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5.3.5 Mechanical indentation measures show collagen hydrogel stiffness increases with 
collagen concentration and OEC encapsulation as measured by mechanical indentation 
When measured by mechanical indentation, the stiffness of collagen hydrogels before and after 
encapsulation of OECs shows similar increases after encapsulation and with increasing collagen 
concentration to those seen when measured by ultrasound elastography. There is a significant effect 
of collagen concentration [F(2,13)=158, p<0.0001], OEC encapsulation [F(1,13)=101, p<0.0001] and an 
interaction effect [F(2,13)=15, p0.0004] (two-way ANOVA) (Figure 5-7A). Post-hoc analysis (Tukey 
HSD) shows a significantly increased modulus of elasticity after OEC encapsulation for 6 and 7.5mg/ml 
gels (from 8.0 ±1.6 to 14.1 ±1.6kPa, factor of 1.76, p=0.0004 and from 10.3 ±1.4kPa to 19.3 ±1.0kPa, 
factor of 1.87, p<0.0001 respectively), but no significant difference after OEC encapsulation in the 
lowest collagen concentration (3mg/ml) – as seen with ultrasound elastography.  
 
A significant increase in elasticity was seen with increasing collagen concentration, specifically 
between 3 and 6mg/ml acellular gels (p=0.0007), and between 3 and 6mg/ml (p<0.0001) and 6 and 
7.5mg/ml (p=0.0015) cellular gels. The increase in elasticity for increasing collagen concentration was 
again linear for both acellular and cellular gels (linear regression showed r = 0.99, R2 = 0.99, p=0.0306 
and r = 0.99, R2 = 0.99, p=0.0064 respectively) (Figure 5-7B). The equation of the line for acellular gels 
was y = 1.789x – 2.93 and for cellular gels was y = 3.397x – 6.21 (where y = modulus of elasticity and 
x = collagen concentration). 
 
Stiffness of collagen gels encapsulating OECs with continued culture up to 4 days was also determined 
by mechanical indentation (Figure 5-7C). Again, similarly to ultrasound elastography, a significant 
effect of time [(F(2,22)=14.2, p=0.0001], collagen concentration [F(2,22)=178, p<0.0001] and an 
interaction effect was seen [F(4,22)=3.2, p=0.033] (two-way ANOVA). Post-hoc analysis (Tukey HSD) 
showed a significant difference between all collagen concentrations at all time-points, but the only 
change within a collagen concentration over time which reached significance was between day 0 and 
day 2 for 6mg/ml collagen (p=0.0024).  
 
5.3.5.1 Encapsulated OEC viability shows no difference over time in culture in this experiment 
An example widefield immunofluorescent image of OECs within a 7.5mg/ml gel at day 4 shows normal 
morphology of cells at this time point (Figure 5-7D). Quantification of LIVE/DEAD staining at day 4 
(example image for same gel in Figure 5-7E) for 2 and 7.5mg/ml gels synthesised and cultured in the 
same manner shows no difference in viability between collagen concentrations and high viability (% 
LIVE = 99.6 ±0.97% and 95.5 ±4.2% respectively) in this preparation (Figure 5-7F).  
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Figure 5-7. Stiffness of collagen hydrogels encapsulating OECs as measured by mechanical indentation 
Stiffness of collagen hydrogels (collagen concentration 3, 6 and 7.5mg/ml) was measured by indentation (n=3-4 
gels per measurement) before and directly after encapsulation of OECs (A). There is a significant effect of collagen 
concentration, OEC encapsulation (p<0.0001) and an interaction effect (p=0.0004, two-way ANOVA). Posthoc 
testing showed a significant increase in modulus of elasticity with encapsulation of cells at 6 and 7.5mg/ml, and 
with increasing collagen concentration for cellular and acellular gels. The increase in modulus of elasticity with 
collagen concentration is linear for acellular and cellular gels (B); r=0.99, R2 = 0.99, p=0.0306 and r=0.99, R2 = 
0.99, p=0.0064 respectively. Measurement of collagen hydrogels encapsulating OECs for up to 4 days (C) shows 
a significant effect of time (p=0.0001), collagen concentration (p<0.0001) and an interaction effect (p=0.033, 
two-way ANOVA). Posthoc testing shows significant differences between all concentrations at all time points 
(not shown), but for time within each collagen concentration the only difference is between day 0 and 2 for 6 
mg/ml collagen (++p=0.0024). An example widefield immunofluorescent image of OECs within 7.5mg/ml 
collagen hydrogel at 4 days is shown in (D) showing normal morphology. Some cells appear dimmer and out of 
focus due to the 3D distribution through the depth of hydrogel. OECs were LIVE/DEAD stained at 4 days, an 
example image in 7.5mg/ml hydrogel is shown (E). Quantification (F) shows high survival (>90%) and no 
difference between 2 and 7.5mg/mL gels. [Mean±SD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001] 
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5.3.6 Ultrasound elastography and mechanical indentation measures of the same samples 
show significant differences in values of measured elasticity  
The above measures by ultrasound elastography and mechanical indentation of acellular (Figure 5-8A) 
and cellular (Figure 5-8B) collagen hydrogels on day 0 were compared. Significantly higher modulus of 
elasticity was seen measured by indentation compared to ultrasound elastography for acellular and 
cellular gels of collagen concentration 6 and 7.5mg/ml (acellular, p=0.036 for both concentrations; 
cellular, p=0.001 and 0.0007 respectively, two-way ANOVA with post-hoc Tukey HSD).  
 
However, a similar increase in modulus of elasticity with increasing collagen concentration was seen, 
with lines of linear regression appearing almost parallel between ultrasound elastography and 
indentation for both acellular and cellular gels, reflected in similar gradients of the line of regression 
(for acellular gels, 1.565 measured by ultrasound elastography and 1.789 measured by indentation; 
for cellular gels, 3.14 measured by ultrasound elastography and 3.397 by indentation).  
 
Analysis of direct correlation between ultrasound and indentation measures was possible for acellular 
gels (not for cellular gels where direct comparison n=2) showing a strong linear correlation between 
measures (r = 0.992, R2 = 985, p=0.039) (Figure 5-8C). Line of linear regression for comparison of 
acellular gels was y = 1.27x + 1.16 and for cellular gels y = 1.08x + 5.5.  
 
Measurement of isolated Zerdine reference material by ultrasound elastography and mechanical 
indentation showed a significant difference between measures only for the 2 highest certified 
elasticities measured – 45 and 80kPa (p<0.0001 for both, two-way ANOVA post-hoc Tukey HSD). A 
strong linear correlation was seen between certified elasticity and measured elasticity for both 
techniques (r = 0.99, R2 = 0.99, p=0.0003 for ultrasound elastography and r = 0.99, R2 = 0.98, p=0.0009 
for indentation). Gradients of the line of regression were y = 0.964x - 1.092 and y = 1.747x - 9.973 
respectively (Figure 5-8D). 
 
Direct correlation between ultrasound elastography and indentation measures of elasticity for 
different Zerdine samples also showed a strong linear correlation between measures (r = 0.993, R2 = 
0.986, p=0.0004) (Figure 5-8E). Line of linear regression for the comparison was y = 1.79x – 7.3.  
 
Indentation measures were consistently higher than ultrasound elastography measures, with no 
significant difference (Kruskall-Wallis) seen in fold change between materials measured; average fold 
change of indentation from ultrasound elastography is 1.54 ±0.1 (Figure 5-8F).  
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Figure 5-8. Comparison of ultrasound elastography and indentation measures of elasticity 
A comparison between the modulus of elasticity of different concentrations of collagen (A) and collagen 
encapsulating OECs (B) as measured by USE and indentation, taken from data in figures 6 and 7, is shown here. 
Indentation measures are significantly higher USE measures for 6 and 7.5mg/ml acellular collagen gels (p=0.035 
and p=0.036) and there is a larger difference for cellular gels (p=0.001 and p=0.0007, two-way ANOVA and 
posthoc Tukey HSD). NB no comparison is possible between 3 or 4.5mg/ml cellular gels. Linear regressions are as 
per figures 6 and 7. A significant linear correlation (r = 0.992, R2 = 985, p=0.039) was seen between USE and 
indentation measures of modulus of elasticity for acellular gels (C, points reflect measured hydrogels and are 
labelled with collagen concentration). Comparison between USE and indentation measures of Zerdine reference 
material of certified elasticities (D) shows a significant difference between higher certified elasticities only (45 
and 80kPa, p<0.0001, two-way ANOVA, posthoc Tukey HSD). A linear relationship is seen for both measures with 
increasing certified elasticity (r = 0.99, R2 = 0.99, p=0.0003 and r = 0.99, R2 = 0.98, p=0.0009).  A significant linear 
correlation between USE and indentation measures of Zerdine was also seen (r = 0.993, R2 = 0.986, p=0.0004) (E, 
points represent Zerdine samples and are labelled with certified elasticity). A summary of the average fold change 
of indentation measures from USE measures shows this relationship is consistent (no significant difference 




5.3.7 Ultrasound elastography and atomic force microscopy measures of the same samples 
show significant differences in values of measured elasticity  
Direct comparison between ultrasound elastography and atomic force microscopy measurement of 
the same collagen hydrogels, Zerdine samples and fixed canine spinal cord sample all showed a 
significant difference between measurement techniques (Figure 5-9).  
 
Ultrasound elastography measures were significantly higher than AFM measures for all concentrations 
of acellular collagen hydrogel measured (p<0.0001 for all concentrations, two-way ANOVA, post hoc 
Tukey HSD) (Figure 5-9A). A significant effect of measurement technique [F(1,212)=223, p<0.0001], 
collagen concentration [F(3,212)=5.5, p=0.013] and interaction [F(3,212)=4.2, p=0064] was seen, 
although on post-hoc analysis no difference between collagen concentrations was seen with AFM 
measures, and the only difference seen with ultrasound elastography was between 4 and 5mg/ml 
(p=0.044). A strong linear correlation between collagen concentration and elasticity was still seen for 
both ultrasound elastography and AFM (shown at magnified scale in Figure 5-9B) (r = 0.96, R2 = 0.92, 
p=0.0429 and r = 0.99, R2 = 0.99, p=0.0027). Equation of the lines of regression showed different 
gradients; y = 0.859x - 0.577 for ultrasound elastography and y = 0.0598x - 0.128 for AFM.  
 
For one 6mg/ml hydrogel [biological n=1, technical measurement repeats n=20-25], the surface 
measurement was compared to measurement of an interior part of the gel after sectioning. The 
interior measure was ~3x higher than surface measure (0.914 ±0.075kPa compared to 0.271 
±0.026kPa).  
 
Correlation analysis between ultrasound and AFM measures of these acellular collagen gels shows a 
significant positive correlation (r = 0.962, R2 = 0.925, p=0.019) despite the different gradients of the 
individual regressions (Figure 5-9C). Line of linear regression for this correlation was y = 0.0643x - 
0.066.  
 
Measurement of Zerdine showed ultrasound elastography to be significantly higher than AFM for all 
certified elasticities except 8kPa (two-way ANOVA, posthoc Tukey HSD) (Figure 5-9D). A linear 
relationship was seen for both measurement techniques (r = 0.99, R2 = 0.99, p=0.0006 for ultrasound 
elastography, r = 0.99, R2 = 0.99, p=0.0004 for AFM). Gradients of the linear regressions y = 0.971x – 
1.72 for ultrasound elastography and y = 0.530x – 2.53 for AFM.  
 
 140 
Correlation between ultrasound and AFM for Zerdine also showed a significant positive correlation (r 
= 0.983, R2 = 0.966, p=0.0013), with equation of line of regression (y = 0.536x - 1.28) (Figure 5-9E).  
 
Finally, measurement of a transverse section of fixed canine spinal cord [biological n=1, technical 
measurement repeats n=20-25] showed ultrasound elastography measures (23.0 ±1.87kPa) to be 
significantly lower than AFM measures (38.3 ±19.8kPa, p=0.0004, unpaired t-test) (Figure 5-9F). The 
ultrasound elastography value for this fixed canine spinal cord was higher than the unfixed post-
mortem cadaver canine spinal cord measures reported above (11.6 ±4.7 kPa).  
 
The average fold change between AFM and ultrasound elastography was inconsistent between 






Figure 5-9. Comparison of ultrasound elastography and atomic force microscopy measures of elasticity 
The modulus of elasticity of three different materials were measured by USE and atomic force microscopy (AFM). 
The same sample [biological n=1, measurement repeats n=20-25] was measured by both techniques within 24 
hours. Measurement of four concentrations of collagen hydrogel (A) showed USE measures to be significantly 
higher than AFM measures at all concentrations (p<0.0001, two-way ANOVA and posthoc Tukey HSD test). AFM 
measures from (A) are shown inset in (B). There is a linear increase in modulus of elasticity with increasing 
collagen concentration with both measurement techniques (r = 0.96, R2 = 0.92, p=0.0429 for USE; r = 0.99, R2 = 
0.99, p=0.0027 for AFM). Direct correlation between USE and AFM measurements of these gels shows a 
significant linear correlation (r = 0.962, R2 = 0.925, p=0.019) (C, points represent hydrogels, collagen 
concentrations are marked). Measurement of five certified elasticities of Zerdine reference material (D) again 
showed USE measures to be significantly higher than AFM for all measures apart from the lowest 8kPa elasticity 
(two-way ANOVA and posthoc Tukey HSD test) and a linear relationship for both techniques (r = 0.99, R2 = 0.99, 
p=0.0006 for USE; r = 0.99, R2 = 0.99, p=0.0004 for AFM). Correlation between USE and AFM measures showed 
significant positive correlation (r = 0.983, R2 = 0.966, p=0.0013) (E, points represent Zerdine samples, labelled 
with certified elasticities). Measurement of a transverse section of PFA fixed canine spinal cord (F) showed USE 
measures to be significantly lower than AFM measures. A summary of the average fold change of AFM measures 
from USE measures shows this relationship is inconsistent between materials (G). [Mean±SD shown, n=1 per 




The results presented here demonstrate that intraoperative ultrasound elastography of the spinal 
cord in pet dogs undergoing decompressive spinal surgery is feasible. The measures obtained show 
that spinal cord stiffness is altered at the injury epicentre compared to more peripheral tissue in this 
cohort of dogs with naturally occurring disc herniation and acute contusive-compressive injuries to 
the spinal cord, corroborating evidence from experimental rodent injuries315,316. There is also an 
indication that the degree of this change may be related to clinical severity, although the number of 
cases is limited.  
 
Ultrasound elastography of collagen hydrogels encapsulating OECs at clinically relevant 
concentrations suggests that the stiffness of this construct could be matched to the stiffness of injured 
canine spinal cord. Comparison between ultrasound elastography, mechanical (macro-)indention and 
AFM measures of the same materials show different values of modulus of elasticity dependent on 
technique. Both indentation and AFM are linearly correlated to ultrasound elastography measures for 
all materials; between ultrasound elastography and mechanical indentation measures the magnitude 
of this difference is consistent between material type, but this is not the case between ultrasound 
elastography and AFM measures. 
 
5.4.1 Intraoperative ultrasound elastography values for spinal cord stiffness fit the range of 
previously reported values for spinal cord stiffness  
In vivo studies of spinal cord stiffness have measured uninjured cord in anaesthetised experimental 
puppies and cats323,324 using invasive mechanical (tensile) methods. These studies reported an elastic 
modulus for normal canine cord of 265 kPa324, higher than that reported for canine cadaver spinal 
cord, 11.9-16.8 kPa, under similar conditions7,325. In a recent report of ultrasound elastography of the 
normal spinal cord in experimental dogs, a value of 18.5±7 kPa was reported for cervical cord426, 
although this value was not calibrated to an ultrasound elasticity phantom.  
 
Our modulus of elasticity results for intraoperative lesion epicentre and periphery canine spinal cord 
(median 18.3 kPa and 47.9 kPa respectively) and cadaver spinal cord (11.6 ± 4.7 kPa) are therefore 
within the range of those previously reported in the literature. However, it is important to note that 
due to the viscoelastic nature of spinal cord, the method of measurement, and indeed exact 
experimental conditions under which the cord is measured (e.g. the strain rate of tensile measures), 
can affect the modulus of elasticity determined328,439. This makes exact quantitative comparison of 
measures between studies challenging.  
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It is important that ultrasound elastography measures are compared to known values for elasticity, 
for example by use of an ultrasound elasticity phantom. To our knowledge this is not something that 
has been reported in the medical literature, but it is vital to allow comparison between centres and 
machine set-ups. It is well established that even when using the same type of ARFI ultrasound 
elastography, both machine440 and transducer441 can affect elastography measures. This is of 
particular relevance in the context of providing a useable reference measurement to other groups, 
e.g. for larger studies comparing stiffness across centres, or for laboratories working on biomaterial 
stiffness requiring a reference.  
 
The extent of spinal cord accessible for measurement in our study was dictated by the surgical bone 
window made in the vertebral column. The lesion epicentre was easily identified, however defining 
the exact boundaries of injury cranial and caudal was more challenging. Whilst we have measured as 
far from the injured site as accessible, it is likely that the surrounding area may contain regions of 
secondary injury, haemorrhage or oedema47,442; hence we have referred to these measures 
throughout as lesion periphery rather than necessarily normal cord. 
 
Magnetic Resonance Elastography (MRE), similarly to ultrasound elastography, is a way of 
quantitatively determining tissue elasticity using specific phase contrast sequences alongside an 
excitation or displacement443. This has been applied to post-mortem dog brain as proof of concept444. 
Using MRE would be a way to access the whole length of the spinal cord, including areas further from 
the site of injury and more likely ‘normal’. MRE would not require surgical exposure and could 
therefore potentially provide serial measures and information about how stiffness of the lesion 
changes with time. Our attempts to use ultrasound elastography per-cutaneously after surgery using 
the laminectomy window were unrewarding. Although an abstract has reported MRE of the spinal 
cord in humans445, it is technically challenging, more expensive and less available than ultrasound 
elastography.  
 
5.4.2 Spinal cord stiffness is reduced in clinical injuries 
The mechanical changes following SCI are only beginning to be understood, with no prior information 
available on the in vivo stiffness of spinal cord after clinical injury. This decreased stiffness at the site 
of injury is contrary to the long-held dogma that the glial scar forms a physical barrier to axon 
growth60,316. However, our intraoperative measures after natural SCI in a large animal model 
corroborate experimental findings in rodents315,316 and are an important extension of this work.  
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All animals in our study had spinal cord stiffness measurements taken less than 2 weeks post-injury in 
the acute or sub-acute stages after injury47. Notably however, the decreased stiffness after injury in 
rodent models was seen by 2 weeks after injury with no difference between measures 2 and 8 weeks 
post-injury315, suggesting our measures may also reflect stiffness in the more chronic phase of injury.  
 
Decreased stiffness at the lesion has been attributed to: (i) increased spinal cord oedema; (ii) necrotic 
and cavitating ECM; (iii) demyelination446; (iv) increased levels of chondroitin-sulphate 
proteoglycans447; (v) presence of reactive astrocytes448; and (vi) increased expression of vimentin, 
GFAP, laminin and collagen IV316. The cellular and microenvironment changes related to local 
inflammation and increased water content are well known in the context of MRI changes seen after 
SCI, with T2-weighted hyperintensity being a common finding due to increased water content and 
increasing T2 relaxation times449.  
 
5.4.2.1 Stiffness of spinal cord injury and association with clinical severity 
A comparison of spinal cord stiffness and clinical severity was not the objective of this study, and these 
results were not the primary purpose of this research, therefore, this analysis was not pre-planned 
and the study power is limited for that reason. However, we see a significant relationship between 
clinical severity and normalised lesion stiffness (the ratio between lesion and periphery cord), 
suggesting the severity of an injury differentially affects spinal cord stiffness. That the only 2 animals 
who did not recover in this cohort were those whose lesion:periphery ratio was greater than 1 (i.e. 
lesion stiffness was greater than periphery stiffness) also adds weight to this observation. However, 
these results have to be taken cautiously and as exploratory findings given the small number of non-
recovering animals. To investigate if ultrasound elastography can help predict recovery for an 
individual dog lacking conscious pain perception a prospective, appropriately powered study would 
be required. 
 
The difference in ratio for the 2 cases not recovering could reflect measurement of a wider lesion area, 
or a wider penumbra area of inflammation, haemorrhage, oedema or necrosis. Indeed, several reports 
investigating MRI findings in dogs following intervertebral disc extrusion suggest that an increased 
length of spinal cord T2-weighted hyperintensity (which could reflect any of these processes) is related 
to poorer long-term ambulatory outcome450–453. Interestingly, the absolute modulus of elasticity for 
these animals in both periphery cord and lesion remains comparatively high, suggesting that increased 
intraspinal haemorrhage may be the most likely cause; haematoma is associated with increased 
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modulus of elasticity454, and intraspinal haemorrhage is associated with increased severity of injury455 
and poor prognosis456.   
 
There is an interesting parallel to the previous experimental results reporting decreased stiffness at 
the lesion after SCI; these two reports both used models of injury (dorsal column crush316 and 
hemisection315) where some recovery of function would be expected. It would be interesting to test 
lesion stiffness in a more severe rodent injury model, where recovery would not be expected, to see 
if changes in stiffness at the lesion are similar to the more severe clinical injuries.  
 
5.4.3 Stiffness measurement of collagen hydrogel  
Despite differences between the absolute values of elastic modulus between measurement 
techniques, the strong linear relationship between increasing collagen concentration and increasing 
hydrogel modulus of elasticity seen here within the range of concentrations tested, with all 
measurement techniques, is consistent with previous reports336,436,457–464.  
 
Comparison of absolute values between studies is challenging due to variables in measurement 
protocol but the values we obtained are in a similar range to those reported in other studies. Only one 
study using ultrasound elastography to determine collagen hydrogel stiffness could be found, which 
reported an initial elastic response of ~2kPa for 2mg/ml and ~6kPa for 5mg/ml collagen hydrogels465, 
similar to the values measured here.  
 
A number of studies measured collagen hydrogel elasticity using mechanical compression or 
indentation measures, with a fairly wide variation in elastic moduli reported. Most are, however, 
within a roughly similar range to that reported here (0.3 – 13.7kPa for 1.5 – 8.5mg/ml collagen). For 
example, compression of 3-9mg/ml collagen gels at similar rates and level of deformation (0.05mm/s 
and 10% strain) to indentation in this study was reported to have slightly lower elastic modulus values 
of 0.5-5kPa436 compared to our results. Other studies using compression show slightly higher results, 
e.g. ~1-6kPa for 0.5-1mg/ml monomer purified collagen (0.02mm/s and measuring at 10-30% 
strain)464 and ~10kPa for 2.8mg/ml collagen (0.2mm/s, 15-30% strain)466. Finally, some studies report 
lower values with compression, e.g. 0.034-0.35kPa for 0.6-3mg/ml collagen (0.02mm/s)336 and  0.4-
1.6kPa for 0.5-4mg/ml collagen  (0.02mm/s , 15-60% strain)462. These differences may be related to 
the exact measurement parameters (e.g. strain or compression rate, sample shape), but differences 
have also been reported due to source of collagen462, pH of final collagen hydrogel467 and ambient 
temperature of measurement468.  
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There is little information on the measurement of pure collagen hydrogel elasticity by AFM. Indeed, 
one study comparing different hydrogels reports being unable to obtain measures of collagen below 
3mg/ml due to adherence of the probe to the gel469. Measures of functionalised collagen470 and an 
alginate-collagen composite471 have been reported with higher elasticities but these are unlikely to be 
relevant comparisons due to differences in the hydrogel composition. It is worth noting that when 
measured by AFM, CNS tissue is generally reported to be ~0.5-1kPa472 and spinal cord ex vivo has 
recently been determined by AFM to have an elastic modulus of ~0.3kPa316. This is softer than 
reported with indentation (~1.3kPa)315 and both our ultrasound elastography measures and those 
reported previously (~18kPa)426. This broadly matches with our results that AFM gives lower measures 
of elasticity than (macro-)indentation or ultrasound elastography measures for soft viscoelastic 
materials.  
 
5.4.4 Effect on stiffness of encapsulation and culture of OECs 
The increase in stiffness after encapsulation of cells by both measurement techniques tested 
(ultrasound elastography and mechanical indentation) for higher concentration collagen gels of 6 and 
7.5mg/ml is consistent with a number of previous reports. Collagen hydrogel (2mg/ml) encapsulating 
mouse pre-osteoblasts at 1 million cells/ml showed an increased stiffness of ~4.5kPa compared to 
collagen alone when measured by dual mode elastography465, a value similar to the one reported here. 
The elasticity of collagen-based hydrogels encapsulating fibroblasts have been reported in studies 
with elasticity measured by a small-bead micro-indentation technique457 and AFM473; in both studies 
hydrogel stiffness was increased by cell encapsulation. Measures by AFM were in the 2-20kPa range 
(>10 fold higher than measured here) but were of a collagen-chitosan blends which are likely to be 
stiffer than pure collagen.  
 
In the above studies, a further increase in stiffness was seen with continued culture with all 
measurement techniques457,465,473. We see a similar increase over 7 days in culture as measured by 
ultrasound elastography but not with mechanical indentation.  The same concentration of OECs and 
similar concentrations of collagen were used between these experiments, however there were some 
differences in the experimental set-up: (i) the size of the gels (300µl for indentation, 500µl for 
ultrasound), (ii) that single measurements of each gel were performed for indentation while repeated 
measures of the same gel were possible for ultrasound, and (iii) that cell survival by LIVE/DEAD was 
lower for ultrasound experiments. 
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This difference in cell survival could be related to the repeated measures of gels and experimental 
protocol requiring more handling of gels containing cells, including moving out of a culture hood to 
allow ultrasound scanning. Although efforts were made to maintain sterility (sterile equipment and 
PBS used out of the hood) and no signs of infection were seen, these cultures would have been more 
at risk. The high concentration of cells used in these experiments could also potentially limit cell 
survival, previous reports in collagen hydrogel suggests increasing cell number and ‘over-populating’ 
the gel can reduce viability, even with much lower cell concentrations of 50,000/ml457,474. The 
concentration of cells used in indentation (where cell survival was good until at least 4 days) and 
ultrasound experiments reported here was the same so we do not see this over-population effect. 
However, it might be possible that in the larger size of ultrasound gels there was reduced diffusion of 
oxygen and nutrients to the centre of the gels and that this in combination with high cell number leads 
to increased cell death at the centre of the gel.  
 
Collagen has a comparatively large pore size compared to other hydrogels475, and pore size is 
concentration dependent. As there is no difference between collagen concentrations this diffusion 
explanation is perhaps less likely. Repeating ultrasound experiments with more rigorous testing for 
infection (e.g. culture and sensitivity, mycoplasma PCR) or further experiments comparing the viability 
of cells cultured in gels of different volumes may help to determine if these are the cause of the poorer 
cell survival.  
 
A difference in cell survival between the experiments could itself explain differences in stiffness 
between indentation and ultrasound. After fibroblast encapsulation, increased stiffness was reported 
to be associated with contraction of the gel over time457; one of the main functions of fibroblasts is to 
contract tissue as part of healing476. This mechanism may not be applicable to OECs but if OECs or their 
secreted ECM were acting to effectively reduce hydrogel stiffness (or balance normal contraction over 
time) then higher cell death in the ultrasound experiments could be a mechanism for increased 
hydrogel stiffness. Alternatively, cell clumping following cell death may have led to an artificial 
increase in stiffness over time in the ultrasound experiment.  
 
How directly cell survival in collagen in vitro relates to cell survival in vivo after transplant is unclear, 
and this is examined more closely in (chapter 6). Further, consideration of stiffness and cell survival in 
vitro at these later time points is only of practical interest up to the point in time at which the hydrogel-
cell construct will be implanted in vivo.  
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5.4.5 Stiffness matching of hydrogel-OEC construct to canine spinal cord 
In the context of injecting hydrogels encapsulating cells which are intended to gel at body temperature 
and conform to lesion sites, the time point immediately after encapsulation of cells is the most 
relevant to consider. Measures of stiffness immediately after encapsulation of OECs (day 0) are 
consistent between ultrasound and indentation and cell viability is high in both at this time point. 
 
By reference to ultrasound elastography, which allows direct comparison without the difficulties of 
comparing measurement technique (discussed below), these results show that collagen hydrogels 
encapsulating OECs are of the same order of stiffness as intraoperative injured canine spinal cord. 
Collagen hydrogel at concentration 7.5mg/ml encapsulating OECs at a clinically relevant concentration 
was measured at 12.8 ±1.0kPa on day 0, median intraoperative lesion epicentre canine spinal cord 
was 18.3kPa (IQR: 11.6-31.1 kPa). Therefore this 7.5mg/ml collagen-OEC construct would be less stiff 
than injured cord and considered safe for transplant.  
 
Given there is a linear relationship between collagen concentration and modulus of elasticity for 
cellular gels on day 0 (y = 3.14x - 10.8) it can be calculated that for a ‘target’ stiffness of 18.3kPa, a 
collagen concentration of 9.3mg/ml would be required for the implant to precisely match spinal cord 
stiffness, assuming the same concentration of encapsulated OECs.  The in vivo effect of matched 
stiffness collagen hydrogel and OEC injectable transplant is explored in the next chapter.  
 
Although groups are working on creating more flexible and less stiff implants to minimise 
inflammatory reaction, particularly in the field of electrode implant in the CNS298,477,478, we are not 
aware of a described method for matching of hydrogel stiffness to CNS stiffness before transplant. 
This approach opens the possibility for bespoke implant matching whereby the stiffness of a patient’s 
injury site could be measured and a matched-stiffness hydrogel-cell construct rapidly and simply 
created for each patient (Figure 5-10). Ultrasound elastography has been used intraoperatively in 
humans in the central nervous system to identify an epileptic focus479, to aid detection and 
discrimination of brain tumours480,481 and to assist decompression of cervical spinal cord482 





Figure 5-10. Graphical summary of implant stiffness matching using ultrasound elastography 
 
5.4.6 Comparison of stiffness measurement techniques 
Comparison between measurement techniques and different studies is complex due to the variety of 
parameters possible for each technique. For example, with ultrasound elastography the type of 
elastography machine, the ultrasound probe and the frequency are important variables; in (macro-
)indentation or AFM the indenter shape and size, approach speed or indentation rate and the 
mathematical approach used to approximate elasticity create variation.  
 
5.4.6.1 Ultrasound elastography and mechanical (macro-)indentation measures 
The results from our study show that although mechanical indentation, in our set-up, tends to 
measure modulus of elasticity significantly higher than ultrasound elastography, this is in a consistent 
manner and linearly correlated. The difference is relatively small, not reaching significance for all 
samples and with a small and consistent average fold change (1.5 ±0.1) meaning values measured are 
of the same order. 
 
No previous reports on comparison of collagen hydrogel stiffness between ultrasound elastography 
and indentation could be found, but similar findings were seen in a study on Zerdine and mammary 
tumour samples483. Indentation with 1 and 2mm indenters was compared to shear wave elastography 
(similar to the elastography used here but requiring operator compression to provide the initial shear 
wave). The agreement between measures was variable depending on sample, with similar values seen 
between measures on low histological grade but not high histological grade tumours where values 
were ~2.5 fold different. This is broadly in agreement with our results, although indentation measures 
were lower than ultrasound in this instance.  
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A report addressing a prototype elastography phantom material (similar to Zerdine) showed good 
agreement between transient elastography (ultrasound shear wave velocity measurement after a 
standard mechanical impulse to trigger shear waves) and whole material compression converted to 
elasticity by linear regression of stress-strain curve at 0-10% strain412. A further study using indentation 
(5mm diameter advanced at 0.01mm/s, comparable to our study) and shear wave imaging measured 
gelatin of different sizes484. This study reported no difference between measures for larger samples 
(70m diameter x 30mm height) but reported ultrasound values to be higher than indentation in 
smaller samples (20mm x 6mm) by up to ~50%. The authors attribute this difference to increased 
effect of boundary conditions dependent on gel size, either increasing shear wave attenuation and 
reducing signal to noise ratio or reducing shear wave attenuation and increasing acoustic echo from 
the plastic below the sample. In our study efforts were taken to minimise these effects. Samples for 
ultrasound were measured on gelatin rather than plastic to reduce acoustic echo; the number of error 
(‘x.xx’) readings, which reflect the internal variability of each ultrasound measure, were greatly 
reduced when this was introduced in preliminary experiments (data not shown).  
 
The authors of this last study suggest that the same findings (congruity between indentation and 
ultrasound measures) might not be expected with more viscoelastic materials, as we have investigated 
here particularly with cellular hydrogels. Our results therefore are to some extent in agreement with 
picture seen in the literature, suggesting that (macro-)indentation and ultrasound elastography 
measures give similar, if not exactly equal, values for modulus of elasticity, which are likely dependent 
on measurement parameters.  
 
For our comparisons between ultrasound elastography and indentation the same sample could not 
be used, and slightly different size and shape samples were compared. However, differences in size 
and shape should be accounted for in mathematical conversion of measured N/mm to Pa (modulus 
of elasticity) for indentation measures. Mechanical indentation measures were performed using a 10N 
load cell, on a machine sensitive to 0.5% of the load cell (i.e. 50mN)485. For the lowest concentration 
hydrogels measured on indentation (1.5mg/ml), measured raw values for load are below this 
threshold peaking at ~20mN, but above 4.5mg/ml peak values are >50mN and for 8.5mg/ml they are 
~200mN. Lower concentration gels have been kept in this analysis as they fit the linear regression well 
and the slope of the regression is similar to ultrasound elastography giving confidence in the 
measures. Further, a similarly sensitive instrument with a 10N load cell has been used in published 
reports of collagen hydrogel elasticity at similar concentrations (2-9mg/ml)436,463.  
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5.4.6.2 Ultrasound elastography and AFM measures 
The comparison between ultrasound and AFM measures has the advantage of measurement of the 
same sample. The difference between measures is variable between materials, with the largest 
difference (>20 fold) seen for measurement of hydrogels.  
 
No reports directly comparing ultrasound and AFM measures of hydrogels could be found, however, 
two recent studies use ultrasound elastography and AFM on the same tissue. In one, 
musculotendinous mouse tissue modulus of elasticity was measured by shear wave elastography to 
be 2-3 fold greater than AFM measures486, significantly closer than seen in our study for hydrogel but 
similar to fixed tissue and Zerdine. The other study used did not quantify ultrasound measures but 
saw a similar profile of elasticity through mammary mass biopsies as with AFM487 implying a linear 
relationship as we saw. This is a similar magnitude of difference to what we see measuring (fixed) 
tissue and Zerdine, although in our experiments AFM values were lower.  
 
Previous literature comparing AFM and other (bulk) measures of elastic modulus has mostly reported 
similarity between these measures. In a study mentioned above, functionalised collagen hydrogels 
had a relatively high and wide range of modulus of elasticity across the gels tested (16-287kPa by AFM) 
which were similar values to compression (30-168kPa)470. Compression of poly(vinyl alcohol) at 
different concentrations showed very similar elasticity to AFM measures in two studies from the same 
group488,489. Tensile (bulk) measurements and AFM have also previously been shown to measure 
similar elasticities for polyacrylamide gels472 and across a range of materials in the MPa range490. All 
these materials are relatively stiff, at least compared to our collagen hydrogels.  
 
Differences have also been reported between AFM and bulk measures. Measurement of alginate and 
collagen gels were 3-fold different between tension (~150kPa) and AFM (50kPa)471. Additionally, 
differences between micro- and nano-scale AFM were reported when measuring cartilage and CSPG-
agarose-collagen hydrogels491 but this is attributed to differential measurement of collagen fibrils and 
inter-fibril agarose gel with nano-scale measurement resulting in a bimodal distribution of elasticity 
measurements, something not expected be seen with the micrometre size AFM tip used here on 
collagen and not expected with more homogenous Zerdine.  
 
Given the variation in experimental protocol and difficulty comparing elasticity measures discussed 
previously, as well as the huge possible variations in AFM set up486 (e.g. tip shape and size, cantilever 
stiffness, calibration, indentation force or speed and mathematical models for analysis) it seems 
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reasonable that values for elasticity may vary slightly (2-3 fold) between measures due to these 
factors. This is the sort of range of difference seen in our study for all materials measured by AFM and 
ultrasound except hydrogels.  
 
The much larger difference between ultrasound and AFM measures of collagen hydrogel seen in our 
results is not reported in the literature, but measures of comparably soft and viscoelastic gels are not 
found. Measurement of soft hydrogels by AFM has been reported to be challenging due to adhesion 
of the AFM indenter to the hydrogel on retraction469. This was appreciated in our experiments but was 
reduced to acceptable levels by modification of measurement technique to determine the surface of 
the gel and calculation of elasticity only from the indentation phase. Hertz model fit was good for all 
curves used in analysis.   
 
Interestingly, when the interior of the gel was measured this was ~3 fold higher than the surface 
measurement (both measures AFM). No reports were found of this effect previously. It is possible 
there is an interaction effect between ‘loose’ surface collagen and PBS, with the interior remaining 
denser, but this was not studied in detail. If this were to be the case these interior measures may 
represent a fairer comparison to ultrasound measures which are measuring the internal structure of 
the gel. Mechanical (macro-)indentation measures are measuring a bulk modulus on a larger scale and 
would be less affected by any surface interaction effect. More repeats across a wider concentration 





In conclusion, intraoperative ultrasound elastography of the spinal cord is feasible and provides 
measures of spinal cord stiffness that could inform research in biomaterial implant design. Using the 
same technique to measure elasticity we demonstrate that collagen hydrogels encapsulating clinically 
relevant concentrations of OECs can be approximately matched to injured canine spinal cord stiffness. 
This approach therefore introduces the possibility of personalised biomimetic hydrogel-cell implants 
for patients. 
 
Use of ultrasound elastography on clinics can aid further understanding of spinal cord mechanical 
properties and how they change after natural injury, which may be an important determinant of 
subsequent regenerative events. These data are the first to investigate the effect of clinical injury on 
spinal cord stiffness and we corroborate experimental results showing a decreased stiffness after 
injury in the sub-acute phase. Further research is warranted to determine if ultrasound elastography 
can provide discrimination of injury severity and prognostic information for dogs with the most severe 
injuries (those lacking conscious pain perception). 
 
When measuring the same materials by ultrasound elastography, mechanical (macro-)indentation and 
AFM techniques all show the same trend for modulus of elasticity for each material type (collagen 
hydrogel ± encapsulation of OECs, Zerdine reference material and fixed spinal cord) and values are 
linearly correlated. However, the absolute modulus of elasticity determined is different dependent on 
technique. Care is therefore required when comparing values for elasticity derived from techniques 
appropriate in vivo (ultrasound elastography) and those more commonly used in the lab. Preliminary 
conversions between these techniques are reported in these results but a larger study would be 




Chapter 6  
 
Preliminary investigation of canine olfactory 
ensheathing cell transplant within collagen hydrogel 





Olfactory ensheathing cells are one of the most promising cell therapies for SCI but like many cell 
transplant approaches are limited by a lack of cell survival after transplantation40,205. As discussed in 
the thesis introduction, cell survival can be improved by transplant within protective hydrogel 
matrices286–288, which also provide a structural and replacement ECM, modifying the local environment 
and promoting axon regeneration262,280.  
 
OEC encapsulation within hydrogels has been explored in vitro in alginate, where OEC morphology 
was changed and abnormal, and Matrigel where OECs proliferated and survived well297. OEC 
encapsulation in vitro has also been tested in three synthetic hydrogel materials showing good viability 
in all294–296. One of these studies, with poly-lactic-coglycolic acid (PLGA), also included in vivo testing 
with transplant of the pre-gelled hydrogel into an acute T9-10 transection in rats. Locomotor 
outcomes (BBB) were improved with PLGA+OEC transplant, although only minimal difference 
between PLGA only and PLGA+OECs was seen (a significantly increased angle was achieved on inclined 
plane test but only at 2 weeks post-transplant). 
 
 OECs have also been transplanted within hydrogel in vivo in rodent studies combined with other 
treatments. OECs were transplanted with Schwann cells inside a polyacrylonitrile/polyvinyl chloride 
channel implanted at the time of T9/10 transection injury; axons were then detected growing into the 
implant at 6 weeks after transplant492. Finally, OECs were injected (in solution) into the cut ends of a 
T8/9 transection that was filled with Matrigel encapsulating Schwann cells and chABC was 
subsequently delivered through an implanted cannula every 2 days for 4 weeks259. Significant 
improvements in BBB score were seen with implant and OECs compared to controls and an additional 
significant improvement detected with the addition of chABC. This last experiment particularly shows 
the degree of complexity that can be involved in trying to deliver combination therapies and highlights 
one of the motivations of this thesis, namely, to try and develop a simplified (at point of delivery) 
means of combing potential treatments.  
 
In two of the three in vivo studies above, surviving OECs were seen but not quantified (at 6 weeks492 
and 8 weeks296 after implant). The third study does not comment on OEC survival259. In all studies, 
transplants were given acutely at the time of injury and biomaterials implanted as a solid construct 
rather than injected in liquid form for post-implantation gelation. Indeed, the majority of experimental 
(rodent) hydrogel investigations have been conducted with transplant in the acute phase after 
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injury493 and injectable hydrogels for SCI repair are less commonly studied than implantation of a pre-
gelled hydrogel construct494. 
 
Injectable hydrogels are considerably less invasive than the surgical approach and resection of the 
injury site required for block transplants264, making them more likely to be adopted on clinics. An 
injectable construct has additional benefits in the context of testing and translating a potential therapy 
to clinics through randomised and blinded trials; being easier to blind and more likely to be ethically 
justifiable for the control group (which would have to receive invasive surgery without trial treatment 
for block transplant).  
 
Additionally, injection of an ‘ungelled’ liquid hydrogel which polymerises in situ within the lesion 
allows the gel to conform to the complex morphologies that are seen in clinical injuries263. A previous 
report of collagen hydrogel implantation in rodent dorsal transection SCI showed that injected 
‘ungelled’ collagen allowed invasion of CST fibres, while implantation of gelled collagen did not, 
potentially due to the physical continuity between spinal cord parenchyma and injected collagen 
reducing the barrier to axon growth429. It is also technically simpler to match the volume of a lesion 
(e.g. as calculated from MR imaging) and inject a patient-matched volume of hydrogel which can then 
fill the lesion, than to surgically implant a construct matched to lesion shape (e.g. using 3D printing as 
has been recently described495).  
 
In this chapter we therefore wanted to investigate whether a clinically relevant injectable hydrogel 
could improve OEC survival after injection into a chronic SCI lesion. We used collagen hydrogel for the 
same reasons as in the previous chapter, because of its use in experimental SCI repair406,429 including 
in dogs293 and for cell encapsulation430,431, because OECs can be grown within it428, and for its 
biocompatibilty7. Collagen is a main constituent of endogenous ECM, is minimally immunogenic in 
humans, and a variety of collagen products from various sources have been FDA approved for use in 
the nervous system39.  
 
This evidence suggests collagen hydrogel would be readily useable on clinics (our short-term objective, 
if collagen encapsulation supports OEC survival, being autologous transplant of OECs encapsulated 
within hydrogel in dogs with chronic SCI). However, all implanted foreign materials, including hydrogel 
biomaterials, will trigger a host response. The nature of this will be dependent on the material itself, 
its mechanical properties, and potentially degradation products (for reviews see Fuhrmann et al. 
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2017493, Mariani et al. 2019496. Another reason to use collagen, therefore, is that it and its degradation 
products are a common component of endogenous ECM.  
 
To investigate this safety aspect, an additional goal of this chapter was to examine the inflammatory 
and immune responses to collagen hydrogel transplant. These responses can also be triggered by a 
mis-match in stiffness298,299 (discussed further in the previous chapter) so we used a collagen hydrogel 
concentration to match the stiffness of rat spinal cord using the collagen hydrogel and OEC 
encapsulation stiffness measurements from the previous chapter (see methods below). 
 
Combination therapy is considered vital to finding an effective therapy for SCI. As such, we further 
wanted to determine whether canine OEC-chABC could also be delivered within an injectable collagen 
hydrogel to provide CSPG digestion in chronic dorsal column crush injuries in rats and examine if this 
affected the degree of axon regeneration seen.  
 
6.1.1 Aims and hypotheses 
Our primary aim in these preliminary experiments was to test whether OEC survival after transplant 
can be improved by injection within a collagen hydrogel in a chronic lesion environment.  
 
Our secondary aims were to: (i) investigate astrocyte and microglial response to the matched-stiffness 
hydrogel; (ii) examine whether injected collagen hydrogel could mould to a cystic cavity; and (iii) look 
for any change in histological markers of axon regeneration between groups.  
 
We hypothesised that injection of OECs encapsulated in matched-stiffness collagen hydrogel would 
increase cell survival, conform to the lesion cavity, facilitate axonal growth and not increase 
inflammatory or immunological responses compared to injection in solution. We further hypothesised 
that OEC-chABC encapsulation would provide delivery of chABC and cause digestion of CSPGs after 









6.2.1 Canine OEC culture, transduction, hydrogel encapsulation, characterisation 
Cells were obtained, transduced, cultured and characterised as per thesis methods. OEC-chABC were 
subsequently FACS sorted, with selection and gating on GFP, by Dr Lorena Sueiro Ballesteros (a 
member of the Flow Cytometry Facility, Cellular and Molecular Medicine, University of Bristol).  
 
For in vitro experiments, cells (OEC-GFP or sorted OEC-chABC) were encapsulated as described in 
thesis methods at 1 million cells/ml in either 2 or 8mg/ml collagen hydrogel. Morgan Elson to 
determine chABC activity was performed as per thesis methods using 50µl samples of culture media 
(n=4 gels for OEC-chABC and OEC-GFP).  
 
In vivo experiments, described below, were performed in 3 ‘batches’. The same source (dog ‘Bethan’) 
and original vial was used for each experiment and transplanted cells were all passage 5 or 6.  
 
6.2.2 Mechanical indentation of rat cervical spinal cord 
Male Wistar rats weighing 250-300g (n=4), terminated at the end of an unrelated study, were used to 
gain an approximation of cervical spinal cord stiffness by mechanical indentation to allow direct 
comparison to our hydrogel stiffness measures in the previous chapter. Immediately after euthanasia 
by intraperitoneal pentobarbital injection, the cervical spinal cord was carefully dissected and placed 
on ice. Each cord was cut into 3 segments transversely and each segment’s elasticity was measured 
by mechanical indentation as described for hydrogels in the previous chapter, with the indenter 
contacting the dorsal spinal cord. Conversion of load-extension graphs was also performed as 
described in the previous chapter based on the gradient of the linear portion of the graph within 5% 
strain, using a value for ‘FEA’ of 6.84 based on an average height (dorsoventral) of spinal cord 
segments of 3.2mm and a Poisson’s ratio for soft tissue of 0.5 as used throughout this thesis.  
 
6.2.3 Experimental groups 
This experiment was exploratory and formal power calculations were not performed. Transplant 
numbers for each batch are summarised in Table 6-1 below. In batch 1, 8 animals were transplanted 
(n=4 media + OEC-GFP and n=4 collagen + OEC-GFP). The experiment was repeated (batch 2) with 2 
media + OEC-GFP and 4 collagen + OEC-GFP transplants. In this experiment, an additional 2 transplants 
of collagen + OEC-chABC were performed as a pilot to test if CSPG digestion was seen. In batch 3, 
transplants were: 1 media + OEC-GFP, 1 collagen + OEC-GFP, 4 collagen + OEC-chABC.  
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 Media + OEC-GFP Collagen + OEC-GFP Collagen + OEC-chABC 
Batch 1 4 4 - 
Batch 2 2 4 2 
Batch 3 1 1 4 
Table 6-1. Number of animals used in each batch of experiment 
 
6.2.4 Surgeries and cell transplantation 
Animals were housed and initial dorsal column crush SCI surgery was performed as described in thesis 
methods. After 3 weeks, animals were re-anaesthetised in the same manner as the initial surgery and 
a repeat approach made to the site of SCI. Fibrous tissue was dissected from the spinal cord to visualise 
the lesion, localised by prior laminectomy and identified by discolouration of the spinal cord. After 
batch 1, due to difficulty dissecting fibrous tissue and exposing the injury site at second surgery for 
transplant, the first (injury) surgery was slightly modified by placement of surgical grade replacement 
dura (Gore Preclude PDX) after injury. This was placed over the SCI site within the laminectomy and 
sutured in place to epaxial muscles laterally on closure to reduce adhesions to the spinal cord.   
 
Cells (OEC-GFP or OEC-chABC) were prepared for transplant similarly to previous chapters, with 
transduction by LV-GFP or LV-chABC 10 days prior to transplant, except that a continued culture of 
OEC-chABC (FACS sorted) was used in both batch 2 and 3. On day of transplant cells were trypsinised 
in batches from 24-well plates, washed in HBSS and resuspended at a concentration of 86,000 cells 
per µL in 1x MEM or collagen hydrogel, in a minimum volume of 3µL, and kept on ice until transplant. 
Collagen concentration of hydrogel was determined based on stiffness measurements of spinal cord 
(see results). In previous preliminary experiments, no difference was seen between lesion size at 2 
and 4 weeks after dorsal column crush injury. The average lesion size was 2.12 ±1.2mm3 (n=5) hence 
2.1µl of transplant material (media or collagen hydrogel) was used in these experiments to match this 
average volume.  
 
A total number of 180,000 cells were transplanted in 2.1µl MEM or hydrogel into the lesion (identified 
as above) within 90 minutes of trypsinisation, at a rate of 250nL/minute using a micro-pump and 
Hamilton syringe clamped in a frame. The surgeon was not blinded to transplant group but the order 
of animals was randomised. Animals were immunosuppressed with cyclosporine from 24 hours before 
cell transplant until termination. In all experiments, animals were terminated and perfuse-fixed as per 
thesis methods 2 weeks after transplant. 
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6.2.5 Immunohistochemistry and image analysis 
The central (dorsal sectioned) region was taken from 10mm cranial to 10mm caudal to the lesion. 
Immunohistochemical and immunofluorescence staining and imaging was performed as per thesis 
methods for GFP, TUJ1, GFAP and IBA1 on dorsal sections 1 in 10 through the lesion. Immunostaining 
and analysis for vGlut1 and 5HT was performed as per thesis methods.  
 
TUJ1, GFAP and IBA1 pixel density was determined as per thesis methods. The lesion region of interest 
was traced by hand in ImageJ and defined by the clearly demarcated GFAP boundary. Regions of 
interest surrounding the lesion for GFAP and IBA1 were defined by automatically generating 4 squares 
of consistent size on each image and positioning these against the cranial, caudal and lateral 
boundaries of the lesion. An average pixel density across these 4 squares was determined for each 
section. Cranial and caudal regions of interest were defined for TUJ1 pixel density, 500µm in length 
from the cranial or caudal extent of the lesion and traced by hand within the white matter. Lesion and 
caudal TUJ1 pixel density was normalised to cranial pixel density. Vales displayed for each animal are 
an average of all sections.  
 
6.2.5.1 Picrosirius red staining and quantification 
Picrosirius red (Sigma, ab150681) staining was performed on 1 in 10 dorsal section through the lesion 
by immersion for 1 hour at room temperature followed by 2 rinses in acetic acid, dehydration through 
serial alcohol (70, 90, 95% ethanol for 1 minute each) and xylene (2 minutes) and mounting of cover 
slips using DPX.  
 
Sections were imaged as per thesis methods with the addition of a polarising filter. Collagen hydrogel 
was determined as any areas showing red/orange-yellow birefringence within the cystic lesion 
area497,498. This was manually traced in ImageJ alongside the total area of the lesion and the 
birefringent area expressed as a percentage of the total lesion area per section. Values displayed for 





6.3.1 Characterisation of transplanted OEC population 
The transplant cell population was characterised in vitro before use in vivo for each batch of animals. 
The proportion of cells p75+ was the same between batches with an overall average of 97.4 ±0.8% 
(Figure 6-2A). The proportion of GFP+ cells, indicating transduction with LV-GFP or LV-chABC, was 
significantly different between (sorted) OEC-chABC and OEC-GFP from all batches [F(3,22)=295, 
p<0.0001 one-way ANOVA; p<0.0001 post-hoc Tukey’s test) (Figure 6-2B). The proportion of GFP+ 
OEC-GFP cells was also significantly different between experiment 1 and 2 (p=0.0261). An example 
immunofluorescent image of the sorted OEC-chABC cells is shown (Figure 6-2C) demonstrating near 
100% p75+ and GFP+ population.  
 
Morgan Elson on media taken from culture wells with 2 and 8mg/ml collagen hydrogel encapsulating 
OEC-GFP or OEC-chABC (n=4) at 1 week after encapsulation shows that active chABC is produced by 
OEC-chABC within collagen hydrogels, and that this OEC-chABC is released from the hydrogel. There 
is no difference in quantity of chABC detected between collagen concentrations tested (Figure 6-2D).  
 
6.3.2 Stiffness of rat spinal cord for matched collagen hydrogel transplant 
Measurement of rat cervical spinal cord stiffness by mechanical macro-indentation (n=4) determined 
a modulus of elasticity of 398.4 ±80.1 Pa. Using indentation measures of collagen hydrogel 
encapsulating OECs determined in the previous chapter and the linear regression describing the 






Figure 6-2. Characterisation of transplanted OEC population 
OEC population was characterised by immunocytochemistry before transplant for each batch of animals (‘Expt’ 
1-3). Proportion of p75+ cells was consistent between batches (A). Proportion of GFP+ cells was significantly 
different in experiment 1 compared to experiment 2 and 3 (*p=0.0261, one-way ANOVA and post-hoc Tukey 
test). Chondroitinase expressing OECs (OEC-chABC), used only in experiment 2 and 3, were FACS sorted on GFP 
to a purity of 98.92 ±0.32 % GFP+ cells so this proportion was significantly different to GFP (only) expressing cells 
(OEC-GFP) used in all experiments (p<0.0001) (B). A representative immunofluorescent image of OEC-chABC in 
culture is shown in (C). OEC-GFP and OEC-chABC were cultured in vitro within collagen hydrogels (2 and 8 mg/ml), 
Morgan Elson at 1 week shows no difference in levels of active chABC present in media from these gels (D), and 
a comparison to concentrations of commercial chABC. [Mean±SD] 
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6.3.3 In vivo cell survival 
One animal in the collagen + OEC-chABC group and one in collagen + OEC-GFP died under anaesthesia 
during the second surgery leaving group sizes of n=7 for media + OEC-GFP, n=8 for collagen + OEC-
GFP and n=5 for collagen + OEC-chABC. No significant differences in cell survival was seen between 
batches so results are reported together.  
 
Example images demonstrating GFP+ cells surviving 2 weeks after transplant are shown for each 
transplant type; media + OEC-GFP, collagen + OEC-GFP and collagen + OEC-chABC (Figure 6-3A-C). 
Surviving GFP+ cells were observed in each group but OEC-GFP transplanted in media were never seen 
within the empty lesion cavity (lesion edge visible by GFAP staining) whereas GFP+ cells in both 
collagen transplant groups were detected within the lesion area. Quantification of GFP+ cells was 
normalised to the number of GFP+ cells transplanted in each animal (determined from transduction 
rate in vitro above) and expressed as a percentage of GFP+ cells transplanted. There were significantly 
(~7.5x) more OEC-GFP cells after transplant in collagen compared to media (4.77 ±2.4% compared to 
0.62 ±0.42%; F(2,17)=15.8, p=0.0001 one-way ANOVA, p=0.0003 post-hoc Tukey’s test) (Figure 6-3D). 
There was a similar number of OEC-chABC cells after transplant in collagen as OEC-GFP after transplant 
in media, corresponding to a significantly lower number of OEC-chABC in collagen compared to OEC-
GFP in collagen  (0.79 ±0.5% compared to 4.77 ±2.4%, p=0.0011 post-hoc Tukey’s test).  
 
CSPG digestion was confirmed after OEC-chABC transplant in collagen by presence of C4S stubs, no 





Figure 6-3. In vivo cell survival and CSPG digestion 
Example dorsal sections immunostained for GFAP and GFP are shown 2 weeks after injection of OECs expressing 
GFP only (OEC-GFP) transplanted in media solution (A, n=7) or liquid ‘un-gelled’ collagen hydrogel (B, n=8). An 
equivalent example image is shown for OECs expressing chACB and GFP (OEC-chABC) after injection in the same 
collagen hydrogel (C, n=5). GFP+ cells were quantified in serial sections through cord and expressed as a 
percentage of the initial number of GFP+ cells transplanted (D). A significant difference in cell number is seen 
between OEC-GFP transplanted in hydrogel and both OEC-GFP transplanted in media (***p=0.0003, one-way 
ANOVA and post-hoc Tukey test) and OEC-chABC transplanted in collagen hydrogel (**p=0.0011). Example dorsal 
sections immunostained for C4S stubs (black) of CSPG digestion taken 2 weeks after transplant of OEC-GFP (E) or 





6.3.4 Collagen hydrogel in vivo 
Images of picrosirius red staining imaged using polarised light microscopy to identify collagen within 
the lesion cavity at 2 weeks after transplant illustrate that in some cords collagen was found 
distributed throughout the lesion cavity (Figure 6-4Ai) but that this was not the case in every cord or 
section, and collagen was often seen only partially filling the lesion cavity (Figure 6-4Aii). The 
distribution of picrosirius red closely matched the distribution of GFP+ transplanted cells seen in serial 
sections (Figure 6-4A).  
 
Quantification of picrosirius red staining showed significantly more staining in collagen transplants 
than media [F(2,17)=49.9, p<0.0001 one-way ANOVA; p<0.0001 and post-hoc Tukey’s test]; picrosirius 
red staining in media + OEC-GFP group covered 1.9±2.7% of lesion area. There was also a significant 
difference between collagen + OEC-GFP and OEC-chABC groups (p=0.0075; picrosirius red staining 
occupying 49.8±11.6% and 31.3±11.0% of lesion volume respectively) (Figure 6-4B).  
 
A linear correlation was seen between amount of picrosirius red staining and number of GFP+ cells for 
all OEC-GFP transplants (r = 0.833, R2 = 0.693, p=0.0001) but not for collagen + OEC-chABC transplants 
(r = 0.121, R2 = 0.0147, p = 0.846) (Figure 6-4C).  
 
6.3.5 Inflammatory response to transplants 
Dorsal sections for each transplant group showing immunofluorescence staining for GFAP (Figure 
6-5A-C) and immunohistochemical staining for IBA1 (Figure 6-5F-H) were quantified showing no 
difference between GFAP or IBA1 levels between groups (Figure 6-5D,I). Invasion of GFAP+ and IBA1+ 
cells into the lesion area were seen for both collagen transplants. Quantified (Figure 6-5E,J), this 
showed a significant difference between media and collagen transplants for GFAP (p=0.0059 Kruskall-
Wallis; post-hoc Dunn’s test p=0.0347 for media + OEC-GFP compared to collagen + OEC-GFP, 
p=0.0268 for media + OEC-GFP compared to collagen + OEC-chABC). A significant difference was seen 
between media + OEC-GFP and collagen + OEC-GFP for IBA1 (p=0.011 Kruskall-Wallis; post-hoc Dunn’s 





Figure 6-4. Quantification of collagen hydrogel in vivo 
Representative dorsal sections immunostained for GFAP and GFP (as figure 3) are shown with a corresponding 
section stained with picrosirius red and imaged under polarised light (A) for 2 separate animals (i, ii) transplanted 
with OEC-GFP in collagen hydrogel. A similar distribution of GFP+ cells and collagen is seen within the lesion. In 
some instances (i) the hydrogel is seen to distribute well through the lesion and appears to conform to it, while 
in others the hydrogel volume does not fill the lesion cavity, and GFP+ cells remain only within the hydrogel (ii). 
The amount of picrosirius red staining is quantified as a percentage of the total lesion volume (B) showing 
significantly increased amounts in both collagen transplanted groups compared to media (p<0.0001, one-way 
ANOVa and post-hoc Tukey test) but significantly less in collagen with OEC-chABC compared to OEC-GFP 
(p=0.0075). A scatter graph showing the % surviving GFP+ cells as compared to amount of picrosirius red staining 
(collagen) per animal is shown (C), symbols reflecting transplant received. A significant positive linear correlation 
is seen between the amount of picrosirius red staining and surviving cells for OEC-GFP (r = 0.833, R2 = 0.693, 




Figure 6-5. Quantification of inflammatory response to transplants 
Example dorsal section immunofluorescent images for GFAP are shown for media + OEC-GFP (A), collagen + OEC-
GFP (B) and collagen + OEC-chABC (C). Quantification of GFAP staining in regions of interest surrounding the 
lesion (D) shows no significant difference between groups. Invasion of GFAP+ cells can be seen into the lesion 
area in both collagen transplant groups, and a significant difference is seen between GFAP+ staining density 
within the lesion between media and both collagen transplants (*p<0.05, one-way ANOVA and Tukey post-hoc 
test). Similar example images are shown for IBA1 immunohistochemical staining after transplant of media + OEC-
GFP (F), collagen + OEC-GFP (G) and collagen + OEC-chABCs. No significant difference is seen in levels of IBA1 
staining around the lesion between groups (I). There is invasion of IBA1+ cells into the lesion in both collagen 
groups, reaching significance after collagen + OEC-GFP transplant (*p<0.05, Kruskal-Wallis and post-hoc Dunn’s 
test).  
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6.3.6 Neuronal invasion into transplants 
TUJ1 staining was used to investigate neuronal response to transplants. Example dorsal sections from 
each group (Figure 6-6A-C) show no TUJ1 staining with the lesion cavity in media transplants, but 
presence of staining within the lesion in both collagen transplants. Quantified, there is a significant 
difference between between media + OEC-GFP and both collagen + OEC-GFP (p=0.0003, Kruskal-
Wallis; p=0.0252, post-hoc Dunn’s test) and collagen + OEC-chABC (p=0.0031) (Figure 6-6D). On 
average there is more TUJ1+ staining in the lesion in collagen + OEC-chABC animals (mean = 3.70±3.4) 
compared to collagen + OEC-GFP (1.10±0.65) but this difference is not significant. Higher magnification 
confocal imaging within the lesion showed a close association between TUJ1+ neurons and GFP+ 
transplanted OECs in collagen within the lesion (Figure 6-6E).  
 
There is also a significant difference between transplant groups when a region of interest caudal to 
the lesion within the white matter is quantified [F(2,27)=3.79, p=0.0436 one-way ANOVA] and a  
similar trend to increasing TUJ1+ staining across the groups (mean = 1.79±1.2 for collagen + OEC-
chABC, 1.18±0.42 for collagen + OEC-GFP and 0.686±0.32 for media + OEC-GFP; Figure 6-6F).  
However, there is a significant difference only between media and collagen transplant of OEC-GFP 
(p=0.0436 post-hoc Tukey’s test). No significant difference is seen between vGlut1 or 5HT specific 





Figure 6-6. Quantification of TUJ1 neuronal staining 
Representative dorsal sections immunostained for GFAP and TUJ1 are shown (A,B,C; cranial to left). TUJ1 positive 
(TUJ1+) staining is seen within the lesion cavity after both collagen OEC-GFP (B) and OEC-chABC (C) transplants 
but not after OEC-GFP transplant in media (A). The number of TUJ1+ pixels within the lesion, demarcated by 
GFAP, was quantified and expressed as a a ratio to TUJ1+ pixels in a region of interest 500µm cranial to the lesion 
within the white matter (D, example region of interest shown in A by dashed white lines). A significant difference 
was seen between both collagen transplants and media (*p=0.0252, **p=0.0031, Kruskal-Wallis and post-hoc 
Dunn’s test). A higher magnification example immunofluorescent confocal image is shown of TUJ1+ axons 
associating with GFP+ transplanted cells within the lesion area (E). TUJ1+ staining within the white matter 500µm 
caudal to the lesion is expressed as a ratio to the cranial region of interest (F, example region of interests shown 
in A). A significant difference is seen between transplant of OEC-GFP in media and collagen (p=0.0404, one-way 






Figure 6-7. Quantification of vGlut1 and 5HT immunostaining on transverse caudal sections 
Transverse sections taken 10mm caudal to the lesion were immunostained for vGlut1 and 5HT and threshold 
images were analysed for positive staining with regions of interest by automated reference to a pre-specified 
template. No significant differences were seen between transplant groups for vGlut1 in laminae 1 and 2 (A), 
laminae 3-5 (B) or laminae 6-9 (C). No significant differences was seen between transplant groups for 5HT in 





The results presented demonstrate that injection of OECs (OEC-GFP) encapsulated in ‘liquid’ collagen 
hydrogel into chronic rat SCI improves cell survival. Distribution of collagen hydrogel at 2 weeks 
(determined by picrosirius red staining) is variable but the amount of remaining collagen is correlated 
to survival of OEC-GFP, adding evidence that collagen hydrogel persistence is important to survival. 
Increased axon regeneration (TUJ1 staining within the lesion and immediately caudal to it) is seen with 
both collagen transplants compared to media and CSPG digestion is seen following OEC-chABC 
transplant in collagen.  
 
6.4.1 Cell survival  
Compared to other reports of cell survival with injectable hydrogels the improvement in OEC survival 
seen here at 2 weeks (~7.5 times as many surviving OEC-GFP in collagen compared to media) is 
marked. Injection of Schwann cells at 1 week after T8 contusion injury in collagen-laminin hydrogel 
led to a ~2 fold increase in surviving cells at 12 weeks499 and injection of HAMC with NPCs 1 week after 
T2 clip compression led to a ~1.5 fold increase in surviving cells at 1 week286. However, the absolute 
number of surviving OECs in collagen here (~4.8%) is still comparatively low compared to other cell 
types (~46% of NPCs and ~27% Schwann cells in the above studies). In these particular studies this 
relatively high cell number could be in part attributable to the fact that Ki67+ Schwann cells and NPCs 
were seen indicating proliferation, something not normally seen in OECs across different species 
(including in dogs123, humans42 and laboratory rodents205,207) and not detected in our lab (data not 
shown). However, as discussed in previous chapters, survival of canine OECs in rats is likely most 
limited by the xenotransplant paradigm.  
 
Survival of OEC-chABC in collagen is significantly less than that of OEC-GFP in collagen and is similar to 
OEC-GFP in media. It is possible that the significantly reduced collagen present at 2 weeks after OEC-
chABC compared to collagen and OEC-GFP transplant is enough to reduce OEC survival; one could 
consider there is a minimum amount of collagen needed to support OEC survival. However, this is not 
consistent with the linear relationship seen between collagen and OEC-GFP survival nor the fact that 
there is no relationship between amount of collagen remaining and OEC-chABC survival (Figure 6-4C).  
 
The OEC-chABC were FACS sorted to purify the population, while OEC-GFP were not. FACS sorting to 
increase the number of transduced cells being transplanted was used both to simplify quantification 
of transplanted cells (virtually all cells being GFP+ after FACS sorting) and to explore a potential 
method of effectively increasing the quantity of chABC being delivered by an OEC-chABC transplant. 
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This disparity between OEC-GFP and OEC-chABC (the cells were otherwise from the same dog, and 
had a similar number of passages prior to transplantation) raises questions as to whether FACS sorting 
affects survival of OECs. While decreased viability is sometimes seen after FACS sorting500, transduced 
rodent OECs have previously been FACS sorted using GFP and successfully transplanted (in solution) 
into a dorsal column lesion in rats190 and we saw no decrease in viability between sorting and 
transplant during in vitro expansion.  
 
The ideal control in this experiment would clearly have been to use the same FACS sorted OEC-chABC 
transplanted in media, but time restrictions and the exploratory nature of this part of the experiment 
meant this was not performed. It is therefore difficult to discriminate if this difference in survival 
represents a ‘real’ difference in survival between OEC-GFP and OEC-chABC in collagen (which we did 
not see in media transplant in chapter 3, is a function of FACS sorting, or represents a technical 
problem with the transplant in this batch of cells. OEC-GFP transplant in collagen and media had 
similar survival across batches so a technical delivery problem is less likely.  
 
CSPG digestion is seen despite the lower cell survival in the OEC-chABC group, consistent with CSPG 
digestion seen with comparable cell survival in chapters 3 and 4 of this thesis in acute dorsal column 
crush and chronic thoracolumbar contusion injury. Combined with the data that shows chABC activity 
is present in vitro in media cultured with OEC-chABC in collagen hydrogel, this suggests collagen 
(including collagen concentration) does not impact on chABC release. Similar in vitro values are seen 
here compared to OEC-chABC grown in 2D on well surfaces (comparable to ~0.1U/ml commercial 
chABC) as in chapter 3 and 4.  
 
6.4.2 Collagen degradation 
Collagen is known to degrade over time, mainly due to enzymatic digestion by endogenous 
collagenases. In an in vivo study of acellular 3mg/ml collagen implanted sub-cutaneously in rats, 50% 
of the gel (by area) had degraded by 1 month501. The rate of this degradation varied by collagen 
concentration, with lower concentration (0.6mg/ml) gels being completely degraded at the same time 
point. Degradation rate is also affected by location of the gel in the body, presumed to be a function 
of the amount of collagenases available in different body compartments. Using non-invasive 
fluorescence imaging collagen (type 2) hydrogels were tracked in athymic mice; gels degraded slower 
after sub-cutaneous compared to intra-muscular and intra-peritoneal implant where 50% had 
degraded by 2 weeks502. A previous report for the rate of degradation of pure collagen in spinal cord 
could not be found but the data presented here showing ~50% of injected 2mg/ml collagen remaining 
 174 
at 2 weeks (49.8±11.6% of lesion volume was filled with collagen in OEC-GFP group at 2 weeks, on 
average the same volume of collagen as the lesion was injected) appears in line with prior reports. 
 
The desired rate of hydrogel degradation is unclear. When using degradable hydrogels the ideal 
situation would be that endogenous ECM, invasion of host cells and regeneration of axons replaces 
the hydrogel over time such that the hydrogel is no longer necessary and regenerated axons survive 
hydrogel degradation503. If degradation occurs too soon, however, regeneration will not survive 
implant degradation (as has been seen in peripheral nerve grafts504). Clearly, the duration of action 
required of a hydrogel will be highly dependent on the nature of injury and would ideally be titrated 
to this, but the factors determining speed of regeneration – especially for an individual injury – are 
not yet understood to this depth.  
 
In some tissue sections in our study (e.g. Figure 6-4Aii), the remaining collagen appears to be in a 
defined area, rather than spread out but patchy through the lesion (e.g. Figure 6-4Ai) as might be 
more expected with degradation. Earlier and/or or serial time points for termination of transplanted 
animals would be required to explore the profile of degradation and confirm degradation was the 
main cause of this loss, rather than (for example) contraction which is known to occur fairly rapidly in 
vitro278 with collagen, or that the exact volume of the lesion was not matched (injected collagen 
volume was based on an average lesion size at 3 weeks).   
 
There are some interesting techniques that could be applied to track collagen degradation and OEC 
survival over time after transplant and avoid termination of animals at serial time points. Collagen 
hydrogel appears hyperintense on T2 weighted and FLAIR MRI, or alternatively gadolinium-
impregnated collagen could be used505. OEC survival could also be tracked over time using a novel in 
vivo bioluminescence technique506 or by labelling of OECs with ferromagnetic nanoparticles that could 
also be detected on MRI428. In clinical transplants (canine or human) it would be feasible and justified 
to characterise the lesion in terms of volume and stiffness, by MRI and ultrasound elastography, prior 
to transplant to provide a personalised hydrogel transplant.  
 
The difference in collagen remaining at two weeks in vivo between OEC-GFP and OEC-chABC 
transplant is unexpected. Chondroitinase ABC is selective in its degradation of GAG side-chains and 
would not be expected to degrade collagen hydrogel221, indeed chABC is used in collagen-
proteoglycan materials (commonly used for engineered cartilage) to selectively degrade GAGs within 
this mixed construct507,508. Additionally, given OECs are known to secrete the protease MMP2 that 
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digests collagen195 and OEC survival is higher in the OEC-GFP group, comparatively increased digestion 
might be expected in this group instead.  
 
6.4.3 Inflammatory response to collagen transplant 
Unlike OECs, which do not appear to migrate out of the gel, astrocytes (GFAP) and microglia (IBA1) 
are seen invading into collagen within the lesion in both collagen transplant groups. There is no 
difference in astrocyte or microglial response surrounding the lesion between collagen and media 
transplants, implying no change in inflammatory or immune response to collagen transplant driving 
this invasion during the time period of this experiment, and providing evidence collagen hydrogel 
would be safe to use on clinics.  
 
Astrocytic invasion into collagen is consistent with prior reports of astrocytes invading into ‘ungelled’ 
collagen (but interestingly not transplanted gelled collagen)429 and also into collagen hydrogel 
impregnated with the growth factor FGF2406. Invasion of GFAP+ cells into transplanted biomaterial 
(polyacrylonitrile/polyvinyl chloride) with OECs  has also been reported492. Collagen type 1 has been 
associated with the conversion of reactive to scar-forming astrocytes509, something that likely needs 
to be avoided if axon regeneration is the intended outcome, so the astrocytic migration into collagen 
gels seen here is positive. It also provides evidence these collagen gels are permissive to cell infiltration 
in vivo, necessary to support regeneration.   
 
There are mixed reports on the inflammatory and immune response to hydrogel implant. In general, 
the potential for beneficial immunomodulation by hydrogels is greatest in acute transplant into lesions 
and is related to a number of factors including both their physical and chemical properties, e.g. 
chemical composition, porosity, topography, mechanical properties, functionalisation (for a review 
see Dumont et al. 2016510). Some previous reports have shown a reduction in inflammatory response 
after transplant, with a decrease in GFAP and IBA1 levels seen 8 weeks after acute injection of a self-
assembling peptide into a T6/7 clip compression511, after a sub-acute injection of synthetic hydrogel 
in a T10/11 contusion512 and after acute implant of a PEG channel system into a T9/10 hemisection513. 
Reduced GFAP was also seen at 8 weeks after acute PLGA and OEC implant in a transection296. 
Interestingly, however, no difference was seen between controls and hydrogel groups at earlier time 
points after injury in all of these studies. Not seeing changes in inflammatory response in our study at 
2 weeks therefore does not rule out a slower onset immunomodulatory effect.   
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6.4.4 Axon regeneration 
The neuronal staining (TUJ1) seen within the lesion cavity in both collagen transplant groups 
compared to media transplant (where the cystic cavity lesion persists), and significantly higher staining 
caudal to the lesion in collagen + OEC-GFP group, suggests collagen hydrogel supports axon growth in 
the presence of OECs in this chronic SCI model. No increased 5HT staining is seen 10mm further caudal 
to the lesion, but this is likely to be due in part to the early time point after transplant (2 weeks). In a 
recent rat study, a 3D printed synthetic biomaterial scaffold with orientated channels was implanted 
acutely after spinal cord transection with neural progenitor cells in a fibrin hydrogel along with 
numerous growth factors. Significant improvements in locomotion (BBB score) and histological signs 
of regeneration were seen, but 5HT stained axons were still only detected a maximum of 3.5mm 
caudal to the lesion at 4 weeks after transplant495.  
 
Similarly, in one of the previous biomaterial and OEC transplants in vivo (with 
polyacrylonitrile/polyvinyl chloride channel, OECs and Schwann cells implanted acutely after 
transection injury) increased axon regeneration is seen at 6 weeks after transplant compared to 
controls492 and 5HT fibres were seen regenerating into the cranial end of the implant but did not 
exceed 1mm in length.   
 
That there is no significant difference in axon regeneration into the lesion between collagen + OEC-
GFP and collagen + OEC-chABC groups suggests that collagen may be the more important factor in 
increasing axon regeneration through the lesion. However, drawing this conclusion is complicated by 
the fact that there is no collagen only control group, which was not included as this experiment was 
primarily aimed at investigating OEC delivery and survival. A collagen only control group would be 
important to include in any future experiments that wished to investigate the comparative 
regenerative effects of OECs or collagen.  
 
There is, however, a trend towards most regeneration in the collagen + OEC-chABC group which does 
not reach significance – the variability is high in this group and ‘n’ number low, and the experiment 
was not powered to detect this difference. Nevertheless, the trend is interesting particularly given 
there are significantly fewer OECs surviving in this group. It suggests that either: (i) OECs are not having 
a large effect on regeneration in this chronic cervical dorsal column crush, which could be consistent 
with the literature as discussed in chapter 3 and 4 suggesting OECs are more effective in 
thoracolumbar than cervical injuries126,362; or (ii) the effect of chABC is marked and increased neuronal 
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staining in this group is largely due to chABC not OECs, potentially due to sprouting from spared axons 
around the dorsal column crush injury into the lesion.   
 
Interestingly, in the previous study of acute OEC transplant in combination with chABC, Matrigel and 
Schwann cells after transection injury259, the degree of axon regeneration (in 5HT fibres) is also highly 
variable in the chABC combination group. In this study there was significantly more 5HT staining in the 
combined treatment groups compared to controls, but there was no evidence of increased CST 
regeneration (based on BDA tracing). After a transection injury, overall increased regeneration in a 
cross-section of spinal cord caudal to the lesion could come from tracts other than the CST, but as the 
dorsal column crush model is selective for the CST and we only examined sections in this plane we are 
looking more specifically for regeneration in this more refractory CST and therefore are likely to see 
less regeneration. It would be ideal to look solely at CST regeneration using BDA tracing (as per chapter 
3) in future experiments.  
 
Although mechanisms underlying axon regeneration were not investigated in detail in our study, it is 
worth noting that OECs associated with TUJ1 stained axons within the lesion cavity in collagen (Figure 
6E), potentially supportive of the guidance ‘pathway hypothesis’ of mechanism of action for OECs189. 
We also see that the distribution of OECs closely matches that of collagen. This is clearly not surprising 
where degradation leaves a cystic cavity, but OECs were rarely found migrating into spinal cord 
parenchyma from collagen. OECs are known to migrate from their injection site towards the lesion by 
chemoattraction169,170,172,205, something also noted in chapter 3, so it is possible that OECs did not leave 
the collagen gel as there was no stimulus for them to migrate away. However, migration in hydrogels 
varies dependent on material514,515, porosity516 and stiffness517. Anecdotally, neural cells are reported 
to migrate faster in fibrin compared to collagen, although published literature using fibroblasts 
suggests migration in collagen is faster than in fibrin514,515. In our lab we see no difference in migration 
speed between collagen concentrations (of necessarily different stiffnesses) and we inconsistently see 
higher migration of OECs in fibrin compared to collagen using a live cell imaging method (unpublished 
MSc project). It would be interesting to see if material or stiffness affected the OEC migration and 
distribution in vivo.  
 
Similar to previous reports we see disordered and non-directional growth of axons within the lesion 
without provision of channels or directional scaffolds for growth277,518. Providing this directionality is 
an area of considerable interest in hydrogel and biomaterial development277,495,513,518–521, but 




This study demonstrates that injectable delivery of OECs in collagen hydrogel into a cystic chronic 
lesion improves OEC survival after transplant. We see no change in inflammatory response between 
media and hydrogel groups, implying safety of transplant in these preliminary experiments, and 
invasion of endogenous cells and axons into the remaining collagen hydrogel.  
 
There is initial evidence that in the presence of OECs collagen hydrogel improves the degree of 
regeneration. We also show that OEC-chABC are able to digest CSPG after collagen delivery. Further 
experiments with more robust controls would be required to explore mechanisms of regeneration, 
identify response of different axon types, and clarify survival of OEC-chABC in collagen hydrogels. 
However, given the marked increase in OEC survival in collagen, further experiments to test for a 
functional improvement (e.g. forepaw reaching) in animals with OECs delivered in collagen compared 





Chapter 7  
 






7.1 Summary of key thesis findings 
In this thesis we have used two in vivo models of rodent SCI (acute cervical dorsal column crush and 
chronic thoracic contusion injuries) to evaluate the potential of canine OECs modified to express 
chABC. To develop an improved approach for OEC survival after transplant, we investigated injection 
of canine OECs encapsulated in collagen hydrogel into chronic dorsal column crush injuries in rats. We 
additionally developed a clinically applicable approach to match this implant stiffness to host SCI 
stiffness.  
 
In chapter 3 we provide proof-of-concept evidence that genetically engineered OECs expressing 
chABC can drive behavioural change where OECs alone do not (improvement in forepaw reaching and 
gait after acute transplant in dorsal column crush rat SCI). We confirm that OEC-chABC are able to 
digest CSPGs and increase sprouting after transplant.  
 
In chapter 4 we confirm that OEC-chABC can digest CSPGs after more severe thoracic contusion 
injuries (similar to natural injuries in humans and dogs) in rats when delivered in the chronic phase at 
3 weeks after injury, a clinically realistic time-point for delivery. We see statistically significant early 
signs of increased axon regeneration or sprouting after OEC-chABC transplant in this model but not 
locomotor recovery. The data in this thesis provides no evidence of efficacy for OEC transplant alone 
in either type of injury. However, canine OEC survival in both of these rodent models is low, likely 
reduced by the xenotransplant paradigm, which may be limiting the degree of recovery seen in these 
experiments.  
 
In chapter 5 we address the need for improved OEC delivery methods, given poor OEC survival is a 
common finding even across experimental allograft rodent205 and autologous clinical transplants123. 
Hydrogel encapsulation is a reported method to increase transplanted cell survival in SCI286,288 and we 
demonstrate intraoperative ultrasound elastography of SCI is a clinically feasible approach to allow 
personalised matched-stiffness implant of a hydrogel-OEC transplant. Our in vivo measures of 
naturally injured spinal cord in dogs address a knowledge gap as to the stiffness of in vivo SCI. They 
also corroborate existing reports315,316 that the injured spinal cord is less stiff than uninjured cord, and 
extend this finding to natural injuries.  
 
Finally, in chapter 6, we confirm that injection of canine OECs encapsulated in ‘un-gelled’ matched-
stiffness collagen hydrogel improves OEC survival at 2 weeks compared to transplant in solution, at a 
clinically relevant chronic injury time point in dorsal column crush rat SCI. We provide preliminary 
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evidence that transplant of OECs and OEC-chABC within collagen hydrogel increases regenerative 
outcomes (increased neuron density caudal to the lesion) and show safety of this transplant with no 
increased inflammatory responses.  
 
7.2 Translation of rodent findings to clinical work 
Rodent models of SCI provide valuable initial information regarding potential efficacy (e.g. recovery 
of locomotion or voluntary movements such as forepaw reaching) and mechanism of action (e.g. 
histological assessment of type of axon regeneration seen) of novel treatments. This thesis uses two 
such rodent models to provide proof-of-principle of a novel combination transplant of matched-
stiffness collagen encapsulated OEC-chABC transplant.  
 
There is, however, a clear multi-factorial issue in translating rodent findings to clinically useful 
treatments522. Rodent models of SCI are designed and selected for their homogeneity of lesion, and 
to reduce variability between animals. This is important to reduce the number of animals required to 
detect differences between treatment groups and increase confidence that any improvement 
detected is specifically due to the intervention rather than random variation. However, clinical injuries 
are necessarily heterogeneous and patients (human or veterinary) present with a wide variety of 
causes of injury (e.g. trauma, cord contusion secondary to disc herniation) and a range of ages, genetic 
backgrounds, severities and levels of injury, and co-morbidities (e.g. obesity, endocrine disorders). On 
this basis, it is perhaps not surprising that small differences in specific outcome measures such as BBB 
score (even if they are statistically significant) often do not produce clinically detectable results in 
natural injuries.  
 
Further, in medicine, the critical interest is in whether an individual patient improves, and what effect 
a treatment may have for a given individual. Group level analyses, even when considering individual 
baseline scores as a covariate (such as ANCOVA or mixed models), do not give this level of information. 
Relevant information such as the number of individuals that respond and the magnitude of each 
response may be lost (i.e. some animals may respond considerably, and others not at all, which is not 
reflected in a summary mean value)523. Such a treatment may still not have a large enough effect to 
be clinically valuable, but it is interesting to note that (as of 2015) the top ten highest grossing drugs 
in the USA benefit only between 1 in 25 and 1 in 4 of the people who take them524. Differences in 
individual responses can of course also be due to normal physiological variability or factors difficult to 
control for within an experiment (e.g. environmental effects on behavioural performance of rodents) 
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which can also skew results particularly with small sample sizes, a known problem within 
neuroscience525.  
 
Reproducibility of effect and replication of studies have also been highlighted as an issue in 
neuroscience and SCI research363, and are considered a key step before translation106. Replication 
studies have rarely been performed and the reproducibility of specific treatments is therefore hard to 
determine, in part due to the experimental variation discussed above. Where studies have been 
directly replicated, these replications have often not supported the original results363 (e.g. OEC 
transplant in thoracic transection injuries)183.  
  
Despite reasonably consistent models of injury and common scoring systems, there remains wide 
variability in other aspects of experimental design and (understandable) differences between labs in 
experimental protocols. For example, quantity of chABC delivered varies between studies as do OEC 
transplantation parameters (e.g. passage and number of cells, site of transplantation, volume and 
speed of injection) and rehabilitation paradigms vary considerably. Studies on combination therapies 
are particularly difficult to tease apart, often not including all control groups if they are not the focus 
of the investigation. In the context of what is logistically feasible within a given lab and to minimise 
the numbers of animals used this makes sense, but again reduces wider comparisons.  
 
Finally, there are a large number of pre-clinical studies on SCI (a simple Pubmed search for (rat OR 
mouse OR mice) AND “spinal cord injury” returns 9259 studies) and a huge number of rodents have 
been used (1164 animals were used in 62 experiments investigating OEC transplant126). Summarising 
and synthesising this information such that it is available and useful to researchers within the field is 
challenging and of increasing interest. Systematic reviews and meta-analyses are the first step towards 
this but there are limited numbers of these within the SCI field. Some organisations are making steps 
to tackle this, including with open-access databases of already synthesised literature for use in future 
meta-analyses526.  Systematic reviews and meta-analyses in the form of ‘living documents’ that are 
regularly updated are an exciting way to provide better evidence accessibility527. This is already being 
applied for clinical topics (5 ‘living systematic reviews’ are currently active on the Cochrane library528) 
but could be equally well applied to pre-clinical evidence529.  
 
7.3 Clinical olfactory ensheathing cell delivery of chondroitinase ABC 
Chondroitinase ABC has not so far been tested for SCI in humans, and therefore its safety profile is 
not yet known. This is distinct from OECs where autologous transplant in both humans42 and dogs123 
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has been shown to be safe. Recent reports of phase 2/3 human trials of condoliase (a chondroitin-
sulphate-ABC endolyase also derived from Proteus vulgaris) for lumbar disc herniation showed no 
adverse effects; no immunological reaction to the bacterially-derived condoliase was detected and 
nor were plasma concentrations after injection into discs218,219, which is promising for future human 
trials of chABC in SCI.  
 
One specific concern with chABC delivery to the spinal cord is that that its ability to increase plasticity 
and sprouting could, if present at too high a level for too long a time, potentially lead to aberrant 
connections causing spasticity or neuropathic pain. For example, increased sprouting of sensory 
afferents after NGF administration into the uninjured spinal cord of rats has been reported to cause 
hyperalgesia530 and neural stem cell transplant after thoracic contusion injury in rats caused aberrant 
axonal sprouting and hypersensitivity in the (motor unaffected) forepaws531. It has also been 
hypothesised that autonomic dysreflexia (episodic hypertension triggered by abnormal spinal reflexes 
after SCI) could be worsened by increased sensory input due to plasticity532. This has not been 
observed in experimental models of SCI with chABC66,244,381 even after long-term (3-month) 
administration of chABC in rodents by viral vector delivery where levels of chABC are expected to be 
high211. Similarly, no change was observed in von Frey filament responses in dogs with natural SCI in 
the 6 months following chABC delivery208.  
 
Such longer-term delivery of chABC is likely to be important. As discussed in chapters 3 and 4 the exact 
duration, timing and dose of chABC required is not clear and is likely to vary for each lesion (dependent 
on severity and number of spared axons, spinal level and chronicity) but will likely need to be for 
longer than that provided by single injection. Gene therapy is a means of providing this211,212 but 
clinical use of direct lentiviral delivery into spinal cord parenchyma would be challenging due to 
concerns about immunogenicity and insertional mutagenesis and the theoretical risk of a 
recombination event resulting in a replication competent lentivirus. Ex vivo transduction of OECs adds 
an additional layer of safety533, obviating the need to expose host tissue to ‘active’ viral vector and 
providing an additional ability to screen transduced OECs in culture for replication competent 
lentivirus or abnormal proliferation behaviour before transplant in vivo. There are a number of human 
trials in progress using this approach of ex vivo cell transduction with third-generation replication-
deficient lentiviral constructs, particularly for leukaemias534, demonstrating the clinical feasibility of 
this approach.  
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A final concern regarding introduction of the chABC, or any, transgene into patients (either by direct 
viral delivery or by OEC delivery) is  the risk of an immune reaction to the transgene by either humoral 
or T-cell responses (for reviews see535,536). This has not been established for chABC gene delivery, but 
a specific T-cell response could be tested for using MHC tetramer based detection537,538 of serum or 
CSF from animals receiving the chABC transgene.  
 
Temporally controllable delivery of chABC would limit many of these concerns and provide an 
additional level of safety. It is also likely that chABC would only be required to form a window of 
neuroplasticity, particularly potent in association with rehabilitation to strengthen functional 
connections246, and that after this stage a return to ‘normal’ levels of plasticity would not affect these 
newly formed connections and any functional recovery would be maintained. OEC death after 
transplant means that delivery of chABC would be time-limited, but this is not controllable and a 
significantly more elegant system would be to use a tetracycline inducible system such as has been 
recently reported for chABC235. The ideal situation would perhaps be to use such a tetracyline 
inducible system to transduce OECs ex vivo before transplant. Hydrogel delivery of OECs in autologous 
or allograft transplant would be expected to result in significantly longer cell survival than we have 
reported here and therefore to increase chABC delivery, potentially increasing any functional 
recovery. This needs to be tested in an autologous transplant model.  
 
7.4 Hydrogel implant and host tissue stiffness matching 
The focus of this thesis, with regard to hydrogel stiffness matching, was to determine the in vivo 
stiffness of the spinal cord after injury in order to be able to match this stiffness with personalised and 
‘bespoke’ implanted constructs to reduce inflammatory or immune reactions.  
 
It seems likely, however, that there would be some tolerance of host tissue to implant stiffness; for 
example, if canine SCI stiffness is ~18kPa it seems unlikely that an implant of 18 ±1kPa would cause 
clinically significant problems, but whether we start to see clinical effects at ±10kPa, ±50kPa, ±100kPa 
etc is unclear. The magnitude of this stiffness tolerance window is not known, most studies where 
significantly increased foreign body reactions have occurred have had a large (~100-fold) disparity 
between host tissue and implant stiffness298,299. Further work to systematically test what could be 
considered a safe stiffness window would be required, for example by transplanting hydrogels of 
varying stiffness into sites of SCI and examining behavioural signs (e.g. of pain by von Frey filament 
testing, locomotor outcomes) and histological markers of inflammation and immunoreaction.  
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This is of particular interest because having developed a process whereby in vivo stiffness of the spinal 
cord can be determined and hydrogel stiffness matched, the next step would be to adjust the implant 
stiffness within a known safety window to achieve the best regenerative outcomes.  
 
In vitro, an interaction is seen between stiffness of substrate and axon growth305–312. However the full 
picture is by no means clear, and how axon outgrowth is affected by stiffness is highly dependent on 
both neuron type (DRG305,306 and spinal cord307 neurites grow more on softer substrates while cortical 
neurons are insensitive to stiffness309) and type of material305,311,312 (for reviews see313,314). Comparison 
of the absolute stiffness involved in these studies to the spinal cord stiffness measured in this study is 
difficult because of the range of measurement techniques used. For example, primary mouse spinal 
cord neurons grew better on 0.23kPa than 0.55kPa gels307, apparently much lower than spinal cord 
seen here, but these values are obtained from rheology and therefore are shear moduli. In one study 
chick DRG neuron outgrowth was greater in 0.8mg/ml collagen hydrogels compared to 2mg/ml gels 
(the highest concentration tested)312, considerably lower than the concentration that would provide 
similar stiffness to our measure of injured canine spinal cord stiffness. However, given that the normal 
stiffness of spinal cord is different between species, it is unclear whether spinal cord neurons of 
different species might preferentially grow on different stiffness substrates comparable to their 
natural environment (i.e. whether canine axons may preferentially grow on higher stiffness substrates 
compared to chick axons). An intriguing set of experiments would be to compare primary culture axon 
growth from different species on substrate stiffnesses normalised to their own natural CNS stiffness.  
 
Most importantly, these in vitro findings need confirmation in vivo. Preliminary information could be 
gained in parallel with inflammatory reaction information discussed above, using a similar method to 
that reported in the previous chapter (collagen hydrogel injected in chronic dorsal column crush 
injuries) with comparison of axon outgrowth, potentially from BDA labelled axons, into collagen 
hydrogels of differing stiffnesses. If lower stiffnesses do prove better for axon regeneration within the 
spinal cord in vivo (there would be a tantalising link here to increased stiffness of injury being related 
to non-recovery in our very small cohort of paraplegic dogs in chapter 5), a lower bound on stiffness 
of an implant would come from the lowest stiffness that still provides an ECM structure for axon 
growth and still supports increased cell survival. This would also need to be systematically tested and 
non-invasive methods to track cell survival more efficiently and with reduced numbers of animals 
were highlighted in the previous chapter.  
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7.5 Pilot canine trial of OEC-chABC delivered in collagen hydrogel 
During this thesis we have explicitly tried to use materials (collagen hydrogel) and approaches (ex vivo 
transduction of an existing cell therapy) that could be feasibly quite quickly translated to clinical work, 
with the short-term aim of testing this therapy in the canine naturally occurring SCI model. To this end 
we have gained Home Office and institutional ethical permission at The Royal Veterinary College to 
perform a pilot phase 1 single-arm safety and feasibility trial of OEC-chABC transplant within collagen 
hydrogel into chronically paraplegic (>3 months) dogs that still have no pain perception.  
 
The outcome measures we plan to use are designed to address some of the safety concerns and 
unanswered questions discussed throughout this thesis, namely we will be testing: (i) von Frey 
aesthesiometer measures above and below the lesion, monitoring for any hyperalgesia or allodynia 
from chABC delivery; (ii) repeat MRI immediately after transplantation to assess hydrogel 
conformation to the lesion (collagen hydrogel is hyperintense on T2 weighted, T2* and FLAIR MR 
imaging); (iii) repeat MRI at 1 month after transplant to assess hydrogel degradation and compare 
diffusion-weighted imaging parameters from pre and post-transplantation to look for any early signs 
of regeneration112,539–541; (iv) CSF and blood (serum) sampling to test for specific immune responses to 
the chABC transgene as described above; (v) kinematic gait analysis123,542 to test for any change in gait 
or fore-hind limb co-ordination over 6 months after transplant.  
 
7.6 Conclusion 
The evidence presented in this thesis suggests that OEC-chABC encapsulated within collagen hydrogel 
represents a potential combination therapy for SCI. Canine OEC-chABC provide a functional benefit 
after transplant in incomplete rodent injury and encapsulation within collagen increases OEC survival 
after transplant. This functional benefit does not extend to more severe chronic contusion injuries and 
further work is required to determine if this is due to poor cell survival, for example in an autologous 
model.   
 
The data generated from this thesis has allowed us to progress and test this developed combination 
OEC-chABC and hydrogel therapy in canine patients, providing just such an autologous model of 
transplant. The hope is that the information gained from this trial, if positive, may take this potential 
therapy and/or its constituent parts (e.g. ex vivo viral delivery of chABC, delivery of OECs in hydrogel) 
closer to a full phase 2 trial, and subsequently potential routine veterinary use or eventual human 
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